pmid	geneId	diseaseId	gene_name	disease_name	label	pred	prob	is_confilct	r1_label	comment	sure	Ann error (GD/ikrm)	Complex(m, M, L, n,  S, C)	Have -	Have +	S no strong	In which snt (0, e, 1, m, bg|d)	snt
1363780	1287	D009394	COL4A5	Alport syndrome	1	1	0.9766972065	0										
1678058	268	D000544	Mis	Alzheimer's disease	0	1	0.9349291921	1	0	only	1	Gi					0	Mis-sense mutation Val----Ile in exon 17 of amyloid precursor protein gene in Japanese familial Alzheimer's disease.
1678058	351	D000544	amyloid precursor protein	Alzheimer's disease	1	1	0.9781524539	0										
1901333	3458	C536141	interferon-gamma	VL	0	0	0.01452028006	0	0.5			Dk	n				m	Leishmanial infection of human monocyte-derived macrophages enhanced the basal TNF alpha production by these cells, and this effect was further potentiated by treatment with recombinant interferon-gamma.
1901333	3458	D007239	interferon-gamma	Leishmanial infection | cryptic leishmanial infection	0	0	0.004595771898	0										
1901333	3458	D007896	interferon-gamma	tegumentary leishmaniasis	0	0	0.01041003317	0										
1901333	3458	D007898	interferon-gamma	visceral leishmaniasis	1	0	0.01905885898	1	0.5			Dr	n				m	Leishmanial infection of human monocyte-derived macrophages enhanced the basal TNF alpha production by these cells, and this effect was further potentiated by treatment with recombinant interferon-gamma.
1901333	3458	D010272	interferon-gamma	parasitism	0	0	0.004849686287	0										
1901333	7124	C536141	TNF alpha | Tumor necrosis factor (cachectin) | tumor necrosis factor-alpha	VL	0	1	0.9903724194	1	1			Dk					e	Thus, serum TNF alpha levels in VL patients are a good parameter to monitor in determining host response to therapy.
1901333	7124	D007239	TNF alpha | Tumor necrosis factor (cachectin) | tumor necrosis factor-alpha	Leishmanial infection | cryptic leishmanial infection	0	0	0.03368373588	0										
1901333	7124	D007896	TNF alpha | Tumor necrosis factor (cachectin) | tumor necrosis factor-alpha	tegumentary leishmaniasis	0	1	0.8861432672	1	0					1			m	Serum TNF alpha levels were also not elevated in 15 normal volunteers (11.3 +/- 15.6 pg/ml) and in 10 patients with tegumentary leishmaniasis (19.1 +/- 10.8 pg/ml).
1901333	7124	D007898	TNF alpha | Tumor necrosis factor (cachectin) | tumor necrosis factor-alpha	visceral leishmaniasis	1	1	0.9901365042	0										
1901333	7124	D010272	TNF alpha | Tumor necrosis factor (cachectin) | tumor necrosis factor-alpha	parasitism	0	0	0.03277185559	0										
2880401	3630	D003924	insulin	Non-insulin-dependent diabetes mellitus | non-insulin-dependent diabetes mellitus	1	1	0.9775436521	0										
3170557	1277	D010013	COL1A1	osteogenesis imperfecta	1	1	0.9385305047	0										
6636041	462	D002543	AT-III | antithrombin III	cerebral hemorrhage	1	0	0.1121074557	1	1				n		1	1	m	AT-III levels assayed by both biological and immunological methods showed a gradual decrease with increasing age, and levels in patients with cerebral thrombosis were lower than those in patients with cerebral hemorrhage.
6636041	462	D002561	AT-III | antithrombin III	cerebrovascular diseases	0	1	0.9665845037	1	0				n				0	Changes of the levels of antithrombin III in patients with cerebrovascular diseases.
6636041	462	D013927	AT-III | antithrombin III	thrombosis	0	1	0.968023181	1	0			Di						
6636041	462	D020767	AT-III | antithrombin III	cerebral thrombosis	1	1	0.7446787953	0	1			Dk	n		1	1	m	AT-III levels assayed by both biological and immunological methods showed a gradual decrease with increasing age, and levels in patients with cerebral thrombosis were lower than those in patients with cerebral hemorrhage.
7543567	1080	D000471	CFTR | cystic fibrosis transmembrane regulator	metabolic alkalosis	0	0	0.03174371272	0										
7543567	1080	D003550	CFTR | cystic fibrosis transmembrane regulator	cystic fibrosis	1	0	0.1254266053	1	1			Dk	M				e	These data suggest that the T3381 mutation is associated with a specific mild CF phenotype.
7543567	1080	D003681	CFTR | cystic fibrosis transmembrane regulator	hypotonic dehydration	0	0	0.03874193877	0										
7543567	1080	D007008	CFTR | cystic fibrosis transmembrane regulator	hypochloremia, hypokalemia	0	0	0.017840866	0										
7543567	1080	D007010	CFTR | cystic fibrosis transmembrane regulator	hyponatremia	0	1	0.5353559256	1	0									
7543567	1080	D008171	CFTR | cystic fibrosis transmembrane regulator	pulmonary	0	0	0.007397480309	0										
7543567	1080	D010195	CFTR | cystic fibrosis transmembrane regulator	pancreatic involvement	0	0	0.00853267312	0										
7581380	1180	C536106	CLCN1	muscle hypertrophy	0	0	0.004762618802	0										
7581380	1180	C536245	CLCN1	non-dystrophic myotonias	0	0	0.3617379069	0										
7581380	1180	D009222	CLCN1	myotonia	0	0	0.005011548754	0										
7581380	1180	D009224	CLCN1	Dominant myotonia congenita | Myotonia levior | Thomsen's disease | dominant myotonias | myotonia levior | recessive myotonia	1	1	0.9935902357	0										
7581380	6329	C536106	SCN4A	muscle hypertrophy	0	0	0.002973208437	0										
7581380	6329	C536245	SCN4A	non-dystrophic myotonias	0	0	0.03695964068	0										
7581380	6329	D009222	SCN4A	myotonia	0	0	0.003119661473	0										
7581380	6329	D009224	SCN4A	Dominant myotonia congenita | Myotonia levior | Thomsen's disease | dominant myotonias | myotonia levior | recessive myotonia	0	0	0.03113731556	0										
7698505	3630	D003924	Proinsulin | insulin | proinsulin	non-insulin-dependent diabetes mellitus	0	0	0.00409263093	0										
7698505	5122	D003924	prohormone convertase 3	non-insulin-dependent diabetes mellitus	0	0	0.005260044243	0										
7698505	5126	D003924	PC2 | PCSK2 | prohormone convertase 2	non-insulin-dependent diabetes mellitus	1	1	0.5849534273	0										
7789624	3630	D003922	IDDM2 | Insulin | insulin	IDDM | insulin-dependent diabetes mellitus	1	1	0.9928879142	0										
7937790	3558	D007153	IL-2	immunodeficiency | immunodeficiency disease | partial immunodeficiency	0	0	0.0132806208	0										
7937790	3558	D053632	IL-2	SCIDX1 syndrome	0	0	0.003205804853	0										
7937790	3559	D007153	IL-2R | interleukin 2 receptor	immunodeficiency | immunodeficiency disease | partial immunodeficiency	0	1	0.9438273311	1	0			Gi						
7937790	3559	D053632	IL-2R | interleukin 2 receptor	SCIDX1 syndrome	0	0	0.008131101727	0										
7937790	3561	D007153	SCIDX1 | interleukin 2 receptor gamma	immunodeficiency | immunodeficiency disease | partial immunodeficiency	0	1	0.9708693027	1	1			Gm					e	This atypical SCIDX1 patient demonstrates that certain IL-2R gamma chain abnormalities can also result in partial immunodeficiency phenotypes
7937790	3561	D053632	SCIDX1 | interleukin 2 receptor gamma	SCIDX1 syndrome	1	0	0.2987159491	1	1			Gm					1bg	X chromosome-linked severe combined immunodeficiency disease (SCIDX1) is characterized by the absence of T-cell and natural killer cell development and results from molecular mutations of the interleukin 2 receptor (IL-2R) gamma chain.
7937790	3565	D007153	IL-4	immunodeficiency | immunodeficiency disease | partial immunodeficiency	0	0	0.01638620161	0										
7937790	3565	D053632	IL-4	SCIDX1 syndrome	0	0	0.003269499866	0										
8083355	2885	D003920	GRB2	diabetes	0	0	0.003086013487	0										
8083355	2885	D003924	GRB2	non-insulin-dependent diabetes	0	0	0.3181617856	0										
8083355	3630	D003920	insulin	diabetes	0	0	0.002980746562	0										
8083355	3630	D003924	insulin	non-insulin-dependent diabetes	0	0	0.1940194368	0										
8083355	3667	D003920	IRS-1 | Insulin receptor substrate-1	diabetes	0	0	0.007780016866	0										
8083355	3667	D003924	IRS-1 | Insulin receptor substrate-1	non-insulin-dependent diabetes	1	1	0.9767505527	0										
8094629	1813	D011618	DRD2 | dopamine receptor D2	schizophrenia or schizoaffective disorder	0	0	0.005308152642	0										
8094629	1813	D012559	DRD2 | dopamine receptor D2	schizophrenia	0	0	0.0524036102	0										
8094629	3145	D011618	PBGD | porphobilinogen deaminase	schizophrenia or schizoaffective disorder	0	0	0.01698671281	0										
8094629	3145	D012559	PBGD | porphobilinogen deaminase	schizophrenia	1	1	0.9874897599	0										
8275568	338	D009765	apo B | apolipoprotein B	obesity	1	1	0.9763660431	0										
8406498	1287	D009394	COL4A5	Alport syndrome	1	1	0.9916180968	0										
8486375	1280	D002357	COL2A1	cartilage diseases | cartilage disorders	0	0	0.2472143769	0										
8486375	1280	D010009	COL2A1	chondrodysplasia | osteochondrodysplasia | spondyloepiphyseal dysplasia	1	1	0.9896098375	0										
8698225	3553	D003092	IL-1beta | interleukin (IL) 1beta | interleukin 1beta	Colitis | colitis	0	0	0.01267410535	0										
8698225	3553	D064420	IL-1beta | interleukin (IL) 1beta | interleukin 1beta	cytotoxicity | toxicity	0	0	0.002592978766	0										
8698225	3569	D003092	IL-6	Colitis | colitis	0	0	0.009950369596	0										
8698225	3569	D064420	IL-6	cytotoxicity | toxicity	0	0	0.002466545207	0										
8698225	4843	D003092	Inducible nitric oxide synthase | iNOS | inducible nitric oxide synthase	Colitis | colitis	1	1	0.9903381467	0										
8698225	4843	D064420	Inducible nitric oxide synthase | iNOS | inducible nitric oxide synthase	cytotoxicity | toxicity	0	0	0.07089413702	0										
8698225	6648	D003092	Manganese superoxide dismutase | MnSOD	Colitis | colitis	0	0	0.07566019148	0										
8698225	6648	D064420	Manganese superoxide dismutase | MnSOD	cytotoxicity | toxicity	0	0	0.003092963248	0										
8698225	7124	D003092	tumor necrosis factor alpha	Colitis | colitis	0	0	0.01007952821	0										
8698225	7124	D064420	tumor necrosis factor alpha	cytotoxicity | toxicity	0	0	0.002472696127	0										
8846404	103694380	D006940	tumor necrosis factor	hyperemia | hyperemic	0	0	0.02100158669	0										
8846404	103694380	D006973	tumor necrosis factor	increase of plantar cutaneous blood flow	0	0	0.01004542876	0										
8846404	103694380	D009336	tumor necrosis factor	tumor necrosis	0	0	0.009642696008	0										
8846404	103694380	D016116	tumor necrosis factor	cutaneous hyperemic	0	0	0.01171009336	0										
8846404	103694380	D020258	tumor necrosis factor	neurotoxic	0	0	0.00956488587	0										
8846404	3553	D006940	IL-1 beta | Interleukin 1 beta | interleukin 1 beta	hyperemia | hyperemic	1	1	0.6796007156	0										
8846404	3553	D006973	IL-1 beta | Interleukin 1 beta | interleukin 1 beta	increase of plantar cutaneous blood flow	0	0	0.01518292446	0										
8846404	3553	D009336	IL-1 beta | Interleukin 1 beta | interleukin 1 beta	tumor necrosis	0	0	0.01880966313	0										
8846404	3553	D016116	IL-1 beta | Interleukin 1 beta | interleukin 1 beta	cutaneous hyperemic	0	0	0.01889893413	0										
8846404	3553	D020258	IL-1 beta | Interleukin 1 beta | interleukin 1 beta	neurotoxic	0	0	0.009074766189	0										
8846404	4049	D006940	TNF beta	hyperemia | hyperemic	0	0	0.007515199948	0										
8846404	4049	D006973	TNF beta	increase of plantar cutaneous blood flow	0	0	0.004527973942	0										
8846404	4049	D009336	TNF beta	tumor necrosis	0	0	0.004456468392	0										
8846404	4049	D016116	TNF beta	cutaneous hyperemic	0	0	0.004896875471	0										
8846404	4049	D020258	TNF beta	neurotoxic	0	0	0.004414013587	0										
8846404	7124	D006940	TNF alpha	hyperemia | hyperemic	0	0	0.01208966784	0										
8846404	7124	D006973	TNF alpha	increase of plantar cutaneous blood flow	0	0	0.005864957348	0										
8846404	7124	D009336	TNF alpha	tumor necrosis	0	0	0.005752315745	0										
8846404	7124	D016116	TNF alpha	cutaneous hyperemic	0	0	0.006509112194	0										
8846404	7124	D020258	TNF alpha	neurotoxic	0	0	0.005763936788	0										
8931914	1636	D012559	ACE | angiotensin converting enzyme	schizophrenia	0	0	0.0295459684	0										
8931914	1636	D019964	ACE | angiotensin converting enzyme	affective disorders	1	1	0.9879001379	0										
8931914	6863	D012559	SP | substance P	schizophrenia	0	0	0.01004276425	0										
8931914	6863	D019964	SP | substance P	affective disorders	0	1	0.8402155042	1	0			Gi						
9058314	1791	D003920	TDT	Diabetes	0	0	0.00208321074	0										
9058314	1791	D003922	TDT	IDDM | insulin-dependent diabetes mellitus	0	1	0.9818704128	1	0			Gi						
9058314	3119	D003920	HLA-DQB1	Diabetes	0	0	0.002190423431	0										
9058314	3119	D003922	HLA-DQB1	IDDM | insulin-dependent diabetes mellitus	0	0	0.1055351645	0										
9058314	3458	D003920	IFN-gamma | IFNG | interferon (IFN)-gamma | interferon-gamma	Diabetes	0	0	0.005082879215	0										
9058314	3458	D003922	IFN-gamma | IFNG | interferon (IFN)-gamma | interferon-gamma	IDDM | insulin-dependent diabetes mellitus	1	1	0.9910641909	0										
9109174	1312	D000437	COMT | catechol-O-methyltransferase	alcohol abuse	0	1	0.9701686502	1	0									
9109174	1312	D012559	COMT | catechol-O-methyltransferase	schizophrenia | schizophrenic	1	1	0.9895267487	0										
9129724	1137	D001008	CHRNA4 | Neuronal nicotinic acetylcholine receptor alpha 4 subunit | neuronal nicotinic acetylcholine receptor alpha 4 subunit	Anxiety disorders	0	0	0.05405659974	0										
9129724	1137	D016584	CHRNA4 | Neuronal nicotinic acetylcholine receptor alpha 4 subunit | neuronal nicotinic acetylcholine receptor alpha 4 subunit	panic disorder	1	1	0.994268775	0										
9187681	6094	D012162	ROM1	retinal degeneration	0	1	0.8366753459	1	0									
9187681	6094	D012174	ROM1	Retinitis pigmentosa | retinitis pigmentosa	1	1	0.9748800397	0										
9210877	7249	D001254	TSC | TSC2	astrocytic gliomas | astrocytomas | pilocytic astrocytomas	0	0	0.02311053686	0										
9210877	7249	D004194	TSC | TSC2	dysplastic glial | glial tumors	0	0	0.00719503453	0										
9210877	7249	D005909	TSC | TSC2	glioblastomas	0	0	0.008388842456	0										
9210877	7249	D005910	TSC | TSC2	gliomas	0	1	0.5835098624	1	0									
9210877	7249	D006222	TSC | TSC2	hamartomas and tumors	0	1	0.8966174722	1	0.5	only		Di					1	The tuberous sclerosis 2 (TSC2) gene is thought to function as a growth suppressor in sporadic and TSC-associated hamartomas and tumors.
9210877	7249	D009369	TSC | TSC2	tumors	0	0	0.01777294651	0										
9210877	7249	D014402	TSC | TSC2	gangliogliomas and cortical tubers in tuberous sclerosis | tuberous sclerosis | tubers	0	1	0.9897758961	1	0				n					
9210877	7249	D018303	TSC | TSC2	gangliogliomas | sporadic gangliogliomas	1	1	0.970115602	0										
9353155	1493	C537447	CTLA-4 | cytotoxic T lymphocyte-associated protein 4	Belgian Diabetes	0	0	0.004183278885	0										
9353155	1493	C538275	CTLA-4 | cytotoxic T lymphocyte-associated protein 4	polyendocrine autoimmunity	0	0	0.004399864469	0										
9353155	1493	D003920	CTLA-4 | cytotoxic T lymphocyte-associated protein 4	diabetes	0	0	0.00291252695	0										
9353155	1493	D003922	CTLA-4 | cytotoxic T lymphocyte-associated protein 4	IDDM | insulin-dependent diabetes mellitus	1	1	0.991799891	0										
9353155	2572	C537447	GAD65	Belgian Diabetes	0	0	0.002492533298	0										
9353155	2572	C538275	GAD65	polyendocrine autoimmunity	0	0	0.00234173052	0										
9353155	2572	D003920	GAD65	diabetes	0	0	0.002273017308	0										
9353155	2572	D003922	GAD65	IDDM | insulin-dependent diabetes mellitus	0	0	0.009258325212	0										
9353155	2752	C537447	glutamate decarboxylase	Belgian Diabetes	0	0	0.002480040304	0										
9353155	2752	C538275	glutamate decarboxylase	polyendocrine autoimmunity	0	0	0.002343708649	0										
9353155	2752	D003920	glutamate decarboxylase	diabetes	0	0	0.002252877923	0										
9353155	2752	D003922	glutamate decarboxylase	IDDM | insulin-dependent diabetes mellitus	0	0	0.00799251534	0										
9353155	3117	C537447	DQA1 | HLA | HLA-DQA1	Belgian Diabetes	0	0	0.003295594128	0										
9353155	3117	C538275	DQA1 | HLA | HLA-DQA1	polyendocrine autoimmunity	0	0	0.00350455544	0										
9353155	3117	D003920	DQA1 | HLA | HLA-DQA1	diabetes	0	0	0.003086164827	0										
9353155	3117	D003922	DQA1 | HLA | HLA-DQA1	IDDM | insulin-dependent diabetes mellitus	0	0	0.4068070948	0										
9353155	3119	C537447	IDDM1	Belgian Diabetes	0	0	0.002504227683	0										
9353155	3119	C538275	IDDM1	polyendocrine autoimmunity	0	0	0.002352438401	0										
9353155	3119	D003920	IDDM1	diabetes	0	0	0.002259947127	0										
9353155	3119	D003922	IDDM1	IDDM | insulin-dependent diabetes mellitus	0	0	0.009142844006	0										
9353155	3126	C537447	DR4	Belgian Diabetes	0	0	0.002500345232	0										
9353155	3126	C538275	DR4	polyendocrine autoimmunity	0	0	0.002350330818	0										
9353155	3126	D003920	DR4	diabetes	0	0	0.002293753671	0										
9353155	3126	D003922	DR4	IDDM | insulin-dependent diabetes mellitus	0	0	0.006740125362	0										
9353155	3630	C537447	IAA | IDDM2 | insulin | insulin (IAA)	Belgian Diabetes	0	0	0.002453398891	0										
9353155	3630	C538275	IAA | IDDM2 | insulin | insulin (IAA)	polyendocrine autoimmunity	0	0	0.002318827668	0										
9353155	3630	D003920	IAA | IDDM2 | insulin | insulin (IAA)	diabetes	0	0	0.002233396284	0										
9353155	3630	D003922	IAA | IDDM2 | insulin | insulin (IAA)	IDDM | insulin-dependent diabetes mellitus	0	0	0.008233305067	0										
9353155	5798	C537447	IA-2	Belgian Diabetes	0	0	0.002504875651	0										
9353155	5798	C538275	IA-2	polyendocrine autoimmunity	0	0	0.00234449585	0										
9353155	5798	D003920	IA-2	diabetes	0	0	0.002283069305	0										
9353155	5798	D003922	IA-2	IDDM | insulin-dependent diabetes mellitus	0	0	0.01607814431	0										
9452024	5009	D020163	OTC | ornithine transcarbamylase	OTC deficiency	1	1	0.9831950068	0										
9502772	2247	D000168	FGF-2	Apert syndrome | Apert syndromic craniosynostosis	0	0	0.02047659084	0										
9502772	2263	D000168	FGFR-2 | fibroblast growth factor receptor 2	Apert syndrome | Apert syndromic craniosynostosis	1	1	0.9907910824	0										
9643286	7356	D001249	CC16	asthma	1	1	0.9944278002	0										
9643286	7356	D007249	CC16	inflammation	0	0	0.06270052493	0										
9649566	348	D006952	APOE*2 | Apoe | Apoe*2 | apoE | apoE2 | apoE3 | apolipoprotein E	Type III hyperlipoproteinemia | type III hyperlipoproteinemia	1	1	0.9869331717	0										
9649566	348	D014973	APOE*2 | Apoe | Apoe*2 | apoE | apoE2 | apoE3 | apolipoprotein E	xanthomas	0	0	0.06012869999	0										
9649566	348	D050197	APOE*2 | Apoe | Apoe*2 | apoE | apoE2 | apoE3 | apolipoprotein E	atherosclerosis | atherosclerotic	1	1	0.9938878417	0										
9663473	2212	C531622	Fcgamma receptor IIa | FcgammaRIIa	lupus anticoagulant	0	0	0.006621866953	0										
9663473	2212	D000743	Fcgamma receptor IIa | FcgammaRIIa	hemolytic anemia	0	0	0.01138758659	0										
9663473	2212	D001168	Fcgamma receptor IIa | FcgammaRIIa	arthritis	0	0	0.006615994964	0										
9663473	2212	D003449	Fcgamma receptor IIa | FcgammaRIIa	cryoglobulinemia	0	0	0.006561833899	0										
9663473	2212	D006402	Fcgamma receptor IIa | FcgammaRIIa	hematologic abnormalities	0	0	0.006904308684	0										
9663473	2212	D007153	Fcgamma receptor IIa | FcgammaRIIa	immunologic abnormalities	0	0	0.006804344244	0										
9663473	2212	D008180	Fcgamma receptor IIa | FcgammaRIIa	SLE | systemic lupus erythematosus	1	1	0.9943249822	0										
9663473	2212	D008199	Fcgamma receptor IIa | FcgammaRIIa	lymphadenitis	0	0	0.006692562252	0										
9663473	2212	D009393	Fcgamma receptor IIa | FcgammaRIIa	nephritis	0	0	0.00663660001	0										
9663473	2212	D011507	Fcgamma receptor IIa | FcgammaRIIa	proteinuria	0	0	0.03006195836	0										
9663473	2212	D012859	Fcgamma receptor IIa | FcgammaRIIa	sicca syndrome	0	0	0.006690616254	0										
9663473	3502	C531622	IgG3	lupus anticoagulant	0	0	0.002850181889	0										
9663473	3502	D000743	IgG3	hemolytic anemia	0	0	0.003254000563	0										
9663473	3502	D001168	IgG3	arthritis	0	0	0.002855350031	0										
9663473	3502	D003449	IgG3	cryoglobulinemia	0	0	0.002844864968	0										
9663473	3502	D006402	IgG3	hematologic abnormalities	0	0	0.00287346635	0										
9663473	3502	D007153	IgG3	immunologic abnormalities	0	0	0.002864380134	0										
9663473	3502	D008180	IgG3	SLE | systemic lupus erythematosus	0	0	0.04766330123	0										
9663473	3502	D008199	IgG3	lymphadenitis	0	0	0.002855712315	0										
9663473	3502	D009393	IgG3	nephritis	0	0	0.002851014258	0										
9663473	3502	D011507	IgG3	proteinuria	0	0	0.004154247232	0										
9663473	3502	D012859	IgG3	sicca syndrome	0	0	0.002854794497	0										
9731715	10	D008175	NAT2	lung cancer	0	1	0.9475662708	1	0					1			e	No significant association was found between NAT2 genotype and lung cancer.
9731715	10	D009369	NAT2	cancer	0	0	0.0207234025	0										
9731715	9	D008175	NAT1	lung cancer	1	1	0.9905810952	0										
9731715	9	D009369	NAT1	cancer	0	0	0.02110602707	0										
9741700	335	D007863	apolipoprotein A-I	familial lecithin:cholesterol acyltransferase deficiency | lecithin:cholesterol acyltransferase (LCAT) deficiency	0	1	0.950718224	1	0									
9741700	3931	D007863	LCAT	familial lecithin:cholesterol acyltransferase deficiency | lecithin:cholesterol acyltransferase (LCAT) deficiency	1	1	0.9896172285	0										
9764905	1234	D015658	CCR-5	HIV infection	1	1	0.9731190205	0										
9764905	7852	D015658	CXCR-4	HIV infection	0	0	0.00760525465	0										
9792863	7389	D000437	URO-D | uroporphyrinogen decarboxylase	alcohol abuse	0	1	0.9290283918	1	0									
9792863	7389	D006432	URO-D | uroporphyrinogen decarboxylase	hemochromatosis	0	1	0.9877659082	1	0				n					
9792863	7389	D017119	URO-D | uroporphyrinogen decarboxylase	Familial porphyria cutanea tarda	1	0	0.3708319068	1	1				n	1	1		1bg	Familial porphyria cutanea tarda (f-PCT) results from the half-normal activity of uroporphyrinogen decarboxylase (URO-D). However, there was no clear correlation between f-PCT disease severity and the URO-D and/or hemochromatosis genotypes.
9800221	1814	D012559	D3 dopamine receptor | DRD3	schizophrenia	1	1	0.9625311494	0										
9843210	2706	C537845	GJB2 | connexin 26	hereditary hearing impairment	0	0	0.004084024113	0										
9843210	2706	D003638	GJB2 | connexin 26	deafness | non-syndromic deafness	0	0	0.01165614743	0										
9843210	2706	D034381	GJB2 | connexin 26	Hearing impairment | autosomal dominant hearing impairment | hearing impairment | hearing loss	0	0	0.03365538269	0										
9843210	2707	C537845	GJB3 | Gjb3 | gap junction protein beta-3	hereditary hearing impairment	0	0	0.3709219098	0										
9843210	2707	D003638	GJB3 | Gjb3 | gap junction protein beta-3	deafness | non-syndromic deafness	1	0	0.1266562194	1	0.5	only			n		1	1	mbg	More than 50% of the cases of profound early-onset deafness are caused by genetic factors. Over 40 loci for non-syndromic deafness have been genetically mapped, and mutations in several genes have been shown to cause hearing loss.
9843210	2707	D034381	GJB3 | Gjb3 | gap junction protein beta-3	Hearing impairment | autosomal dominant hearing impairment | hearing impairment | hearing loss	0	1	0.9807443023	1	1								e	These findings suggest that mutations in GJB3 may be responsible for bilateral high-frequency hearing impairment.
9843210	3592	C537845	p35	hereditary hearing impairment	0	0	0.003873408772	0										
9843210	3592	D003638	p35	deafness | non-syndromic deafness	0	0	0.01019482128	0										
9843210	3592	D034381	p35	Hearing impairment | autosomal dominant hearing impairment | hearing impairment | hearing loss	0	0	0.00888671726	0										
10323730	190	C536757	DAX-1 | DAX1	X-linked AHC | X-linked congenital adrenal hypoplasia	1	1	0.9944043159	0										
10323730	190	D000312	DAX-1 | DAX1	AHC	0	1	0.9516712427	1	0.5	only		Dr	n				1bg	We identified a DAX1 missense mutation, a substitution of arginine for leucine at codon 466 (Leu466Arg), in an infant with X-linked congenital adrenal hypoplasia (AHC).
10487688	5979	D006623	RET	VHL tumor | VHL-associated tumors | von-Hippel-Lindau disease	0	0	0.02427119017	0										
10487688	5979	D009369	RET	tumor	0	0	0.003134189406	0										
10487688	5979	D010673	RET	pheochromocytoma | pheochromocytomas | sporadic pheochromocytomas	0	0	0.08888221532	0										
10487688	5979	D018813	RET	multiple endocrine neoplasia type 2	0	0	0.004812528845	0										
10487688	7428	D006623	VHL	VHL tumor | VHL-associated tumors | von-Hippel-Lindau disease	0	0	0.02599306405	0										
10487688	7428	D009369	VHL	tumor	0	0	0.004611948971	0										
10487688	7428	D010673	VHL	pheochromocytoma | pheochromocytomas | sporadic pheochromocytomas	0	1	0.8353500962	1	0.5	only		Gm	n				1bg	Although the two major familial forms of pheochromocytomas, multiple endocrine neoplasia type 2 and von-Hippel-Lindau disease (VHL), have been associated with mutations of the RET and VHL genes, respectively, the molecular pathogenesis of sporadic pheochromocytomas is largely unknown.
10487688	7428	D018813	VHL	multiple endocrine neoplasia type 2	0	0	0.01179205347	0										
10487688	8453	D006623	CUL2	VHL tumor | VHL-associated tumors | von-Hippel-Lindau disease	0	0	0.4245435297	0										
10487688	8453	D009369	CUL2	tumor	0	0	0.04662279785	0										
10487688	8453	D010673	CUL2	pheochromocytoma | pheochromocytomas | sporadic pheochromocytomas	1	1	0.9779892564	0	1						1	1	e	Although our findings suggest that CUL2 does not play a major role in the pathogenesis of pheochromocytomas, it is still unknown whether epigenetic mechanisms are involved in its inactivation in VHL-associated tumors.
10487688	8453	D018813	CUL2	multiple endocrine neoplasia type 2	0	0	0.006846896373	0										
10545596	2022	D013683	ENDOGLIN | endoglin	autosomal dominant vascular disorder hereditary hemorrhagic telangiectasia type | hereditary hemorrhagic telangiectasia	1	1	0.9864968657	0										
10545596	2022	D058495	ENDOGLIN | endoglin	haploinsufficiency	0	1	0.9549667835	1	0									
10690530	7421	D008545	VDR | Vitamin D receptor | vitamin D receptor	malignant melanoma	1	1	0.9802748561	0										
10690530	7421	D009101	VDR | Vitamin D receptor | vitamin D receptor	MM	0	1	0.983525753	1	1	annotation different in Web		Dk					e	These data suggest that 1,25(OH)2D3, the ligand of the VDR, may have a protective influence in MM, as has been proposed for other malignancies.
10690530	7421	D009369	VDR | Vitamin D receptor | vitamin D receptor	malignancies | thicker tumors	0	0	0.007411813829	0										
10694685	7051	D007057	TGM1 | transglutaminase 1	ichthyosis	0	0	0.05924919993	0										
10694685	7051	D017490	TGM1 | transglutaminase 1	Lamellar ichthyosis | lamellar ichthyosis	1	1	0.980902791	0										
10770218	359	D006319	aquaporin-2	sensorineural deafness	0	1	0.5088200569	1	1	only							m	In addition, a recurrent missense mutation (A147T) within the aquaporin-2 gene was identified in a female patient with autosomal recessive NDI associated with sensorineural deafness.
10770218	359	D018500	aquaporin-2	NDI | X-Linked nephrogenic diabetes insipidus | autosomal recessive NDI | nephrogenic diabetes insipidus	0	0	0.09729639441	0										
10770218	359	D030342	aquaporin-2	inherited disorder | molecular defects	0	0	0.003091257997	0										
10770218	551	D006319	vasopressin	sensorineural deafness	0	0	0.1201139465	0										
10770218	551	D018500	vasopressin	NDI | X-Linked nephrogenic diabetes insipidus | autosomal recessive NDI | nephrogenic diabetes insipidus	0	0	0.4518021941	0										
10770218	551	D030342	vasopressin	inherited disorder | molecular defects	0	0	0.007249449845	0										
10770218	554	D006319	AVPR2	sensorineural deafness	0	0	0.02786670253	0										
10770218	554	D018500	AVPR2	NDI | X-Linked nephrogenic diabetes insipidus | autosomal recessive NDI | nephrogenic diabetes insipidus	1	0	0.2109764665	1	1	only							1bg	X-Linked nephrogenic diabetes insipidus (NDI) is a rare inherited disorder characterized by the excretion of abnormal large volumes of diluted urine mainly caused by mutations in the V2 vasopressin receptor (AVPR2) gene.
10770218	554	D030342	AVPR2	inherited disorder | molecular defects	0	0	0.004571763333	0										
10794074	4987	D007022	Nociceptin receptor | nociceptin receptor	hypotension	0	1	0.9594786763	1	1	annotation different in Web							0	Nociceptin receptor activation produces nitric oxide-mediated systemic hypotension.
10794074	5368	D007022	Nociceptin | nociceptin	hypotension	1	0	0.4699173868	1	0	annotation different in Web		Gi						
10914558	4609	D009190	c-MYC	myelodysplastic syndrome	1	1	0.9649864435	0										
10914558	4609	D054198	c-MYC	acute lymphoblastic leukemia	0	1	0.9815272689	1	1	only							0	Double minute chromosomes and c-MYC amplification in a child with secondary myelodysplastic syndrome after treatment for acute lymphoblastic leukemia.
11153915	1544	D017119	CYP1A2	porphyria cutanea tarda	1	1	0.9872357249	0										
11161635	348	D000544	APOE	AD | Alzheimer's Disease | Alzheimer's disease	0	0	0.01460671704	0										
11161635	4353	D000544	MPO | Myeloperoxidase	AD | Alzheimer's Disease | Alzheimer's disease	1	1	0.9946259856	0										
11167791	2815	D001606	GPIX | glycoprotein IX	BSS	1	1	0.9854405522	0										
11167791	81890	D001606	TGT	BSS	0	0	0.009920561686	0										
11219777	6817	D001943	SULT1A1 | Sulfotransferase (SULT) 1A1 | Sulfotransferase 1A1	breast cancer	1	1	0.993999362	0										
11219777	6817	D015663	SULT1A1 | Sulfotransferase (SULT) 1A1 | Sulfotransferase 1A1	cohort of postmenopausal Iowa	0	0	0.007338851225	0										
11226630	2918	D005911	Metabotropic glutamate receptor 8 | mGluR8 | metabotropic glutamate receptor 8	gliosis	1	0	0.3936085105	1	1	only							e	The present novel finding of induced expression of mGluR8 in astrocytes APISE suggests that it may be linked to gliosis.
11226630	2918	D013226	Metabotropic glutamate receptor 8 | mGluR8 | metabotropic glutamate receptor 8	status epilepticus	0	1	0.9928526282	1	1			Di	n				0	Metabotropic glutamate receptor 8 in the rat hippocampus after pilocarpine induced status epilepticus.
11226630	759	D005911	CA1	gliosis	0	0	0.007240677252	0										
11226630	759	D013226	CA1	status epilepticus	0	0	0.1398929358	0										
11239195	4846	D002340	NOS 3 | eNOS | endothelial nitric oxide synthase	carotid atherosclerosis	0	1	0.9939326644	1	1		1						e	Homozygosity for Asp298, a common variant of the eNOS gene, is an independent risk factor for carotid atherosclerosis in this study population.
11239195	4846	D006973	NOS 3 | eNOS | endothelial nitric oxide synthase	hypertension	0	1	0.5716254711	1	0									
11239195	4846	D050197	NOS 3 | eNOS | endothelial nitric oxide synthase	atherosclerotic process	1	1	0.9494137764	0										
11244490	348	D000544	APOE | apolipoprotein E	AD | Alzheimer's disease	0	1	0.9885454774	1	0.5	only			n		1	1	e	We obtained no evidence for the possible interactions between the BDNF and apolipoprotein E (APOE) genes, suggesting that the possible effect of the BDNF gene on the development of late-onset AD might be independent of the APOE genotype.
11244490	348	D019636	APOE | apolipoprotein E	neurodegenerative diseases	0	0	0.002735319547	0										
11244490	627	D000544	BDNF | brain-derived neurotrophic factor	AD | Alzheimer's disease	1	1	0.9904862046	0										
11244490	627	D019636	BDNF | brain-derived neurotrophic factor	neurodegenerative diseases	0	0	0.01802254282	0										
11303694	4524	C537357	MTHFR | Methylenetetrahydrofolate reductase | methylenetetrahydrofolate reductase	Methylenetetrahydrofolate reductase T	0	0	0.1165811121	0										
11303694	4524	D002318	MTHFR | Methylenetetrahydrofolate reductase | methylenetetrahydrofolate reductase	cardiovascular disease	0	1	0.9636434913	1	0		1							
11303694	4524	D003324	MTHFR | Methylenetetrahydrofolate reductase | methylenetetrahydrofolate reductase	coronary artery disease	0	0	0.01465202309	0										
11303694	4524	D003920	MTHFR | Methylenetetrahydrofolate reductase | methylenetetrahydrofolate reductase	diabetes mellitus	0	0	0.01292364765	0										
11303694	4524	D006973	MTHFR | Methylenetetrahydrofolate reductase | methylenetetrahydrofolate reductase	hypertension	0	0	0.02095783688	0										
11303694	4524	D009203	MTHFR | Methylenetetrahydrofolate reductase | methylenetetrahydrofolate reductase	premature myocardial infarction	1	1	0.9603817463	0										
11328206	1636	D000544	ACE | angiotensin-converting enzyme	Alzheimer's dementia | Alzheimer's disease	0	1	0.9592172503	1	0			Dr		1			m	Paraoxonase, ACE, and MTHFR polymorphisms were not associated with VD or LOAD
11328206	1636	D003704	ACE | angiotensin-converting enzyme	dementia	0	0	0.01125947293	0										
11328206	1636	D015140	ACE | angiotensin-converting enzyme	vascular dementia	0	0	0.05019047856	0										
11328206	348	D000544	apo E	Alzheimer's dementia | Alzheimer's disease	1	1	0.808814466	0										
11328206	348	D003704	apo E	dementia	0	0	0.00418265909	0										
11328206	348	D015140	apo E	vascular dementia	1	0	0.0153378658	1	1			Dk	n		1	1	m	epsilon4 allele was more frequent in LOAD (17.5%) and VD (13.3%) compared with controls (9.2%), but the difference was not statistically significant.
11328206	4524	D000544	MTHFR | methylenetetrahydrofolate reductase	Alzheimer's dementia | Alzheimer's disease	0	1	0.98454988	1	0					1			m	Paraoxonase, ACE, and MTHFR polymorphisms were not associated with VD or LOAD
11328206	4524	D003704	MTHFR | methylenetetrahydrofolate reductase	dementia	0	0	0.02362857759	0										
11328206	4524	D015140	MTHFR | methylenetetrahydrofolate reductase	vascular dementia	0	0	0.3350259066	0										
11328206	5444	D000544	Paraoxonase | paraoxonase	Alzheimer's dementia | Alzheimer's disease	0	1	0.57044065	1	0					1			m	Paraoxonase, ACE, and MTHFR polymorphisms were not associated with VD or LOAD
11328206	5444	D003704	Paraoxonase | paraoxonase	dementia	0	0	0.00489788875	0										
11328206	5444	D015140	Paraoxonase | paraoxonase	vascular dementia	0	0	0.01540330611	0										
11373419	3929	D018805	LBP | lipopolysaccharide binding protein	lethality of sepsis | sepsis	1	1	0.9945322275	0										
11373419	6690	D018805	PstI	lethality of sepsis | sepsis	0	0	0.02591617964	0										
11373419	671	D018805	BPI | bactericidal/permeability increasing protein	lethality of sepsis | sepsis	1	0	0.4420681894	1	0				S	1			m	The genotype frequencies in the BPI gene did not differ between patients and control individuals.
11378843	2558	D001714	GABRA5	bipolar | bipolar affective disorder | bipolar affective illness | bipolar disorder	1	1	0.9784467816	0										
11378843	2558	D019964	GABRA5	affective disorders	0	0	0.0276556313	0										
11378843	2562	D001714	GABRB3	bipolar | bipolar affective disorder | bipolar affective illness | bipolar disorder	0	1	0.9360753894	1	0					1			e	In conclusion, the GABRB3 CA-repeat polymorphism we investigated does not present the observed association between bipolar affective illness and GABRA5.
11378843	2562	D019964	GABRB3	affective disorders	0	0	0.02177616023	0										
11438180	3123	D009103	HLA DRB1	MS | multiple sclerosis	0	1	0.9886373878	1	0									
11438180	356	D009103	Fas ligand	MS | multiple sclerosis	1	1	0.9902194142	0										
11454514	3630	D003920	insulin	diabetes | diabetic	0	0	0.003436480649	0										
11454514	3630	D003924	insulin	type 2 diabetes mellitus	0	0	0.01438144315	0										
11454514	3630	D009765	insulin	obesity	0	0	0.06782431901	0										
11454514	7421	D003920	VDR | Vitamin D receptor | vitamin D receptor	diabetes | diabetic	0	0	0.01112359203	0										
11454514	7421	D003924	VDR | Vitamin D receptor | vitamin D receptor	type 2 diabetes mellitus	0	1	0.926187396	1	0.5			Dk	n	1	1	1	m	VDR is not a major gene for T2DM in French Caucasians. However, polymorphisms in the VDR gene are associated with the susceptibility to obesity in subjects with early-onset T2DM.
11454514	7421	D009765	VDR | Vitamin D receptor | vitamin D receptor	obesity	1	1	0.9899851084	0										
11470490	146	D006330	alpha1	heart malformations	0	0	0.01310536265	0										
11470490	146	D018636	alpha1	hypoplastic left heart syndrome	0	0	0.03754367679	0										
11470490	2697	D006330	connexin43	heart malformations	0	1	0.9760969877	1	1	only							mbg	Previous results have shown that connexin43 channels are intricately gated by phosphorylation and that disruption of this regulation gives rise to severe heart malformations and defects of laterality in human, chick and frog.
11470490	2697	D018636	connexin43	hypoplastic left heart syndrome	1	1	0.986271143	0										
11502906	1641	C536298	DCX	agyria and pachygyria	0	0	0.005348862149	0										
11502906	1641	D000014	DCX	malformations	0	0	0.003716111649	0										
11502906	1641	D054082	DCX	lissencephaly	0	0	0.02270424552	0										
11502906	1641	D054221	DCX	Classical lissencephaly	0	0	0.01719583012	0	1	only	1						1bg	Classical lissencephaly is a disorder of neuroblast migration with most patients having mutations of either the LIS1 or DCX genes.
11502906	5048	C536298	LIS1	agyria and pachygyria	0	1	0.8216513991	1	1	only, ann d		Dk	n				m	Most patients with lissencephaly secondary to LIS1 mutations have a severe malformation consisting of generalized agyria and pachygyria.
11502906	5048	D000014	LIS1	malformations	0	1	0.9718994498	1	1	ann d			n				e	The authors suggest that the few patients found thus far with missense mutations of LIS1 results from an underascertainment of patients with more subtle malformations and that abnormalities of the LIS1 gene may account for a greater spectrum of neurologic problems in childhood than has previously been appreciated.
11502906	5048	D054082	LIS1	lissencephaly	0	1	0.987778604	1	1		1						0	LIS1 missense mutations cause milder lissencephaly phenotypes including a child with normal IQ.
11502906	5048	D054221	LIS1	Classical lissencephaly	1	0	0.4677972198	1	1	only	1						1bg	Classical lissencephaly is a disorder of neuroblast migration with most patients having mutations of either the LIS1 or DCX genes.
11522684	2353	D007027	c-Fos	hypothalamic	0	0	0.06554929167	0										
11522684	2353	D009765	c-Fos	obese | obesity | obesity onset	0	1	0.7586889267	1	0									
11522684	9607	D007027	CART | Cocaine- and amphetamine-regulated transcript	hypothalamic	0	0	0.07046493143	0										
11522684	9607	D009765	CART | Cocaine- and amphetamine-regulated transcript	obese | obesity | obesity onset	1	1	0.9943911433	0										
11558492	348	D000544	APOE | apolipoprotein E	Alzheimer's disease	1	1	0.9941012263	0										
11558492	348	D058225	APOE | apolipoprotein E	Abeta deposition	0	1	0.5417140722	1	0					1			m	The amount of Abeta deposition was independent of APOE genotype in our cohort.
11558492	351	D000544	Abeta	Alzheimer's disease	0	1	0.8945940733	1	0									
11558492	351	D058225	Abeta	Abeta deposition	0	0	0.004777967464	0										
11578815	4137	C564486	FTDP-17 | microtubule associated protein, tau	parkinsonism linked	0	0	0.01335272845	0										
11578815	4137	D003704	FTDP-17 | microtubule associated protein, tau	dementia	0	0	0.008557124995	0										
11578815	4137	D013494	FTDP-17 | microtubule associated protein, tau	PSP | supranuclear palsy	1	1	0.991963625	0										
11578815	4137	D024801	FTDP-17 | microtubule associated protein, tau	tauopathies	0	0	0.4870464802	0										
11595595	1234	D006679	CCR5 | ccr5	HIV seropositive	0	0	0.1016749963	0										
11595595	1234	D007239	CCR5 | ccr5	infection	0	0	0.01840396598	0										
11595595	1234	D015658	CCR5 | ccr5	HIV-1 infection	1	1	0.7407260537	0										
11668623	5092	D003920	DCoH | DcoH | PCBD | dimerization cofactor of HNF-1	diabetes | diabetes mellitus | diabetic	0	0	0.01069995388	0										
11668623	5092	D003924	DCoH | DcoH | PCBD | dimerization cofactor of HNF-1	type 2 diabetes	1	1	0.9819451571	0										
11668623	5092	D003928	DCoH | DcoH | PCBD | dimerization cofactor of HNF-1	diabetic renal dysfunction	0	0	0.01414613426	0										
11668623	5092	D007674	DCoH | DcoH | PCBD | dimerization cofactor of HNF-1	nephropathy	0	1	0.5605883002	1	0									
11668623	6927	D003920	HNF-1	diabetes | diabetes mellitus | diabetic	0	0	0.002435822971	0										
11668623	6927	D003924	HNF-1	type 2 diabetes	0	0	0.01057199016	0										
11668623	6927	D003928	HNF-1	diabetic renal dysfunction	0	0	0.003181855893	0										
11668623	6927	D007674	HNF-1	nephropathy	0	0	0.006173902657	0										
11668623	6928	D003920	HNF-1beta | MODY5 | TCF2 | hepatocyte nuclear factor-1beta	diabetes | diabetes mellitus | diabetic	0	0	0.01506678294	0										
11668623	6928	D003924	HNF-1beta | MODY5 | TCF2 | hepatocyte nuclear factor-1beta	type 2 diabetes	1	1	0.9802784324	0										
11668623	6928	D003928	HNF-1beta | MODY5 | TCF2 | hepatocyte nuclear factor-1beta	diabetic renal dysfunction	0	0	0.3221828341	0										
11668623	6928	D007674	HNF-1beta | MODY5 | TCF2 | hepatocyte nuclear factor-1beta	nephropathy	0	0	0.4191400111	0										
11675150	1543	D008175	CYP1A1	lung cancer	1	1	0.6430145502	0										
11675150	1571	D008175	CYP2E1	lung cancer	1	1	0.9542853236	0										
11675150	2944	D008175	GSTM1	lung cancer	1	1	0.9942037463	0										
11675150	717	D008175	c2 and 2	lung cancer	0	0	0.01436232217	0										
11712813	7515	D015179	XRCC1	colorectal cancer	1	1	0.993399024	0										
11789558	7421	D000230	VDR | vitamin D receptor	adenocarcinoma	0	0	0.09510445595	0										
11789558	7421	D011471	VDR | vitamin D receptor	aggressive prostate cancer | prostate cancer	1	1	0.9944429994	0										
11819862	3123	D019693	DRB1 | HLA | HLA-DRB1	autoimmune hepatitis	1	1	0.9896887541	0										
11819862	3126	D019693	DR4	autoimmune hepatitis	0	1	0.9213750958	1	1		1	Dk					e	AIH in Chinese is associated with HLA-DR4.
11829455	1672	D029424	beta-defensin-1 | hBD-1	COPD | Chronic obstructive pulmonary disease | chronic obstructive pulmonary disease	1	1	0.9931749701	0										
11829455	1672	D029481	beta-defensin-1 | hBD-1	chronic bronchitis	0	0	0.3080851734	0										
11857065	3123	D001172	DRB1 | HLA-DRB1	RA | Rheumatoid arthritis | rheumatoid arthritis	1	1	0.9946746826	0										
11857576	1621	D001289	DBH | dopamine-beta-hydroxylase	ADHD | Attention-deficit/hyperactivity disorder | attention-deficit/hyperactivity disorder	1	1	0.9937500358	0										
11857576	1621	D001523	DBH | dopamine-beta-hydroxylase	psychiatric disorder	0	0	0.008957498707	0										
11857576	1621	D006948	DBH | dopamine-beta-hydroxylase	hyperactive	0	0	0.0112606464	0										
11857576	1621	D051271	DBH | dopamine-beta-hydroxylase	impulsive symptoms	0	0	0.01002954226	0										
11860278	1812	D004827	D1/D2 receptor	epilepsy | epileptic seizures	0	1	0.6392918229	1	0.5	only		GiDi					1bg	Dopamine (DA), through D1/D2 receptor-mediated signaling, plays a major role in the control of epileptic seizures arising in the limbic system.
11860278	1812	D012640	D1/D2 receptor	seizures	0	0	0.02348145656	0										
11860278	1812	D019636	D1/D2 receptor	neurodegeneration	0	0	0.005993389059	0										
11860278	1812	D020258	D1/D2 receptor	neurotoxicity	0	0	0.004315261263	0										
11860278	1813	D004827	D2R | Dopamine D2 receptor	epilepsy | epileptic seizures	0	0	0.1228047237	0										
11860278	1813	D012640	D2R | Dopamine D2 receptor	seizures	1	1	0.9820076823	0										
11860278	1813	D019636	D2R | Dopamine D2 receptor	neurodegeneration	0	0	0.01022995356	0										
11860278	1813	D020258	D2R | Dopamine D2 receptor	neurotoxicity	0	0	0.0469128266	0										
11860821	183	D006973	AGT | angiotensinogen	hypertension	1	1	0.9247285128	0										
11860821	183	D009101	AGT | angiotensinogen	MM	0	0	0.1630114466	0										
11912155	3283	C537243	HSD3B | HSD3B1	hereditary prostate cancer | hereditary type of prostate cancer	0	0	0.01617209427	0										
11912155	3283	D011471	HSD3B | HSD3B1	prostate cancer | sporadic prostate cancer	1	1	0.9908151627	0										
11912155	3284	C537243	HSD3B2	hereditary prostate cancer | hereditary type of prostate cancer	0	0	0.01199610997	0										
11912155	3284	D011471	HSD3B2	prostate cancer | sporadic prostate cancer	1	1	0.9637457728	0										
11934439	10	D001943	N-acetyltransferases 2 | NAT2	breast cancer	1	1	0.9911252856	0										
11934439	10	D009369	N-acetyltransferases 2 | NAT2	cancer	0	0	0.01417445112	0										
11934439	1543	D001943	CYP1A1	breast cancer	1	1	0.9877581	0										
11934439	1543	D009369	CYP1A1	cancer	0	0	0.003722035559	0										
11934439	2944	D001943	GSTM1	breast cancer	1	1	0.9913595319	0										
11934439	2944	D009369	GSTM1	cancer	0	0	0.02650733292	0										
11934439	2952	D001943	GSTT1	breast cancer	1	1	0.990567863	0										
11934439	2952	D009369	GSTT1	cancer	0	0	0.01524073351	0										
11934439	373156	D001943	glutathione S-transferase	breast cancer	0	1	0.9786449671	1	0									
11934439	373156	D009369	glutathione S-transferase	cancer	0	0	0.002813363215	0										
11940086	19	D003324	ABCA1	coronary artery disease	1	1	0.9921602607	0										
11940086	19	D050197	ABCA1	atherosclerosis	0	1	0.9888472557	1	1		1						e	These data suggest that common variation in non-coding regions of ABCA1 may significantly alter the severity of atherosclerosis, without necessarily influencing plasma lipid levels.
11943931	2153	D009101	factor V Leiden	MM | multiple myeloma | myeloma	1	1	0.9682815075	0										
11943931	2153	D011125	factor V Leiden	APC	0	0	0.02467324771	0										
11943931	2153	D013923	factor V Leiden	Thromboembolism	0	0	0.01283431053	0										
11943931	2153	D013927	factor V Leiden	thrombotic complications	0	1	0.9545058608	1	1		1						0	Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications.
11943931	2153	D019851	factor V Leiden	hypercoagulability	1	0	0.03347685933	1	0									
11943931	2153	D020246	factor V Leiden	deep venous thrombosis	1	0	0.3878289759	1	0			n						
11950517	3565	D000544	IL4 | Interleukin-4	AD | Alzheimer's disease	1	1	0.9943314791	0										
11950517	3565	D007249	IL4 | Interleukin-4	inflammation	0	1	0.6664363146	1	1	only							1bg	Interleukin-4 (IL4) is an anti-inflammatory cytokine that may play a role in the inflammation pathology observed surrounding senile plaques, and may also associate with Alzheimer's disease (AD) pathogenesis.
11950863	8481	D009958	Cxorf5 | OFD1	oral-facial-digital syndrome	1	1	0.9802587032	0										
11956643	367	D009369	AR | androgen receptor	tumor	0	0	0.009096583351	0										
11956643	367	D010051	AR | androgen receptor	ovarian cancer	1	1	0.9943512678	0										
11978563	3119	C537055	DQB1	alopecia universalis	0	0	0.006634281017	0										
11978563	3119	D000505	DQB1	alopecia totalis/alopecia	0	0	0.006688296795	0										
11978563	3119	D000506	DQB1	alopecia areata	1	1	0.9889926314	0										
11978563	3123	C537055	DRB1	alopecia universalis	0	0	0.004946605768	0										
11978563	3123	D000505	DRB1	alopecia totalis/alopecia	0	0	0.004995342344	0										
11978563	3123	D000506	DRB1	alopecia areata	1	1	0.89105618	0										
12022286	2153	D012170	factor V Leiden	retinal vein occlusion | retinal vein occlusions	1	1	0.9794305563	0										
12022286	2153	D013927	factor V Leiden	thrombotic	0	0	0.1503624916	0										
12022286	2153	D019851	factor V Leiden	thrombophilic	0	1	0.6634699106	1	0									
12022286	2153	D020521	factor V Leiden	occlusive vascular accident	0	0	0.01002931036	0										
12023989	100760716	D003643	insulin	death	0	0	0.002817740897	0										
12023989	100760716	D007333	insulin	impaired insulin	0	0	0.005893976428	0										
12023989	100760716	D044882	insulin	altered glucose homeostasis	0	0	0.002951873234	0										
12023989	100760716	D056731	insulin	Rabson-Mendenhall syndrome | inherited insulin-resistant disorders leprechaunism | leprechaunism	0	0	0.07300254703	0										
12023989	3630	D003643	insulin	death	0	0	0.003563497681	0										
12023989	3630	D007333	insulin	impaired insulin	0	0	0.004916154779	0										
12023989	3630	D044882	insulin	altered glucose homeostasis	0	0	0.003834217321	0										
12023989	3630	D056731	insulin	Rabson-Mendenhall syndrome | inherited insulin-resistant disorders leprechaunism | leprechaunism	0	0	0.3347650468	0										
12023989	3643	D003643	insulin receptor	death	0	0	0.006379050668	0										
12023989	3643	D007333	insulin receptor	impaired insulin	0	0	0.02814431116	0										
12023989	3643	D044882	insulin receptor	altered glucose homeostasis	0	0	0.00713379262	0										
12023989	3643	D056731	insulin receptor	Rabson-Mendenhall syndrome | inherited insulin-resistant disorders leprechaunism | leprechaunism	1	1	0.9644517899	0										
12043886	1636	D005076	ACE | Angiotensin-converting enzyme	malar rash	0	0	0.01515924837	0										
12043886	1636	D006973	ACE | Angiotensin-converting enzyme	hypertension	0	0	0.005612292327	0										
12043886	1636	D007674	ACE | Angiotensin-converting enzyme	renal dysfunction | renal involvement	0	0	0.09779452533	0										
12043886	1636	D008180	ACE | Angiotensin-converting enzyme	SLE | Systemic lupus erythematosus	1	1	0.9838013053	0										
12043886	1636	D008181	ACE | Angiotensin-converting enzyme	lupus nephritis	0	1	0.5119127631	1	0					1			m	There were no significant differences between the distribution of ACE gene genotypes and lupus nephritis and its related parameters, including WHO classification, activity index, chronicity index, renal dysfunction and amount of 24 h urinary protein.
12043886	1636	D009393	ACE | Angiotensin-converting enzyme	nephritis	0	0	0.006032326724	0										
12043886	1636	D012700	ACE | Angiotensin-converting enzyme	serositis	0	0	0.3572539985	0										
12043886	1636	D014652	ACE | Angiotensin-converting enzyme	vascular involvement	0	0	0.01123229414	0										
12043886	1636	D056587	ACE | Angiotensin-converting enzyme	inflammatory multisystem disease	0	0	0.007367680781	0										
12043886	183	D005076	angiotensin II	malar rash	0	0	0.003379614325	0										
12043886	183	D006973	angiotensin II	hypertension	0	0	0.002335451543	0										
12043886	183	D007674	angiotensin II	renal dysfunction | renal involvement	0	0	0.003527924651	0										
12043886	183	D008180	angiotensin II	SLE | Systemic lupus erythematosus	0	0	0.005440510809	0										
12043886	183	D008181	angiotensin II	lupus nephritis	0	0	0.002316242084	0										
12043886	183	D009393	angiotensin II	nephritis	0	0	0.00239738985	0										
12043886	183	D012700	angiotensin II	serositis	0	0	0.009294378571	0										
12043886	183	D014652	angiotensin II	vascular involvement	0	0	0.002278830623	0										
12043886	183	D056587	angiotensin II	inflammatory multisystem disease	0	0	0.002526432509	0										
12072061	3857	D006331	EPPK | K9 | k9 | keratin 9	heart disease	0	1	0.6317618489	1	0			Dm						
12072061	3857	D007645	EPPK | K9 | k9 | keratin 9	palmoplantar keratoderma	0	1	0.9855223894	1	0			Dm						
12072061	3857	D009369	EPPK | K9 | k9 | keratin 9	cancer	0	0	0.02383668721	0										
12072061	3857	D015776	EPPK | K9 | k9 | keratin 9	diffuse palmoplantar keratoderma	0	1	0.9266119599	1	0			Dm						
12072061	3857	D053546	EPPK | K9 | k9 | keratin 9	confirmation of epidermolytic palmoplantar keratoderma	1	1	0.7793753743	0										
12080446	2559	D007029	GABRA6	hypothalamic-pituitary-adrenal systems	0	0	0.01541451178	0										
12080446	2559	D009765	GABRA6	obesity	1	1	0.885479033	0										
12080446	2559	D056128	GABRA6	abdominal obesity | hypercortisolism and perhaps abdominal obesity	0	1	0.9905818701	1	1		1						e	These findings suggest a role of the 1519T&gt;C polymorphism in GABRA6 in the predisposition to hypercortisolism and perhaps abdominal obesity.
12101111	1029	D001523	CDKN2 | INK4a | MTS-1 | p16	tumor aggressiveness	0	0	0.1295816749	0										
12101111	1029	D002294	CDKN2 | INK4a | MTS-1 | p16	squamous cell carcinoma	0	1	0.9474303722	1	0			Dik	n	1			e	None of these differences were statistically significant. We conclude that these polymorphic p16 genotypes or haplotypes may not play a major role in the etiology of SCCHN
12101111	1029	D006258	CDKN2 | INK4a | MTS-1 | p16	head and neck cancer	1	1	0.9170783162	0	1	only							1bg	The frequent loss or promoter methylation of the tumor suppressor gene p16 in head and neck cancer suggests an etiologic role of p16 in this disease.
12101111	1029	D009369	CDKN2 | INK4a | MTS-1 | p16	tumor	0	0	0.08356589079	0										
12101111	7157	D001523	p53	tumor aggressiveness	0	0	0.01168558467	0										
12101111	7157	D002294	p53	squamous cell carcinoma	0	0	0.006512104068	0										
12101111	7157	D006258	p53	head and neck cancer	0	0	0.003635627218	0										
12101111	7157	D009369	p53	tumor	0	0	0.003219408914	0										
12111193	7248	D004194	TSC | TSC1	multisystem disease	0	0	0.4163476825	0										
12111193	7248	D014402	TSC | TSC1	Tuberous sclerosis | tuberous sclerosis	1	1	0.9400777221	0										
12111193	7249	D004194	TSC2	multisystem disease	0	0	0.01077458635	0										
12111193	7249	D014402	TSC2	Tuberous sclerosis | tuberous sclerosis	1	1	0.5335872173	0										
12126966	6352	D006528	RANTES | regulated upon activation, normal T-cell expressed and secreted	hepatoma	0	1	0.6920817494	1	0									
12126966	6352	D008105	RANTES | regulated upon activation, normal T-cell expressed and secreted	primary biliary cirrhosis	1	1	0.9943040013	0										
12138283	4846	D003920	ecNOS | endothelial nitric oxide synthase	diabetic hemodialysis	0	0	0.01998859458	0										
12138283	4846	D003928	ecNOS | endothelial nitric oxide synthase	diabetic nephropathy	0	0	0.09978356212	0										
12138283	4846	D007674	ecNOS | endothelial nitric oxide synthase	nondiabetic nephropathy | renal disease	1	1	0.986315906	0										
12138283	4846	OMIM:612551	ecNOS | endothelial nitric oxide synthase	nondiabetic hemodialysis	0	0	0.01730471663	0										
12148094	1636	D006973	ACE | Angiotensin-converting enzyme	hypertension	0	0	0.1519929022	0										
12148094	1636	D007674	ACE | Angiotensin-converting enzyme	kidney disease | renal diseases	1	1	0.9871997237	0										
12148094	183	D006973	angiotensin II	hypertension	0	0	0.0100179771	0										
12148094	183	D007674	angiotensin II	kidney disease | renal diseases	0	0	0.01100744307	0										
12181777	672	D001943	BRCA1	breast cancer	0	1	0.9225334525	1	1		1						m	The prevalence of BRCA1 or BRCA2 mutations among case subjects with breast cancer was 6.7% (95% confidence interval [CI] 4.1%-9.4%), and that among case subjects with ovarian cancer was 15.8% (95% CI 9.2%-22.4%).
12181777	672	D009369	BRCA1	cancer	0	0	0.01298716571	0										
12181777	672	D010051	BRCA1	ovarian cancer	1	1	0.825283587	0	1		1						m	The prevalence of BRCA1 or BRCA2 mutations among case subjects with breast cancer was 6.7% (95% confidence interval [CI] 4.1%-9.4%), and that among case subjects with ovarian cancer was 15.8% (95% CI 9.2%-22.4%).
12181777	672	D061325	BRCA1	breast and ovarian cancer	0	1	0.9688115716	1	1								e	These results suggest that recessively inherited genes may contribute to breast and ovarian cancer risk in Pakistan.
12181777	675	D001943	BRCA2	breast cancer	0	1	0.5699082017	1	1		1						m	The prevalence of BRCA1 or BRCA2 mutations among case subjects with breast cancer was 6.7% (95% confidence interval [CI] 4.1%-9.4%), and that among case subjects with ovarian cancer was 15.8% (95% CI 9.2%-22.4%).
12181777	675	D009369	BRCA2	cancer	0	0	0.0135764908	0										
12181777	675	D010051	BRCA2	ovarian cancer	1	0	0.4566792548	1	1		1						m	The prevalence of BRCA1 or BRCA2 mutations among case subjects with breast cancer was 6.7% (95% confidence interval [CI] 4.1%-9.4%), and that among case subjects with ovarian cancer was 15.8% (95% CI 9.2%-22.4%).
12181777	675	D061325	BRCA2	breast and ovarian cancer	0	1	0.9680212736	1	1								e	These results suggest that recessively inherited genes may contribute to breast and ovarian cancer risk in Pakistan.
12186157	1636	C562935	ACE | angiotensin converting enzyme	lipid abnormalities	0	0	0.01087674592	0										
12186157	1636	D003327	ACE | angiotensin converting enzyme	coronary heart disease	0	0	0.01558922231	0										
12186157	1636	D020138	ACE | angiotensin converting enzyme	hyperhomocysteinemia	0	0	0.03221963719	0										
12186157	1636	D030342	ACE | angiotensin converting enzyme	atherothrombotic disease	0	0	0.003197511425	0										
12186157	335	C562935	Apo A1	lipid abnormalities	0	0	0.01139244623	0										
12186157	335	D003327	Apo A1	coronary heart disease	0	0	0.01693395525	0										
12186157	335	D020138	Apo A1	hyperhomocysteinemia	0	0	0.02216149867	0										
12186157	335	D030342	Apo A1	atherothrombotic disease	0	0	0.003045863472	0										
12186157	4524	C562935	5,10-methylenetetrahydrofolate reductase | MTHFR | Methylenetetrahydrofolate reductase	lipid abnormalities	0	0	0.3826656044	0										
12186157	4524	D003327	5,10-methylenetetrahydrofolate reductase | MTHFR | Methylenetetrahydrofolate reductase	coronary heart disease	1	1	0.9666697979	0										
12186157	4524	D020138	5,10-methylenetetrahydrofolate reductase | MTHFR | Methylenetetrahydrofolate reductase	hyperhomocysteinemia	1	1	0.9821924567	0										
12186157	4524	D030342	5,10-methylenetetrahydrofolate reductase | MTHFR | Methylenetetrahydrofolate reductase	atherothrombotic disease	0	0	0.009399607778	0										
12186157	875	C562935	CBS | cystathionine beta-synthase	lipid abnormalities	0	0	0.05446412042	0										
12186157	875	D003327	CBS | cystathionine beta-synthase	coronary heart disease	1	0	0.0756644085	1	0									
12186157	875	D020138	CBS | cystathionine beta-synthase	hyperhomocysteinemia	1	0	0.0732479766	1	1			Dk					m	Heterozygosity for T833C mutation in the CBS gene was observed in 9.99% (2/22) of our patients with HCA.
12186157	875	D030342	CBS | cystathionine beta-synthase	atherothrombotic disease	0	0	0.004610727541	0										
12227853	335	D003324	apolipoprotein AI	coronary artery disease	0	0	0.004317925777	0										
12227853	949	D003324	SR-BI	coronary artery disease	1	1	0.6501563191	0										
12351377	1050	D007938	C/EBPalpha | CEBPA	Leukemia	0	1	0.7445037961	1	0			Di						
12351377	1050	D015470	C/EBPalpha | CEBPA	AML | acute myeloid leukemia	1	1	0.9859082103	0										
12351377	1050	D054198	C/EBPalpha | CEBPA	Acute Leukemia	0	0	0.2685392201	0										
12351377	2322	D007938	FLT3	Leukemia	0	0	0.006269753911	0										
12351377	2322	D015470	FLT3	AML | acute myeloid leukemia	0	0	0.01926933229	0										
12351377	2322	D054198	FLT3	Acute Leukemia	0	0	0.01087304763	0										
12399943	4916	D016584	NTRK3	panic disorder	1	1	0.9847069383	0										
12437612	1234	D001249	CCR5 | chemokine receptor 5	asthma	1	1	0.9947257638	0										
12485445	4153	D003882	MBL	dermatomyositis	1	1	0.9901400208	0										
12485445	4153	D008178	MBL	cutaneous lupus erythematosus	1	0	0.1813712865	1	0					1			m	None of the three variant MBL alleles considered individually was significantly associated with either subacute cutaneous lupus erythematosus or discoid lupus.
12485445	4153	D008179	MBL	discoid lupus	0	0	0.3068536818	0	0					1			m	None of the three variant MBL alleles considered individually was significantly associated with either subacute cutaneous lupus erythematosus or discoid lupus.
12485445	4153	D010787	MBL	photosensitive autoimmunity	0	0	0.4276840687	0										
12485445	4153	D012871	MBL	autoimmune skin disease | autoimmune skin diseases	0	0	0.008429015987	0										
12485445	4153	D058495	MBL	decreased MBL protein	0	1	0.6379776001	1	0			Di						
12485445	7124	D003882	TNFalpha | tumor necrosis factor alpha	dermatomyositis	0	1	0.6788961887	1	1	only	1						mbg	We previously found an association of the overproducing TNFalpha-308 A variant with adult dermatomyositis and with subacute cutaneous lupus erythematosus.
12485445	7124	D008178	TNFalpha | tumor necrosis factor alpha	cutaneous lupus erythematosus	0	0	0.03461953998	0	1	only	1						mbg	We previously found an association of the overproducing TNFalpha-308 A variant with adult dermatomyositis and with subacute cutaneous lupus erythematosus.
12485445	7124	D008179	TNFalpha | tumor necrosis factor alpha	discoid lupus	0	0	0.003879006021	0										
12485445	7124	D010787	TNFalpha | tumor necrosis factor alpha	photosensitive autoimmunity	0	0	0.005048914813	0										
12485445	7124	D012871	TNFalpha | tumor necrosis factor alpha	autoimmune skin disease | autoimmune skin diseases	0	0	0.009308952838	0										
12485445	7124	D058495	TNFalpha | tumor necrosis factor alpha	decreased MBL protein	0	0	0.008147038519	0										
12501224	5053	C535569	phenylalanine hydroxylase	psychosocial burden	0	0	0.02072187886	0										
12501224	5053	D010661	phenylalanine hydroxylase	Hyperphenylalaninemia | classic phenylketonuria | hyperphenylalaninemia | phenylalanine hydroxylase deficiency | phenylketonuria	1	1	0.9803512692	0										
12501224	5053	D030342	phenylalanine hydroxylase	inherited metabolic disease	0	0	0.003718877444	0										
12508391	4843	D001327	NOS2 | Nitric oxide synthase 2 | inducible NO synthase	autoimmune disease	0	0	0.02091445029	0										
12508391	4843	D008180	NOS2 | Nitric oxide synthase 2 | inducible NO synthase	SLE | lupus erythematosus | systemic lupus erythematosus	1	1	0.9949170351	0										
12508391	4843	D008288	NOS2 | Nitric oxide synthase 2 | inducible NO synthase	malaria	0	0	0.1807841808	0										
12516098	5727	C537538	PTCH1 | Ptch1	Drosophila segment polarity	0	0	0.07742036134	0										
12516098	5727	D001943	PTCH1 | Ptch1	breast cancer | breast carcinoma | breast carcinomas	1	1	0.9945530891	0										
12516098	5727	D009369	PTCH1 | Ptch1	cancer | tumors	0	0	0.009578067809	0										
12516098	6469	C537538	SHH	Drosophila segment polarity	0	0	0.002673314884	0										
12516098	6469	D001943	SHH	breast cancer | breast carcinoma | breast carcinomas	0	1	0.9576320648	1	1	only							e	Our novel observation of a differential effect of OC use on breast cancer risk by PTCH1 1315Leu-carrier status suggests the interesting possibility of the Sonic hedgehog/Patched (SHH/PTCH1) signaling pathway being involved in hormone-induced development of breast carcinoma.
12516098	6469	D009369	SHH	cancer | tumors	0	0	0.00252153934	0										
12524158	2944	D010300	GSTM1 | Glutathione S-transferase M1	PD | Parkinson's disease	1	1	0.9868314266	0										
12524158	2950	D010300	GSTP1	PD | Parkinson's disease	1	1	0.9877915382	0										
12524158	2952	D010300	GSTT1	PD | Parkinson's disease	1	1	0.9880886674	0										
12524158	373156	D010300	GSTs | glutathione S-transferases	PD | Parkinson's disease	0	0	0.0197800044	0										
12542551	348	D002318	apolipoprotein E	cardiovascular disease	0	0	0.3234217167	0										
12542551	348	D003327	apolipoprotein E	Coronary heart disease	1	0	0.005080651492	1	0									
12542551	348	D003643	apolipoprotein E	death	0	0	0.01186543703	0										
12542551	3569	D002318	interleukin-6	cardiovascular disease	0	1	0.5537611246	1	0									
12542551	3569	D003327	interleukin-6	Coronary heart disease	1	0	0.006427627522	1	0									
12542551	3569	D003643	interleukin-6	death	0	0	0.01857124828	0										
12542551	4023	D002318	lipoprotein lipase	cardiovascular disease	0	0	0.4566848278	0										
12542551	4023	D003327	lipoprotein lipase	Coronary heart disease	1	0	0.005868770182	1	0									
12542551	4023	D003643	lipoprotein lipase	death	0	0	0.0155318547	0										
12610797	7133	D001172	TNFR2 | Tumor necrosis factor receptor 2 | tumor necrosis factor receptor 2	RA | rheumatoid arthritis	1	1	0.9950278401	0										
12610797	7133	D012218	TNFR2 | Tumor necrosis factor receptor 2 | tumor necrosis factor receptor 2	rheumatoid nodules	0	0	0.05015712976	0										
12610797	7133	D012859	TNFR2 | Tumor necrosis factor receptor 2 | tumor necrosis factor receptor 2	Sjogren's syndrome	0	0	0.04096044973	0										
12651074	3117	D002446	DQA1 | HLA | HLA-DQA1	celiac disease	1	1	0.9934297204	0										
12651074	3119	D002446	DQB1	celiac disease	1	1	0.5957098007	0										
12651074	3123	D002446	DRB1	celiac disease	1	0	0.00603441475	1	0									
12651074	3126	D002446	DRB4	celiac disease	0	0	0.006130870432	0										
12700447	3565	D000163	IL-4	AIDS	0	0	0.1323875785	0										
12700447	3565	D015658	IL-4	HIV infection | HIV-1 disease | HIV-1-infected	1	1	0.9921219349	0										
12727304	322	D000544	APBB1 | FE65	AD | Alzheimer's disease	1	1	0.9909434915	0										
12727304	322	D003704	APBB1 | FE65	dementia	0	0	0.009290365502	0										
12727304	322	D019636	APBB1 | FE65	neurodegenerative disorder	0	0	0.008134436794	0										
12749050	3552	D007239	IL-1 alpha	infection	0	1	0.7107799649	1	0									
12749050	3552	D010019	IL-1 alpha	osteomyelitis	1	1	0.982498765	0										
12749050	3553	D007239	IL-1 | IL-1 beta	infection	0	0	0.003763556248	0										
12749050	3553	D010019	IL-1 | IL-1 beta	osteomyelitis	1	1	0.6625782847	0										
12749050	3569	D007239	IL-6	infection	0	0	0.003846811596	0										
12749050	3569	D010019	IL-6	osteomyelitis	0	1	0.8280814886	1	0									
12749050	7124	D007239	TNF-alpha	infection	0	0	0.003438680666	0										
12749050	7124	D010019	TNF-alpha	osteomyelitis	0	1	0.644525528	1	0									
12756133	4137	C536599	FTDP-17	tau dysfunction	0	0	0.005716662854	0										
12756133	4137	D003704	FTDP-17	dementia	1	0	0.01301965676	1	0			Di						
12756133	4137	D019636	FTDP-17	neurodegeneration	0	0	0.005394328851	0										
12756133	4137	D057180	FTDP-17	FTD | familial FTD	0	1	0.9930452704	1	1		1		M				m	The P301L mutation was detected in 11% of familial FTD cases.
12768194	122481	C562839	AK7	Malignant mesothelioma | malignant mesothelioma	0	0	0.1288641244	0										
12768194	122481	D008654	AK7	mesothelioma	0	0	0.04241244495	0										
12768194	122481	D009101	AK7	MM	0	0	0.007261079736	0										
12768194	122481	D009369	AK7	tumor | tumors	0	0	0.005854580086	0										
12768194	122481	D010411	AK7	fibrous stroma	0	0	0.008606581017	0										
12768194	3458	C562839	IFN-gamma | interferon gamma | interferon gamma (IFN-gamma	Malignant mesothelioma | malignant mesothelioma	0	0	0.2084361166	0										
12768194	3458	D008654	IFN-gamma | interferon gamma | interferon gamma (IFN-gamma	mesothelioma	1	0	0.01839198172	1	0	pmid not sure								
12768194	3458	D009101	IFN-gamma | interferon gamma | interferon gamma (IFN-gamma	MM	0	0	0.004085172433	0										
12768194	3458	D009369	IFN-gamma | interferon gamma | interferon gamma (IFN-gamma	tumor | tumors	0	0	0.003740784945	0										
12768194	3458	D010411	IFN-gamma | interferon gamma | interferon gamma (IFN-gamma	fibrous stroma	0	0	0.004524740856	0										
12768194	7040	C562839	TGF-beta	Malignant mesothelioma | malignant mesothelioma	0	0	0.02476784401	0										
12768194	7040	D008654	TGF-beta	mesothelioma	0	0	0.1199968904	0										
12768194	7040	D009101	TGF-beta	MM	0	0	0.007954518311	0										
12768194	7040	D009369	TGF-beta	tumor | tumors	0	0	0.006371451076	0										
12768194	7040	D010411	TGF-beta	fibrous stroma	0	0	0.009682549164	0										
12778448	185	D006973	AT(1)R | angiotensin II type 1 receptor	hypertension | hypertensive | hypertensives	1	1	0.9947190285	0										
12807755	7421	D015179	VDR | Vitamin D receptor | vitamin D receptor	colorectal cancer | colorectal carcinoma	1	1	0.9944227338	0										
12808428	3084	D012559	neuregulin 1	schizophrenia | schizophrenic	1	1	0.9919676185	0										
12815604	672	D001943	BRCA1	breast cancer	1	1	0.9941171408	0										
12830465	4318	D003928	MMP9 | matrix metalloproteinase 9	diabetic nephropathy	0	0	0.03378469497	0										
12830465	4318	D007674	MMP9 | matrix metalloproteinase 9	renal disease | renal diseases	0	1	0.9938778281	1	1	only							mbg	Expression of the matrix metalloproteinase 9 (MMP9) gene is increased in a variety of renal diseases.
12830465	4318	D007676	MMP9 | matrix metalloproteinase 9	ESRD | end-stage renal disease	1	1	0.9932727814	0										
12837926	6352	D004715	RANTES	endometriosis	1	1	0.9940874577	0										
12837926	6352	D051437	RANTES	endometriotic lesions	0	1	0.7007165551	1	1	only							mbg	The RANTES (regulated upon activation normal T cells expressed and secreted) chemokine, is known to be expressed in endometriotic lesions in a concentration correlating with the severity of endometriosis.
12852830	196	D000544	Ahr | aryl hydrocarbon receptor	AD | Senile dementia | senile dementia	0	1	0.983884275	1	0					1			e	However, it did not support the association of Ahr gene polymorphism with higher risk of senile dementia.
12852830	196	D003704	Ahr | aryl hydrocarbon receptor	dementia	1	0	0.04221370444	1	0									
12852830	2099	D000544	ER-alpha	AD | Senile dementia | senile dementia	0	1	0.9403548837	1	1		1						e	he results suggested that ER-alpha gene polymorphisms might be related to the individual susceptibility to AD
12852830	2099	D003704	ER-alpha	dementia	1	0	0.006022465415	1	0									
12860808	778	C536647	CACNA1F	ophthalmologic	0	0	0.163431555	0										
12860808	778	D001766	CACNA1F	blindness	0	1	0.8326500058	1	0			Di						
12860808	778	D009896	CACNA1F	optic disc atrophy	1	1	0.9940227866	0										
12860808	778	D014786	CACNA1F	decline of visual function | reduction of visual acuity	0	0	0.01195042953	0										
12864773	1636	D004408	ACE	thrombophilic alterations	0	0	0.003498761915	0										
12864773	1636	D013927	ACE	thrombosis	0	0	0.006291353609	0										
12864773	1636	D020246	ACE	deep venous thrombosis	0	0	0.009724420495	0										
12864773	1636	D054556	ACE	venous thromboembolism | venous thromboembolism in hyperhomocysteinaemic	1	1	0.9735429883	0										
12864773	185	D004408	AT1R	thrombophilic alterations	0	0	0.003518705256	0										
12864773	185	D013927	AT1R	thrombosis	0	0	0.006413911469	0										
12864773	185	D020246	AT1R	deep venous thrombosis	0	0	0.00975269638	0										
12864773	185	D054556	AT1R	venous thromboembolism | venous thromboembolism in hyperhomocysteinaemic	0	1	0.9819616675	1	0									
12864773	2153	D004408	Factor V Leiden	thrombophilic alterations	0	0	0.003723549657	0										
12864773	2153	D013927	Factor V Leiden	thrombosis	0	0	0.007030252367	0										
12864773	2153	D020246	Factor V Leiden	deep venous thrombosis	0	0	0.01066278294	0										
12864773	2153	D054556	Factor V Leiden	venous thromboembolism | venous thromboembolism in hyperhomocysteinaemic	0	1	0.986679256	1	0									
12864773	5972	D004408	renin	thrombophilic alterations	0	0	0.003545549931	0										
12864773	5972	D013927	renin	thrombosis	0	0	0.006550010759	0										
12864773	5972	D020246	renin	deep venous thrombosis	0	0	0.1421141028	0										
12864773	5972	D054556	renin	venous thromboembolism | venous thromboembolism in hyperhomocysteinaemic	0	1	0.9617139697	1	0									
12865660	3553	D007249	IL-1beta and 1	inflammation	0	0	0.00432424061	0										
12865660	3553	D009102	IL-1beta and 1	multiple organ failure	0	0	0.002717124298	0										
12865660	3553	D009369	IL-1beta and 1	tumor	0	0	0.003166828072	0										
12865660	3553	D012128	IL-1beta and 1	ARDS | respiratory distress syndrome	0	0	0.006232954562	0										
12865660	3553	D014947	IL-1beta and 1	trauma	0	0	0.002560316818	0										
12865660	3553	D015427	IL-1beta and 1	postischemic reperfusion injury	0	0	0.008195068687	0										
12865660	3553	D018805	IL-1beta and 1	sepsis	0	0	0.004031447694	0										
12865660	3576	D007249	IL-8 | interleukin 8 | interleukin-8	inflammation	0	1	0.9012966156	1	0									
12865660	3576	D009102	IL-8 | interleukin 8 | interleukin-8	multiple organ failure	0	0	0.2650641501	0										
12865660	3576	D009369	IL-8 | interleukin 8 | interleukin-8	tumor	0	0	0.09273163974	0										
12865660	3576	D012128	IL-8 | interleukin 8 | interleukin-8	ARDS | respiratory distress syndrome	0	1	0.9752013683	1	0									
12865660	3576	D014947	IL-8 | interleukin 8 | interleukin-8	trauma	0	0	0.04741989449	0										
12865660	3576	D015427	IL-8 | interleukin 8 | interleukin-8	postischemic reperfusion injury	1	1	0.981556654	0										
12865660	3576	D018805	IL-8 | interleukin 8 | interleukin-8	sepsis	0	1	0.9544109702	1	0									
12921568	7157	C562729	p53	esophageal squamous cell carcinoma	0	0	0.01309127174	0										
12921568	7157	D002289	p53	non-small cell lung carcinoma	0	0	0.1710202843	0										
12921568	7157	D004938	p53	esophageal cancer	1	1	0.8274388313	0										
12921568	7157	D008175	p53	lung cancer	1	1	0.9809635878	0										
12921568	7157	D009369	p53	cancer | cancers	0	0	0.006324601825	0										
12926068	330	D001749	cIAP-2	bladder cancer | bladder tumour	1	1	0.988109827	0										
12926068	330	D009369	cIAP-2	tumours	0	0	0.007737324107	0										
12926068	355	D001749	CD95	bladder cancer | bladder tumour	0	0	0.0848960802	0										
12926068	355	D009369	CD95	tumours	0	0	0.003707311116	0										
12926068	8743	D001749	TRAIL	bladder cancer | bladder tumour	0	0	0.1413743943	0										
12926068	8743	D009369	TRAIL	tumours	0	0	0.004192656837	0										
12928512	348	D000544	APOE | apolipoprotein	AD | Alzheimer Disease | Alzheimer's disease	1	1	0.994194448	0										
12944983	3586	D011565	IL-10 | interleukin-10	psoriasis	1	1	0.9941260815	0										
14512715	348	D000544	ApoE | Apolipoprotein E | apolipoprotein E	AD | Alzheimer's disease	1	1	0.9917533398	0										
14512715	348	D003704	ApoE | Apolipoprotein E | apolipoprotein E	dementia	0	0	0.09245330095	0										
14512715	348	D015140	ApoE | Apolipoprotein E | apolipoprotein E	vascular dementia	1	0	0.02161524259	1	0		1	Dk		1			e	The present study demonstrates a strong association between the ApoE epsilon4 allele and AD, but not between the ApoE epsilon4 allele and VaD.
14517949	64324	C537340	NSD1	autosomal dominant overgrowth syndrome	0	0	0.005577010568	0										
14517949	64324	D008607	NSD1	mental retardation	0	0	0.004453575704	0										
14517949	64324	D019465	NSD1	craniofacial dysmorphic features	0	0	0.004662882537	0										
14517949	64324	D058495	NSD1	Sotos syndrome | haploinsufficiency	1	1	0.906263113	0										
14518562	5743	D000544	COX-2 | cyclooxygenase-2	AD	0	1	0.9594239593	1	0			Di						
14518562	5743	D004827	COX-2 | cyclooxygenase-2	behavioral seizures	0	0	0.008552130312	0										
14518562	5743	D012640	COX-2 | cyclooxygenase-2	convulsions | seizure | seizures	1	1	0.9906715155	0										
14555511	672	D006432	BRCA1 | BRCA1 and 2	HH	0	1	0.8762990832	1	0			Di						
14555511	672	D010051	BRCA1 | BRCA1 and 2	epithelial ovarian cancer | invasive epithelial ovarian cancer | ovarian cancer	1	1	0.9944816828	0										
14555511	672	D061325	BRCA1 | BRCA1 and 2	breast and ovarian cancer	0	0	0.01990503445	0										
14555511	675	D006432	BRCA2	HH	0	1	0.9821096659	1	0			Di						
14555511	675	D010051	BRCA2	epithelial ovarian cancer | invasive epithelial ovarian cancer | ovarian cancer	1	1	0.9712976217	0										
14555511	675	D061325	BRCA2	breast and ovarian cancer	0	0	0.3396037519	0										
14616291	1234	D009103	CCR5 | chemokine receptor-5	multiple sclerosis	1	1	0.9638826251	0										
14616291	1234	D009369	CCR5 | chemokine receptor-5	tumor	0	0	0.00669845473	0										
14616291	1493	D009103	CTLA-4	multiple sclerosis	1	1	0.9561531544	0										
14616291	1493	D009369	CTLA-4	tumor	0	0	0.003605774604	0										
14616291	3586	D009103	IL-10 | interleukin-10	multiple sclerosis	1	1	0.9867406487	0										
14616291	3586	D009369	IL-10 | interleukin-10	tumor	0	0	0.00489165727	0										
14616291	7124	D009103	TNFalpha	multiple sclerosis	1	1	0.7705481648	0										
14616291	7124	D009369	TNFalpha	tumor	0	0	0.003126272233	0										
14633711	6528	D007239	NIS	multiplicity of infection	0	0	0.01490902435	0										
14633711	6528	D009369	NIS	cancer | tumor	0	0	0.01338235568	0										
14633711	6528	D011471	NIS	Prostate cancer | prostate cancer	1	1	0.9945874214	0										
14633711	6528	D011472	NIS	non-prostate tumor	0	0	0.01259866171	0										
14644396	2944	D003327	GSTM1	coronary heart disease	0	0	0.07863702625	0										
14644396	2944	D007249	GSTM1	inflammation	0	1	0.9864576459	1	1								e	The results of this study provide some limited evidence that GSTM1 and GSTT1 polymorphisms modify the effect of smoking on inflammation
14644396	2944	D014842	GSTM1	von Willebrand	0	0	0.2048287243	0										
14644396	2944	D050197	GSTM1	atherosclerosis	1	0	0.1449009329	1	0									
14644396	2952	D003327	GSTT1 | GSTT1-1	coronary heart disease	0	0	0.107394889	0										
14644396	2952	D007249	GSTT1 | GSTT1-1	inflammation	0	1	0.9894757271	1	1								e	The results of this study provide some limited evidence that GSTM1 and GSTT1 polymorphisms modify the effect of smoking on inflammation
14644396	2952	D014842	GSTT1 | GSTT1-1	von Willebrand	0	0	0.02333126962	0										
14644396	2952	D050197	GSTT1 | GSTT1-1	atherosclerosis	1	0	0.07758587599	1	0									
14644396	3383	D003327	ICAM-1	coronary heart disease	0	0	0.003629457671	0										
14644396	3383	D007249	ICAM-1	inflammation	0	0	0.02130271681	0										
14644396	3383	D014842	ICAM-1	von Willebrand	0	0	0.007615154143	0										
14644396	3383	D050197	ICAM-1	atherosclerosis	0	0	0.006356555037	0										
14644396	373156	D003327	GSTs | Glutathione-S-transferase	coronary heart disease	0	0	0.002743364545	0										
14644396	373156	D007249	GSTs | Glutathione-S-transferase	inflammation	0	0	0.01041222923	0										
14644396	373156	D014842	GSTs | Glutathione-S-transferase	von Willebrand	0	0	0.003122694092	0										
14644396	373156	D050197	GSTs | Glutathione-S-transferase	atherosclerosis	0	0	0.006430734415	0										
14644396	7412	D003327	VCAM-1	coronary heart disease	0	0	0.003160737455	0										
14644396	7412	D007249	VCAM-1	inflammation	0	0	0.01269822195	0										
14644396	7412	D014842	VCAM-1	von Willebrand	0	0	0.004957051948	0										
14644396	7412	D050197	VCAM-1	atherosclerosis	0	0	0.004988343455	0										
14669219	2984	D029424	GCC	chronic obstructive pulmonary disease	0	0	0.02512442879	0										
14669219	3586	D029424	IL-10 | interleukin-10	chronic obstructive pulmonary disease	1	1	0.9911455512	0										
14681904	1814	D003072	DRD3	cognitive dysfunctions	0	1	0.9000700712	1	0									
14681904	1814	D012559	DRD3	schizophrenia	1	1	0.9897910953	0										
14681904	1814	D012735	DRD3	dysfunctions	0	0	0.06855590641	0										
14681904	6531	D003072	DAT | dopamine transporter	cognitive dysfunctions	0	1	0.9311776757	1	0									
14681904	6531	D012559	DAT | dopamine transporter	schizophrenia	1	1	0.9759395123	0										
14681904	6531	D012735	DAT | dopamine transporter	dysfunctions	0	0	0.02257520892	0										
14687815	23436	D002114	Fecal elastase 1	calcifications	0	0	0.005396125838	0										
14687815	23436	D003920	Fecal elastase 1	Diabetic | diabetes mellitus | diabetic	0	0	0.004078968894	0										
14687815	23436	D003967	Fecal elastase 1	diarrhea	0	0	0.004735103808	0										
14687815	23436	D007153	Fecal elastase 1	immunodeficiency	0	0	0.004363359883	0										
14687815	23436	D009369	Fecal elastase 1	cancer	0	0	0.005383796524	0										
14687815	23436	D010188	Fecal elastase 1	Pancreatic exocrine insufficiency | pancreatic exocrine insufficiency | pancreatic insufficiency	1	0	0.1043562815	1	1								m	Diagnosis of pancreatic insufficiency was established for a fecal E1 &lt;200 microg/g.
14687815	23436	D010190	Fecal elastase 1	pancreas	0	0	0.005051998422	0										
14687815	23436	D010195	Fecal elastase 1	pancreatitis	0	0	0.004397757817	0										
14702425	1401	D003920	C-reactive protein	diabetes	0	0	0.003158651292	0										
14702425	1401	D007249	C-reactive protein	inflammation	0	0	0.05421225354	0										
14702425	1401	D050197	C-reactive protein	Atherosclerosis | atherosclerosis	0	0	0.05703414604	0										
14702425	240	D003920	5-lipoxygenase | Arachidonate 5-lipoxygenase	diabetes	0	0	0.01057123765	0										
14702425	240	D007249	5-lipoxygenase | Arachidonate 5-lipoxygenase	inflammation	0	1	0.8196336627	1	1				n				e	Variant 5-lipoxygenase genotypes identify a subpopulation with increased atherosclerosis. The observed diet-gene interactions further suggest that dietary n-6 polyunsaturated fatty acids promote, whereas marine n-3 fatty acids inhibit, leukotriene-mediated inflammation that leads to atherosclerosis in this subpopulation.
14702425	240	D050197	5-lipoxygenase | Arachidonate 5-lipoxygenase	Atherosclerosis | atherosclerosis	1	1	0.9914190769	0										
14765395	64127	D003424	CARD15 | NOD2	Crohn's disease	1	1	0.9811385274	0										
14961299	5925	D006528	Rb | retinoblastoma	hepatocellular carcinoma	1	0	0.4581416249	1	1	only	1						1bg	Alterations in the retinoblastoma ( Rb) gene have been correlated with a large number and wide variety of human tumors, including hepatocellular carcinoma.
14961299	5925	D008113	Rb | retinoblastoma	liver tumor | liver tumors | medaka liver tumors	0	1	0.989359498	1	1		1						0	Retinoblastoma gene mutations in chemically induced liver tumor samples of Japanese medaka
14961299	5925	D009369	Rb | retinoblastoma	tumors	0	0	0.0189441219	0										
14961299	5925	D012175	Rb | retinoblastoma	Retinoblastoma	0	0	0.008272243664	0										
14968442	2944	D009369	GSTM1	cancer	0	0	0.02034218609	0										
14968442	2944	D011471	GSTM1	prostate cancer	0	1	0.967074573	1	0					1			m	No increased PC risk was observed for men carrying any of the GSTM1 or GSTT1 genotypes
14968442	2944	D015324	GSTM1	PC disease	0	0	0.04319090024	0										
14968442	2947	D009369	GSTM3	cancer	0	0	0.01278920751	0										
14968442	2947	D011471	GSTM3	prostate cancer	1	1	0.971744895	0										
14968442	2947	D015324	GSTM3	PC disease	0	0	0.02117476799	0										
14968442	2952	D009369	GSTT1	cancer	0	0	0.03816018999	0										
14968442	2952	D011471	GSTT1	prostate cancer	0	1	0.9828723073	1	1	only	1						e	GSTT1 null was overrepresented in men with advanced PC disease
14968442	2952	D015324	GSTT1	PC disease	0	1	0.7978417873	1	1	only	1						e	GSTT1 null was overrepresented in men with advanced PC disease
14968442	373156	D009369	GST | Glutathione S-transferase	cancer	0	0	0.002680345671	0										
14968442	373156	D011471	GST | Glutathione S-transferase	prostate cancer	0	0	0.009249725379	0										
14968442	373156	D015324	GST | Glutathione S-transferase	PC disease	0	0	0.003142853966	0										
14974917	367	D003251	AR | androgen receptor	stenosis	0	0	0.04028816521	0										
14974917	367	D003324	AR | androgen receptor	coronary artery disease	1	1	0.986412406	0										
15007136	5048	D054221	LIS1	classic lissencephaly | lissencephaly and subcortical band heterotopia | subcortical band heterotopia	1	1	0.9855216146	0										
15023552	3779	C537034	beta1	LQT3	0	0	0.002725333674	0										
15023552	3779	D001145	beta1	arrhythmia syndromes	0	0	0.002765904879	0										
15023552	3779	D008133	beta1	congenital long QT syndrome	0	0	0.00283439015	0										
15023552	3779	D014693	beta1	ventricular fibrillation	0	0	0.005053072702	0										
15023552	3779	D053840	beta1	Brugada syndrome	0	0	0.006730922032	0										
15023552	3779	OMIM:610141	beta1	HV interval delay	0	0	0.003133693011	0										
15023552	6331	C537034	SCN5A | hNav1.5	LQT3	0	0	0.04030063748	0										
15023552	6331	D001145	SCN5A | hNav1.5	arrhythmia syndromes	0	0	0.1523059756	0										
15023552	6331	D008133	SCN5A | hNav1.5	congenital long QT syndrome	0	0	0.4337876737	0										
15023552	6331	D014693	SCN5A | hNav1.5	ventricular fibrillation	0	1	0.5537043214	1	0									
15023552	6331	D053840	SCN5A | hNav1.5	Brugada syndrome	1	1	0.9855819345	0										
15023552	6331	OMIM:610141	SCN5A | hNav1.5	HV interval delay	0	0	0.03685230017	0										
15083068	7421	D001943	VDR | Vitamin D receptor | vitamin D receptor	breast cancer	1	1	0.9942990541	0										
15083068	7421	D010024	VDR | Vitamin D receptor | vitamin D receptor	osteoporosis	0	1	0.8585225344	1	0									
15083068	7421	D011471	VDR | Vitamin D receptor | vitamin D receptor	prostate cancer	0	1	0.5343074203	1	0									
15088107	107794811	D002318	GST | Glutathione S-transferase	cardiovascular disease	0	0	0.01342311967	0										
15088107	107794811	D003324	GST | Glutathione S-transferase	Coronary artery disease | coronary artery disease	0	0	0.1196863279	0										
15088107	107794811	D003327	GST | Glutathione S-transferase	coronary heart disease	0	0	0.002827032935	0										
15088107	107794811	D009203	GST | Glutathione S-transferase	myocardial infarction	0	0	0.003428906668	0										
15088107	107794811	D058226	GST | Glutathione S-transferase	coronary atheroma	0	0	0.002968475688	0										
15088107	2944	D002318	GSTM1	cardiovascular disease	0	0	0.1219963804	0										
15088107	2944	D003324	GSTM1	Coronary artery disease | coronary artery disease	1	1	0.9685339332	0										
15088107	2944	D003327	GSTM1	coronary heart disease	0	0	0.03506623581	0	1		1						m	We found that the null GSTM1 and GSTT1 genotypes were associated with an increase in the risk of developing coronary heart disease
15088107	2944	D009203	GSTM1	myocardial infarction	1	0	0.01894432493	1	0									
15088107	2944	D058226	GSTM1	coronary atheroma	0	0	0.0126088988	0										
15088107	2952	D002318	GSTT1	cardiovascular disease	0	0	0.02078487724	0										
15088107	2952	D003324	GSTT1	Coronary artery disease | coronary artery disease	1	1	0.9390169978	0										
15088107	2952	D003327	GSTT1	coronary heart disease	0	0	0.06048609316	0	1		1						m	We found that the null GSTM1 and GSTT1 genotypes were associated with an increase in the risk of developing coronary heart disease
15088107	2952	D009203	GSTT1	myocardial infarction	1	0	0.01309774909	1	0									
15088107	2952	D058226	GSTT1	coronary atheroma	0	0	0.00941677019	0										
15088107	373156	D002318	Glutathione S-transferase	cardiovascular disease	0	0	0.003932027612	0										
15088107	373156	D003324	Glutathione S-transferase	Coronary artery disease | coronary artery disease	0	1	0.6093105078	1	1		1						0	Glutathione S-transferase gene polymorphism as a susceptibility factor in smoking-related coronary artery disease.
15088107	373156	D003327	Glutathione S-transferase	coronary heart disease	0	0	0.002766960301	0										
15088107	373156	D009203	Glutathione S-transferase	myocardial infarction	0	0	0.003243075218	0										
15088107	373156	D058226	Glutathione S-transferase	coronary atheroma	0	0	0.002892175922	0										
15108192	93986	D001321	FOXP2	autism | autistic disorder	1	1	0.994630456	0										
15108192	93986	D007806	FOXP2	language disorder	0	1	0.6047984958	1	0									
15121491	1636	D006333	ACE | Angiotensin-converting enzyme	chronic heart failure | heart failure	1	1	0.9928261042	0										
15129790	1636	D003324	Angiotensin-converting enzyme | angiotensin-converting enzyme	atherosclerotic coronary artery disease | coronary artery disease	1	1	0.991992712	0										
15166293	2847	D004342	MCHR1	hypersensitivity	0	0	0.003720218316	0										
15166293	2847	D006963	MCHR1	hyperphagia	0	0	0.003126569325	0										
15166293	2847	D007029	MCHR1	hypothalamus	0	0	0.005203389097	0										
15166293	2847	D009765	MCHR1	obesity | obesity must	1	0	0.1838235706	1	1		1						m	Among 106 subjects with severe early onset obesity and a history of hyperphagia, we found two missense variants in MCHR1: Y181H and R248Q.
15166293	5367	D004342	MCH | Melanin-concentrating hormone	hypersensitivity	0	0	0.007384452038	0										
15166293	5367	D006963	MCH | Melanin-concentrating hormone	hyperphagia	0	0	0.004563182127	0										
15166293	5367	D007029	MCH | Melanin-concentrating hormone	hypothalamus	0	0	0.491007179	0										
15166293	5367	D009765	MCH | Melanin-concentrating hormone	obesity | obesity must	0	1	0.9908192754	1	1							1	e	In conclusion, mutations in the MCH receptors are not commonly found in humans with severe early onset obesity.
15166293	84539	D004342	MCHR2	hypersensitivity	0	0	0.003815875156	0										
15166293	84539	D006963	MCHR2	hyperphagia	0	0	0.00287940749	0										
15166293	84539	D007029	MCHR2	hypothalamus	0	0	0.00529392669	0										
15166293	84539	D009765	MCHR2	obesity | obesity must	0	0	0.05367313698	0										
15173859	4513	D015179	COX2	colorectal cancer | colorectal cancers	0	1	0.5781834126	1	0									
15173859	5743	D015179	PTGS2 | cyclooxygenase 2	colorectal cancer | colorectal cancers	1	1	0.9946054816	0										
15179015	10194	D011605	CAA	psychotic disorders	0	0	0.03984572738	0										
15179015	10194	D012559	CAA	paranoid schizophrenic | schizophrenia | schizophrenic	0	1	0.9181381464	1	1								m	However, in the subtype of paranoid schizophrenic patients, we found that the (CAA)(3)/(CAA)(5) heterozygotes were more often represented.
15179015	2932	D011605	GSK-3beta	psychotic disorders	0	0	0.06398969144	0										
15179015	2932	D012559	GSK-3beta	paranoid schizophrenic | schizophrenia | schizophrenic	1	1	0.9367525578	0										
15248218	1555	C564499	CYP2B6	premature ovarian failure	0	0	0.003435185878	0										
15248218	1555	D007676	CYP2B6	ESRD | end-stage renal disease	1	0	0.01088640373	1	1		1						m	In a survival analysis, patients homozygous for CYP2B6*5 (n = 3) or CYP2C19*2 (n = 4) had a higher probability of reaching ESRD
15248218	1555	D008181	CYP2B6	lupus nephritis	0	0	0.3319862485	0										
15248218	1555	D064420	CYP2B6	toxicity	0	0	0.003599112853	0										
15248218	1557	C564499	CYP2C19	premature ovarian failure	0	0	0.02934391424	0										
15248218	1557	D007676	CYP2C19	ESRD | end-stage renal disease	1	0	0.1591909379	1	1		1						m	In a survival analysis, patients homozygous for CYP2B6*5 (n = 3) or CYP2C19*2 (n = 4) had a higher probability of reaching ESRD
15248218	1557	D008181	CYP2C19	lupus nephritis	0	0	0.4901078641	0										
15248218	1557	D064420	CYP2C19	toxicity	0	0	0.008339169435	0										
15248218	1559	C564499	CYP2C9	premature ovarian failure	0	0	0.00357014616	0										
15248218	1559	D007676	CYP2C9	ESRD | end-stage renal disease	0	0	0.007696925197	0										
15248218	1559	D008181	CYP2C9	lupus nephritis	0	0	0.05534054711	0										
15248218	1559	D064420	CYP2C9	toxicity	0	0	0.003727987176	0										
15248218	1577	C564499	CYP3A5	premature ovarian failure	0	0	0.003774045268	0										
15248218	1577	D007676	CYP3A5	ESRD | end-stage renal disease	0	0	0.008648473769	0										
15248218	1577	D008181	CYP3A5	lupus nephritis	0	0	0.07173577696	0										
15248218	1577	D064420	CYP3A5	toxicity	0	0	0.003974090796	0										
15248218	4051	C564499	CYP | Cytochrome P450 | cytochrome P450	premature ovarian failure	0	0	0.003518492915	0										
15248218	4051	D007676	CYP | Cytochrome P450 | cytochrome P450	ESRD | end-stage renal disease	0	0	0.006676326972	0										
15248218	4051	D008181	CYP | Cytochrome P450 | cytochrome P450	lupus nephritis	0	0	0.09592696279	0										
15248218	4051	D064420	CYP | Cytochrome P450 | cytochrome P450	toxicity	0	0	0.003986679483	0										
15267201	7421	D011471	VDR | vitamin D receptor	prostate cancer	1	1	0.9929325581	0										
15271856	6790	D000782	Aurora A | Aurora-A | BTAK | STK15	aneuploidy	0	0	0.2616561651	0										
15271856	6790	D001943	Aurora A | Aurora-A | BTAK | STK15	breast cancer | breast carcinoma	1	1	0.9944928885	0										
15271856	6790	D002277	Aurora A | Aurora-A | BTAK | STK15	ER-carcinomas	0	0	0.008380073123	0										
15271856	6790	D004938	Aurora A | Aurora-A | BTAK | STK15	advanced disease status of esophageal cancer	0	0	0.1971296966	0										
15271856	6790	D009362	Aurora A | Aurora-A | BTAK | STK15	metastasis and disease	0	0	0.006527831312	0										
15271856	6790	D009369	Aurora A | Aurora-A | BTAK | STK15	cancer | cancers | tumors	0	0	0.005723475013	0										
15271856	6790	D061325	Aurora A | Aurora-A | BTAK | STK15	benign breast diseases	0	0	0.01440348756	0										
15312365	4524	D001943	MTHFR | methylenetetrahydrofolate reductase	breast cancer	1	1	0.9949263334	0										
15312365	4524	D009369	MTHFR | methylenetetrahydrofolate reductase	cancer	0	0	0.1693958491	0										
15319168	7124	D003920	TNF-alpha | Tumor necrosis factor-alpha | tumor necrosis factor-alpha	diabetes mellitus	1	0	0.1569191366	1	0									
15319168	7124	D006973	TNF-alpha | Tumor necrosis factor-alpha | tumor necrosis factor-alpha	hypertension	1	0	0.426656872	1	0									
15319168	7124	D009765	TNF-alpha | Tumor necrosis factor-alpha | tumor necrosis factor-alpha	obesity	1	1	0.9912533164	0										
15319168	7124	D050197	TNF-alpha | Tumor necrosis factor-alpha | tumor necrosis factor-alpha	atherosclerosis	0	1	0.9695152044	1	0									
15328537	2010	C579969	emerin	Emerin caps	0	1	0.5321223736	1	0									
15328537	2010	D020389	emerin	X-linked Emery-Dreifuss muscular dystrophy	1	1	0.8210007548	0										
15328537	2934	C579969	gelsolin	Emerin caps	0	0	0.008493880741	0										
15328537	2934	D020389	gelsolin	X-linked Emery-Dreifuss muscular dystrophy	0	0	0.004094887525	0										
15328537	6709	C579969	alphaII-spectrin	Emerin caps	0	0	0.01073737536	0										
15328537	6709	D020389	alphaII-spectrin	X-linked Emery-Dreifuss muscular dystrophy	0	0	0.004538261797	0										
15331147	4023	D000544	LPL | lipoprotein lipase	AD | Alzheimer's disease	1	1	0.9913914204	0										
15374636	2064	D001943	HER-2	breast cancer	1	1	0.9934923053	0										
15385443	51733	C563210	UPB1 | beta-Ureidopropionase | beta-ureidopropionase	beta-ureidopropionase deficiency	1	0	0.058000613	1	1			GDm					m	Our results demonstrate that the N-carbamyl-beta-amino aciduria in these patients is due to a deficiency of beta-ureidopropionase, which is caused by mutations in the UPB1 gene.
15385443	51733	D008661	UPB1 | beta-Ureidopropionase | beta-ureidopropionase	inborn error	0	1	0.8660757542	1	0			Di						
15385443	51733	D009461	UPB1 | beta-Ureidopropionase | beta-ureidopropionase	neurological abnormalities	0	1	0.9851383567	1	0									
15386471	2739	D001321	GLO1 | Glo1 | glyoxalase I	Autism | autism | autism brains	1	1	0.9943722486	0										
15386471	2739	D001523	GLO1 | Glo1 | glyoxalase I	repetitive behaviors	0	0	0.01497251447	0										
15386471	2739	D002658	GLO1 | Glo1 | glyoxalase I	neurodevelopmental disability	0	0	0.01006003562	0										
15386471	2739	D058495	GLO1 | Glo1 | glyoxalase I	protein abnormalities	0	0	0.03570152074	0										
15447944	1636	D000544	ACE	Alzheimer's dementia	0	1	0.8821886182	1	0.5	only					1	1	1bg	The angiotensin-converting enzyme (ACE) gene insertion/deletion polymorphism influences ACE activity, cardiovascular risk, blood pressure, and possibly the risk of developing Alzheimer's dementia.
15447944	1636	D006973	ACE	hypertension	1	0	0.4196899235	1	1		1						m	Most specifically, the association of the deletion allele with hypertension was most pronounced in subjects with mild to moderate degrees of sleep apnea
15447944	1636	D012891	ACE	sleep apnea | sleep-disordered breathing	0	1	0.7854214311	1	1		1						m	Most specifically, the association of the deletion allele with hypertension was most pronounced in subjects with mild to moderate degrees of sleep apnea
15447944	1636	D020181	ACE	apnea-hypopnea	0	0	0.004963006359	0										
15477198	3077	C538137	HFE	Hyperferritinemia	0	0	0.007192480844	0										
15477198	3077	D006432	HFE	Hemochromatosis | hemochromatosis | hemochromatosis-associated molecular defects	1	1	0.9889588356	0										
15477198	3077	D030342	HFE	genetic disorder	0	0	0.005862967111	0										
15477198	7018	C538137	transferrin	Hyperferritinemia	0	0	0.003137439955	0										
15477198	7018	D006432	transferrin	Hemochromatosis | hemochromatosis | hemochromatosis-associated molecular defects	0	1	0.9731473327	1	0									
15477198	7018	D030342	transferrin	genetic disorder	0	0	0.00295088673	0										
15479493	354	D009369	prostate-specific antigen	cancer	0	0	0.003072834574	0										
15479493	354	D011471	prostate-specific antigen	prostate cancer	0	1	0.9659951329	1	0									
15479493	367	D009369	androgen receptor	cancer	0	0	0.004158727825	0										
15479493	367	D011471	androgen receptor	prostate cancer	1	1	0.9896195531	0										
15492837	1029	D006987	p16 | p16INK4a	reduced tumour	0	0	0.3915517628	0										
15492837	1029	D008545	p16 | p16INK4a	melanoma	0	0	0.04269087315	0										
15492837	1029	D009369	p16 | p16INK4a	decreased tumour | tumour	0	0	0.2293558121	0										
15492837	1029	D015179	p16 | p16INK4a	colorectal cancer | colorectal tumours | sporadic colorectal cancer	1	1	0.992460072	0										
15520322	6331	D002037	SCN5A	bundle-branch block	0	0	0.02225912549	0										
15520322	6331	D019571	SCN5A	arrhythmogenic disease	0	0	0.009530390613	0										
15520322	6331	D053840	SCN5A	Brugada syndrome	1	1	0.9913789034	0										
15520322	6331	D054537	SCN5A	atrioventricular block	0	0	0.01104559097	0										
15531451	3077	C562385	HFE	iron deficiency	0	1	0.8907535076	1	1	only							1bg	HFE mutations, frequent in Caucasian populations, can cause increased intestinal iron absorption and thus could protect against the development of iron deficiency.
15531451	3077	D000740	HFE	deficiency anemia	0	1	0.8304952979	1	0									
15531451	3077	D006432	HFE	Hemochromatosis	1	1	0.7797740698	0										
15535847	6648	D001943	Manganese superoxide dismutase | MnSOD | manganese superoxide dismutase	Breast Cancer | Breast cancer | breast cancer | breast cancer carcinogenesis	1	1	0.9911361933	0										
15607627	1812	D006973	DRD1 | dopamine receptor type 1 (DRD1	hypertension | hypertensive	1	1	0.9915864468	0										
15617192	1373	D020165	CPSI | carbamoylphosphate synthetase I	synthetase I deficiency	1	1	0.9472844005	0										
15622766	2539	D005955	G6PD	G6PD deficient	1	1	0.9806050062	0										
15660115	3630	D008659	insulin	metabolic disturbances	0	0	0.003478045575	0										
15660115	3630	D009765	insulin	obese | obesity	0	0	0.007267729845	0										
15660115	3952	D008659	leptin	metabolic disturbances	0	0	0.004291550722	0										
15660115	3952	D009765	leptin	obese | obesity	0	0	0.01048352104	0										
15660115	3953	D008659	LEPR | leptin receptor	metabolic disturbances	0	1	0.9359927177	1	1		1						e	To conclude, our results support the hypothesis that Gln223Arg polymorphism of LEPR in Mexican adolescents is associated with haemodynamic and metabolic disturbances related to obesity.
15660115	3953	D009765	LEPR | leptin receptor	obese | obesity	1	1	0.9934357405	0										
15671210	10	D012004	NAT2	rectal cancer	0	0	0.007567469031	0										
15671210	10	D015179	NAT2	colon cancer | colorectal cancer	1	1	0.969058454	0										
15671210	1543	D012004	CYP1A1	rectal cancer	0	0	0.005469417199	0										
15671210	1543	D015179	CYP1A1	colon cancer | colorectal cancer	1	1	0.9784846902	0										
15671210	2944	D012004	GSTM1	rectal cancer	0	0	0.0098094102	0										
15671210	2944	D015179	GSTM1	colon cancer | colorectal cancer	1	1	0.945667088	0										
15684872	3077	D004393	HFE	GH	0	1	0.960917592	1	1		1						1	In Spain, 85% of patients with genetic hemochromatosis (GH) are homozygous for the C282Y mutation of the HFE gene.
15684872	3077	D006432	HFE	genetic hemochromatosis | hemochromatosis	1	1	0.9885595441	0										
15731584	3565	D004342	interleukin 4	allergic | allergy | hypersensitivity	0	0	0.003244510619	0										
15731584	3565	D020315	interleukin 4	latex allergy | rubber latex allergy	0	0	0.01037923992	0										
15731584	3596	D004342	IL13 | interleukin 13	allergic | allergy | hypersensitivity	0	0	0.2811409533	0										
15731584	3596	D020315	IL13 | interleukin 13	latex allergy | rubber latex allergy	1	1	0.9840698242	0										
15731584	3606	D004342	IL18 | interleukin 18	allergic | allergy | hypersensitivity	0	1	0.867272675	1	0									
15731584	3606	D020315	IL18 | interleukin 18	latex allergy | rubber latex allergy	1	1	0.9929983616	0										
15735794	2153	D013927	factor V Leiden	thrombosis | thrombotic	0	1	0.9742514491	1	0									
15735794	2153	D019851	factor V Leiden	thrombophilic defects	0	0	0.003521545324	0										
15735794	2153	D020246	factor V Leiden	venous thrombosis	0	0	0.06808825582	0										
15735794	2153	D054556	factor V Leiden	venous thromboembolism	1	0	0.005998689216	1	0									
15735794	2157	D013927	FVIII | factor VIII	thrombosis | thrombotic	0	1	0.9765781164	1	1								m	Carriership of the 1241E allele, potentially conferring protection from thrombosis, was found in 22.8% of controls and in 15.3% of cases.
15735794	2157	D019851	FVIII | factor VIII	thrombophilic defects	0	0	0.03038508818	0										
15735794	2157	D020246	FVIII | factor VIII	venous thrombosis	0	1	0.9830657244	1	1									
15735794	2157	D054556	FVIII | factor VIII	venous thromboembolism	1	1	0.679104507	0										
15767331	7422	D008175	VEGF | Vascular endothelial growth factor | vascular endothelial growth factor	lung cancer	1	1	0.9935805798	0										
15767331	7422	D009362	VEGF | Vascular endothelial growth factor | vascular endothelial growth factor	metastasis of malignant tumors	0	0	0.06209718063	0										
15767331	7422	D009369	VEGF | Vascular endothelial growth factor | vascular endothelial growth factor	tumor	0	0	0.04326371104	0										
15767331	7422	D018288	VEGF | Vascular endothelial growth factor | vascular endothelial growth factor	small cell carcinoma	0	0	0.09647779167	0										
15767331	81890	D008175	TGT	lung cancer	0	0	0.02555143274	0										
15767331	81890	D009362	TGT	metastasis of malignant tumors	0	0	0.002837331267	0										
15767331	81890	D009369	TGT	tumor	0	0	0.002387041226	0										
15767331	81890	D018288	TGT	small cell carcinoma	0	0	0.002861919114	0										
15777502	672	D001943	BRCA1	breast cancer	1	1	0.9942341447	0										
15781210	2944	D008175	GSTM1 | glutathione-S-transferase M1	lung cancer	1	1	0.9912160635	0										
15781210	2944	D009369	GSTM1 | glutathione-S-transferase M1	tumor initiation	0	0	0.007653953973	0										
15781210	4968	D008175	8-oxoguanine-DNA glycosylase | OGG1	lung cancer	1	1	0.9790249467	0										
15781210	4968	D009369	8-oxoguanine-DNA glycosylase | OGG1	tumor initiation	0	0	0.003242867067	0										
15781210	8644	D008175	AKR1C3 | aldo-keto reductase 1C3	lung cancer	1	1	0.9878669977	0										
15781210	8644	D009369	AKR1C3 | aldo-keto reductase 1C3	tumor initiation	0	0	0.003672672901	0										
15784470	10344	D001172	Eotaxin-3 | eotaxin-3	RA | rheumatoid arthritis	1	1	0.9933568835	0										
15784470	10344	D001249	Eotaxin-3 | eotaxin-3	asthma	0	1	0.9308353066	1	1		1						m	We previously suggested that Eo2+179T&gt;C and Eo2+275C&gt;T of the eotaxin-2, and Eo3+2497T&gt;G of the eotaxin-3 were significantly associated with susceptibility to asthma.
15784470	10344	D001327	Eotaxin-3 | eotaxin-3	autoimmune disease	0	0	0.02163820527	0										
15784470	10344	D004342	Eotaxin-3 | eotaxin-3	allergic diseases	0	1	0.7420158386	1	0									
15784470	6356	D001172	eotaxin	RA | rheumatoid arthritis	0	0	0.02190394513	0										
15784470	6356	D001249	eotaxin	asthma	0	0	0.01395237818	0										
15784470	6356	D001327	eotaxin	autoimmune disease	0	0	0.004855838604	0										
15784470	6356	D004342	eotaxin	allergic diseases	0	0	0.2588077188	0										
15784470	6369	D001172	eotaxin-2	RA | rheumatoid arthritis	0	0	0.3824815154	0										
15784470	6369	D001249	eotaxin-2	asthma	0	0	0.475635916	0										
15784470	6369	D001327	eotaxin-2	autoimmune disease	0	0	0.007553722709	0										
15784470	6369	D004342	eotaxin-2	allergic diseases	0	0	0.1232800856	0										
15803363	11200	D001943	CHEK2	breast cancer	1	1	0.9939851165	0										
15820494	11005	C566404	LEKTI | SPINK5	atopic diseases	0	1	0.9550034404	1	1	only							1bg	The SPINK5 gene, encoding the serine protease inhibitor LEKTI maps to chromosome 5q32, and has been suggested to be a locus predisposing to atopic diseases in general.
15820494	11005	D001249	LEKTI | SPINK5	asthma	1	1	0.9662715197	0										
15820494	11005	D003876	LEKTI | SPINK5	atopic dermatitis	0	1	0.5697427392	1	1	only			M				mbg	The Glu420Lys variant showed significant association with atopy, asthma and atopic dermatitis in recent studies.
15820494	2147	C566404	serine protease	atopic diseases	0	0	0.3895440996	0										
15820494	2147	D001249	serine protease	asthma	0	0	0.0342759192	0										
15820494	2147	D003876	serine protease	atopic dermatitis	0	0	0.04562529176	0										
15844218	5373	C535739	PMM2	Congenital disorder of Glycosylation type Ia | defective N-glycosylation and phosphomannomutase (PMM) deficiency	1	1	0.9039452076	0										
15844218	5373	D002493	PMM2	central nervous system dysfunction and multiorgan failure	0	0	0.006812972482	0										
15844218	5373	D030342	PMM2	autosomal recessive disorder	0	0	0.007978949696	0										
15848982	100130889	D011565	PSORS1C3	psoriasis | psoriasis skin	0	1	0.9873399138	1	0						1	1	m	When comparing the frequencies of PSORS1C3 variants in a case-control material in the Swedish population, three single nucleotide polymorphisms displayed significant association with psoriasis.
15848982	3107	D011565	HLA-C | PSORS1	psoriasis | psoriasis skin	1	1	0.9739397168	0										
15848982	5460	D011565	POU5F1	psoriasis | psoriasis skin	0	0	0.1120857149	0										
15851630	183	D002318	Angiotensin II | angiotensin II	cardiovascular disease	0	0	0.004670368508	0										
15851630	183	D006331	Angiotensin II | angiotensin II	cardiac NAD(P)H	0	0	0.01564294472	0										
15851630	183	D006332	Angiotensin II | angiotensin II	cardiac hypertrophy	1	1	0.9597827792	0										
15851630	183	D006973	Angiotensin II | angiotensin II	hypertension	1	0	0.007415350527	1	1				n				0	Cyclooxygenase-2 inhibitors attenuate angiotensin II-induced oxidative stress, hypertension, and cardiac hypertrophy in rats.
15851630	55968	D002318	p47	cardiovascular disease	0	0	0.003946484532	0										
15851630	55968	D006331	p47	cardiac NAD(P)H	0	0	0.02053276449	0										
15851630	55968	D006332	p47	cardiac hypertrophy	0	0	0.07763113827	0										
15851630	55968	D006973	p47	hypertension	0	0	0.003532406641	0										
15851630	5742	D002318	cyclooxygenase-1	cardiovascular disease	0	0	0.004259696696	0										
15851630	5742	D006331	cyclooxygenase-1	cardiac NAD(P)H	0	0	0.006912186276	0										
15851630	5742	D006332	cyclooxygenase-1	cardiac hypertrophy	0	0	0.09283577651	0										
15851630	5742	D006973	cyclooxygenase-1	hypertension	0	0	0.003359511495	0										
15851630	5743	D002318	Cyclooxygenase-2 | cyclooxygenase-2	cardiovascular disease	0	0	0.04767395183	0										
15851630	5743	D006331	Cyclooxygenase-2 | cyclooxygenase-2	cardiac NAD(P)H	0	0	0.01049626991	0										
15851630	5743	D006332	Cyclooxygenase-2 | cyclooxygenase-2	cardiac hypertrophy	0	1	0.9022303224	1	1				n				0	Cyclooxygenase-2 inhibitors attenuate angiotensin II-induced oxidative stress, hypertension, and cardiac hypertrophy in rats.
15851630	5743	D006973	Cyclooxygenase-2 | cyclooxygenase-2	hypertension	0	0	0.007302162237	0	1				n				0	Cyclooxygenase-2 inhibitors attenuate angiotensin II-induced oxidative stress, hypertension, and cardiac hypertrophy in rats.
15852425	11200	D001943	CHEK2	breast and colorectal cancers | breast cancer	0	1	0.9893432856	1	1	only	1						1bg	The CHEK2 1100delC mutation was recently identified as a low-penetrance breast cancer susceptibility allele.
15852425	11200	D009369	CHEK2	tumor	0	0	0.01170174126	0										
15852425	11200	D015179	CHEK2	Colorectal cancer	1	0	0.4290955961	1	1			Dr					e	Together, the results are consistent with a low-penetrance effect (OR 1.5-2.0) of the CHEK2 1100delC on CRC risk.
15852425	11200	D016889	CHEK2	colorectal and endometrial cancer	0	0	0.01383230649	0										
15879435	115	D001249	AC9 | adenylyl cyclase type 9 | adenylyl cyclase type 9 (AC9	asthma	0	1	0.9920428395	1	1								e	The Met772-AC9 polymorphism represents one of most likely several multi-gene polymorphisms along the receptor-relaxation axis, which together may provide for a composite pharmacogenetic index for asthma therapy.
15879435	154	D001249	beta2-adrenergic receptors | beta2AR	asthma	1	0	0.01424476597	1	1								1bg	In asthma, the response to beta-agonists acting at beta2-adrenergic receptors (beta2AR) displays extensive interindividual variation.
15893580	3356	D012559	5-HT2A receptor | HTR2A	schizophrenia	0	1	0.9699488878	1	1				C	1	1		e	However, subject with 5-HTR2A*TT genotype were found to have lower age of onset, compared to their counterparts (p=0.01).
15893580	6532	D012559	5-HTTLPR | serotonin transporter	schizophrenia	1	1	0.9892710447	0	0		1			1			e	These results suggest that the interaction between 5-HTTLPR and 5-HTR2A polymorphisms may not contribute to susceptibility to schizophrenia as well as some clinical factors such as antipsychotic response, at least in the Korean population.
15902657	199720	D000505	GGN	Androgenetic alopecia | androgenetic alopecia | baldness	0	0	0.1448581964	0										
15902657	367	D000505	androgen receptor	Androgenetic alopecia | androgenetic alopecia | baldness	1	1	0.9828710556	0										
15905799	10	D001749	NAT2	bladder cancer | schistosomiasis-associated bladder cancer | urinary bladder cancer	1	1	0.9942134023	0										
15905799	10	D007239	NAT2	infection	0	0	0.01432970725	0										
15905799	10	D012552	NAT2	schistosomiasis infection	0	0	0.03289515898	0										
15906354	7157	D001745	TP53	bladder carcinogens	0	0	0.01047046948	0										
15906354	7157	D001749	TP53	bladder cancer | bladder cancers | invasive bladder cancer	1	1	0.9937864542	0										
15906354	7157	D009369	TP53	tumors	0	0	0.006736612413	0										
15923132	538	C535468	ATP7A	copper deficiency	0	1	0.7313216925	1	0									
15923132	538	D000860	ATP7A	hypoxic	0	0	0.02105900645	0										
15923132	538	D007706	ATP7A	Menkes disease	1	1	0.787618041	0										
15923132	538	D019636	ATP7A	neurodegeneration	0	0	0.02073684707	0										
15923132	538	D020271	ATP7A	X-linked recessive neurodegenerative disorder	0	0	0.01160583273	0										
15923132	619570	C535468	U95	copper deficiency	0	0	0.01863545366	0										
15923132	619570	D000860	U95	hypoxic	0	0	0.01299602538	0										
15923132	619570	D007706	U95	Menkes disease	0	0	0.05947640166	0										
15923132	619570	D019636	U95	neurodegeneration	0	0	0.008734378964	0										
15923132	619570	D020271	U95	X-linked recessive neurodegenerative disorder	0	0	0.003379371949	0										
15928304	112304	D006528	Par 1	hepatocellular carcinoma	0	0	0.009556383826	0										
15928304	112304	D008113	Par 1	liver tumors	0	0	0.007951911539	0										
15928304	112304	D009362	Par 1	lung metastases | metastases | pulmonary metastases	0	0	0.002953709336	0										
15928304	112304	D009369	Par 1	solid tumors | tumor	0	0	0.002288281219	0										
15928304	112304	D063646	Par 1	liver carcinogenesis	0	0	0.003553743241	0										
15928304	4830	D006528	NM23 | NM23-M1 | Nm23 | Nm23-M1	hepatocellular carcinoma	0	1	0.9898611307	1	1	bg d							0	Increased lung metastasis in transgenic NM23-Null/SV40 mice with hepatocellular carcinoma.
15928304	4830	D008113	NM23 | NM23-M1 | Nm23 | Nm23-M1	liver tumors	0	1	0.9902436137	1	1								m	In both models, Nm23-M1 and/or Nm23-M2 were overexpressed in the primary liver tumors compared with nontumor liver tissue
15928304	4830	D009362	NM23 | NM23-M1 | Nm23 | Nm23-M1	lung metastases | metastases | pulmonary metastases	1	0	0.4333587289	1	1		1						m	Statistically significantly more ASV/NM23-M1(-/-) mice than ASV/NM23-M1(+/+) mice developed lung metastases
15928304	4830	D009369	NM23 | NM23-M1 | Nm23 | Nm23-M1	solid tumors | tumor	0	1	0.9439043403	1	0									
15928304	4830	D063646	NM23 | NM23-M1 | Nm23 | Nm23-M1	liver carcinogenesis	0	1	0.8352782726	1	1		1						e	The lack of NM23-M1 expression promotes metastasis in the SV40 animal model of liver carcinogenesis.
15928304	4831	D006528	Nm23-M2	hepatocellular carcinoma	0	0	0.01275291294	0										
15928304	4831	D008113	Nm23-M2	liver tumors	0	0	0.02097791247	0										
15928304	4831	D009362	Nm23-M2	lung metastases | metastases | pulmonary metastases	0	0	0.003136078827	0										
15928304	4831	D009369	Nm23-M2	solid tumors | tumor	0	0	0.002683258615	0										
15928304	4831	D063646	Nm23-M2	liver carcinogenesis	0	0	0.003860710887	0										
15966462	1813	D001480	DRD2 | dopamine D2-receptor	EPS | extrapyramidal symptoms	1	1	0.9873313308	0										
15966462	1813	D012559	DRD2 | dopamine D2-receptor	schizophrenic	0	1	0.8414087296	1	0									
15980987	11200	D001943	CHEK2	Breast cancer | breast cancer	1	1	0.9797894955	0	1	only	1						mbg	n Poland founder alleles of the BRCA1, CHEK2 and NBS1 genes have been associated with an increased risk of breast cancer, but the relative contribution of each of these alleles to the overall breast cancer burden has not yet been determined.
15980987	11200	D009369	CHEK2	cancer	0	0	0.00667713955	0										
15980987	26716	D001943	OR=6.2	Breast cancer | breast cancer	0	0	0.2106238157	0										
15980987	26716	D009369	OR=6.2	cancer	0	0	0.002987831831	0										
15980987	389090	D001943	OR=2.1	Breast cancer | breast cancer	0	0	0.04215981066	0										
15980987	389090	D009369	OR=2.1	cancer	0	0	0.003444041358	0										
15980987	391107	D001943	OR=1.4	Breast cancer | breast cancer	0	0	0.03048121557	0										
15980987	391107	D009369	OR=1.4	cancer	0	0	0.003216326935	0										
15980987	4683	D001943	NBS1	Breast cancer | breast cancer	1	0	0.4621665776	1	1	only	1						mbg	n Poland founder alleles of the BRCA1, CHEK2 and NBS1 genes have been associated with an increased risk of breast cancer, but the relative contribution of each of these alleles to the overall breast cancer burden has not yet been determined.
15980987	4683	D009369	NBS1	cancer	0	0	0.003220959101	0										
15980987	672	D001943	BRCA1	Breast cancer | breast cancer	1	1	0.9894390702	0	1	only	1						mbg	n Poland founder alleles of the BRCA1, CHEK2 and NBS1 genes have been associated with an increased risk of breast cancer, but the relative contribution of each of these alleles to the overall breast cancer burden has not yet been determined.
15980987	672	D009369	BRCA1	cancer	0	0	0.003510597395	0										
15988600	5468	D001172	PPARgamma2 | peroxisome proliferator activated receptor-gamma2	RA | rheumatoid arthritis	1	1	0.9924620986	0	0					1			e	Our results suggest that genetic polymorphisms of CAT and PPARgamma2 do not play a significant role in the susceptibility to RA among Koreans.
15988600	5468	D007249	PPARgamma2 | peroxisome proliferator activated receptor-gamma2	inflammation	0	1	0.962382853	1	1	only							1bg	Catalase (CAT) and peroxisome proliferator activated receptor-gamma2 (PPARgamma2) are important regulators of oxidative stress and inflammation, and may contribute to the development of rheumatoid arthritis (RA).
15988600	847	D001172	CAT | Catalase	RA | rheumatoid arthritis	0	1	0.9800017476	1	0					1			e	Our results suggest that genetic polymorphisms of CAT and PPARgamma2 do not play a significant role in the susceptibility to RA among Koreans.
15988600	847	D007249	CAT | Catalase	inflammation	0	1	0.6617011428	1	1	only							1bg	Catalase (CAT) and peroxisome proliferator activated receptor-gamma2 (PPARgamma2) are important regulators of oxidative stress and inflammation, and may contribute to the development of rheumatoid arthritis (RA).
16005527	1493	C537312	CTLA4	Norwegian multiple sclerosis	0	0	0.01315975096	0										
16005527	1493	D001791	CTLA4	familial aggregation	0	0	0.003599803895	0										
16005527	1493	D009103	CTLA4	multiple sclerosis	0	1	0.8004817963	1	0		1			1			0	Lack of association with the CD28/CTLA4/ICOS gene region among Norwegian multiple sclerosis patients.
16005527	29851	C537312	ICOS	Norwegian multiple sclerosis	0	0	0.005148269236	0										
16005527	29851	D001791	ICOS	familial aggregation	0	0	0.002900671447	0										
16005527	29851	D009103	ICOS	multiple sclerosis	0	1	0.5773859024	1	0		1			1			0	Lack of association with the CD28/CTLA4/ICOS gene region among Norwegian multiple sclerosis patients.
16005527	3119	C537312	DQB1	Norwegian multiple sclerosis	0	0	0.002605670132	0										
16005527	3119	D001791	DQB1	familial aggregation	0	0	0.002679468831	0										
16005527	3119	D009103	DQB1	multiple sclerosis	1	0	0.03763569891	1	0.5						1	1	m	Associations were neither found when stratifying the material for the HLA-DRB1*1501, DQB1*0602 haplotype, gender, age at onset, disease course nor familial aggregation.
16005527	3123	C537312	HLA-DRB1	Norwegian multiple sclerosis	0	0	0.002602889435	0										
16005527	3123	D001791	HLA-DRB1	familial aggregation	0	0	0.002561552916	0										
16005527	3123	D009103	HLA-DRB1	multiple sclerosis	1	0	0.03596780449	1	0.5						1	1	m	Associations were neither found when stratifying the material for the HLA-DRB1*1501, DQB1*0602 haplotype, gender, age at onset, disease course nor familial aggregation.
16005527	940	C537312	CD28	Norwegian multiple sclerosis	0	0	0.01220225077	0										
16005527	940	D001791	CD28	familial aggregation	0	0	0.004532208201	0										
16005527	940	D009103	CD28	multiple sclerosis	0	1	0.8848799467	1	0		1			1			0	Lack of association with the CD28/CTLA4/ICOS gene region among Norwegian multiple sclerosis patients.
16013913	10858	D000544	CYP46A1	Alzheimer's disease	1	1	0.967495501	0	1	only	1						m	We identified a cluster of polymorphisms in APOE, SOAT1, APOE 5'-untranslated region, OLR1, CYP46A1, LPL, LIPA, and APOA4 conferring significant (p = .0002) susceptibility for Alzheimer's disease.
16013913	337	D000544	APOA4	Alzheimer's disease	0	1	0.9840304852	1	1	only	1						m	We identified a cluster of polymorphisms in APOE, SOAT1, APOE 5'-untranslated region, OLR1, CYP46A1, LPL, LIPA, and APOA4 conferring significant (p = .0002) susceptibility for Alzheimer's disease.
16013913	348	D000544	APOE	Alzheimer's disease	1	1	0.9885814786	0	1	only	1						m	We identified a cluster of polymorphisms in APOE, SOAT1, APOE 5'-untranslated region, OLR1, CYP46A1, LPL, LIPA, and APOA4 conferring significant (p = .0002) susceptibility for Alzheimer's disease.
16013913	3988	D000544	LIPA	Alzheimer's disease	1	1	0.9861397743	0	1	only	1						m	We identified a cluster of polymorphisms in APOE, SOAT1, APOE 5'-untranslated region, OLR1, CYP46A1, LPL, LIPA, and APOA4 conferring significant (p = .0002) susceptibility for Alzheimer's disease.
16013913	4023	D000544	LPL	Alzheimer's disease	1	1	0.9826646447	0	1	only	1						m	We identified a cluster of polymorphisms in APOE, SOAT1, APOE 5'-untranslated region, OLR1, CYP46A1, LPL, LIPA, and APOA4 conferring significant (p = .0002) susceptibility for Alzheimer's disease.
16013913	4973	D000544	OLR1	Alzheimer's disease	1	1	0.9846611619	0	1	only	1						m	We identified a cluster of polymorphisms in APOE, SOAT1, APOE 5'-untranslated region, OLR1, CYP46A1, LPL, LIPA, and APOA4 conferring significant (p = .0002) susceptibility for Alzheimer's disease.
16013913	6646	D000544	SOAT1	Alzheimer's disease	1	1	0.956992507	0	1	only	1						m	We identified a cluster of polymorphisms in APOE, SOAT1, APOE 5'-untranslated region, OLR1, CYP46A1, LPL, LIPA, and APOA4 conferring significant (p = .0002) susceptibility for Alzheimer's disease.
16046317	197	D003920	AHSG | alpha2-Heremans-Schmid glycoprotein | alpha2-Heremans-schmid glycoprotein	diabetes	0	0	0.1173610091	0										
16046317	197	D003924	AHSG | alpha2-Heremans-Schmid glycoprotein | alpha2-Heremans-schmid glycoprotein	type 2 diabetes	1	1	0.9937036633	0										
16046317	197	D008659	AHSG | alpha2-Heremans-Schmid glycoprotein | alpha2-Heremans-schmid glycoprotein	metabolic syndrome	0	0	0.3866007924	0										
16076618	185	D011225	AT1 | angiotensin II type 1 receptor	preeclampsia	1	1	0.9911267161	0										
16098373	5175	D001749	CD31	bladder carcinoma	0	0	0.03601642698	0										
16098373	5175	D009369	CD31	tumor	0	0	0.002825875999	0										
16098373	5175	D014842	CD31	von Willebrand	0	0	0.01257468946	0										
16098373	5743	D001749	COX-2 | cyclooxygenase-2	bladder carcinoma	1	1	0.9938815832	0										
16098373	5743	D009369	COX-2 | cyclooxygenase-2	tumor	0	0	0.005706264172	0										
16098373	5743	D014842	COX-2 | cyclooxygenase-2	von Willebrand	0	0	0.00832589902	0										
16126967	1810	D001172	DR1	RA | rheumatoid arthritis	0	0	0.07204122096	0										
16126967	3123	D001172	DRB1 | HLA | HLA-DRB1	RA | rheumatoid arthritis	1	1	0.993483007	0										
16126967	3126	D001172	DR4	RA | rheumatoid arthritis	0	0	0.01495360211	0										
16142697	5444	D001932	PON | PON1 | paraoxonase1	brain tumours	1	1	0.9901340604	0										
16142697	5444	D005910	PON | PON1 | paraoxonase1	gliomas	0	1	0.7905285358	1	0					1			m	We found that in both tumour groups serum PON1 activity was significantly lower than the control group (p &lt; 0.001), but did not differ between meningiomas and high grade gliomas.
16142697	5444	D008579	PON | PON1 | paraoxonase1	meningiomas	0	1	0.9915097952	1	0					1			m	We found that in both tumour groups serum PON1 activity was significantly lower than the control group (p &lt; 0.001), but did not differ between meningiomas and high grade gliomas.
16142697	5444	D009369	PON | PON1 | paraoxonase1	tumour	0	0	0.03238959238	0										
16143514	54577	D008175	UDP-glucuronosyltransferase (UGT) 1A7 | UDP-glucuronosyltransferase 1A7 | UGT1A7	lung cancer	1	1	0.9940903783	0										
16145050	1910	D006627	EDNRB | endothelin receptor B	Hirschsprung disease	0	0	0.4565962851	0	1			Dk					e	Our data strongly suggest that EDNRB is involved in predisposition for two different multigenic disorders, HSCR and melanoma.
16145050	1910	D008545	EDNRB | endothelin receptor B	malignant melanoma | melanoma	1	1	0.9942722321	0										
16145050	1910	D009101	EDNRB | endothelin receptor B	MM	0	1	0.986695528	1	1			Dk					e	Our data strongly suggest that EDNRB is involved in predisposition for two different multigenic disorders, HSCR and melanoma.
16152821	185	D006973	AT1R	hypertension	1	1	0.5385658741	0										
16152821	185	D007022	AT1R	hypotensive	0	0	0.005243266933	0										
16152821	185	D016710	AT1R	hypertension of Yin-deficiency	0	0	0.006738450378	0										
16152821	185	D018149	AT1R	blood glucose	0	0	0.03158308193	0										
16152821	185	D061325	AT1R	TCM syndrome | TCM syndrome type of EH	0	1	0.9747280478	1	0								m	A1166C gene type is related to EH in the Chinese, C allele might a susceptible gene to hypertension, while TCM syndrome type of EH patients might not be related to whether C allele was borne.
16152821	283	D006973	Ang	hypertension	0	0	0.03695981205	0										
16152821	283	D007022	Ang	hypotensive	0	0	0.002231891267	0										
16152821	283	D016710	Ang	hypertension of Yin-deficiency	0	0	0.002479787683	0										
16152821	283	D018149	Ang	blood glucose	0	0	0.372261703	0										
16152821	283	D061325	Ang	TCM syndrome | TCM syndrome type of EH	0	0	0.0974451527	0										
16152821	796	D006973	CGRP | calcitonin-gene related peptide	hypertension	0	0	0.08385821432	0										
16152821	796	D007022	CGRP | calcitonin-gene related peptide	hypotensive	0	0	0.002395426854	0										
16152821	796	D016710	CGRP | calcitonin-gene related peptide	hypertension of Yin-deficiency	0	0	0.002682855353	0										
16152821	796	D018149	CGRP | calcitonin-gene related peptide	blood glucose	0	1	0.8401530385	1	0									
16152821	796	D061325	CGRP | calcitonin-gene related peptide	TCM syndrome | TCM syndrome type of EH	0	0	0.185825184	0										
16153823	2099	C563468	ERalpha | estrogen receptor alpha	impaired healing	0	0	0.02122333273	0										
16153823	2099	D014647	ERalpha | estrogen receptor alpha	Venous ulcers | venous ulceration	1	1	0.9135895967	0										
16153823	2100	C563468	ERbeta | estrogen receptor beta	impaired healing	0	0	0.0702322349	0										
16153823	2100	D014647	ERbeta | estrogen receptor beta	Venous ulcers | venous ulceration	1	1	0.9928874373	0										
16166815	4524	D001927	MTHFR	encephalopathy	0	0	0.005501133855	0										
16166815	4524	D007938	MTHFR	leukemia	0	1	0.5419883728	1	0									
16166815	4524	D009369	MTHFR	tumor	0	0	0.005978312343	0										
16166815	4524	D020258	MTHFR	neurotoxicity	0	0	0.4497712851	0										
16166815	4524	D064420	MTHFR	toxicity	1	0	0.007760932669	1	1								e	We suggest that plasma homocysteine, pretreatment plasma folate and possibly the presence of MTHFR mutations may be biomarkers of methotrexate toxicity and possibly its antifolate effect targeted towards the tumor as well.
16167906	1636	D006973	ACE | angiotensin-converting enzyme	hypertension | hypertensive	1	1	0.9934666753	0										
16169407	1813	D006966	DRD2 | dopamine receptor D2	hyperprolactinemia	1	1	0.9928120971	0										
16169407	1813	D015175	DRD2 | dopamine receptor D2	prolactinomas	0	0	0.02156956866	0										
16169407	1813	D030342	DRD2 | dopamine receptor D2	molecular defect	0	0	0.006437074859	0										
16175507	351	D000799	aminopeptidase P	angioedema	0	0	0.2381389886	0										
16175507	351	D002318	aminopeptidase P	cardiovascular diseases	0	0	0.003426248208	0										
16175507	7512	D000799	XPNPEP2 | membrane-bound APP	angioedema	1	1	0.9876319766	0										
16175507	7512	D002318	XPNPEP2 | membrane-bound APP	cardiovascular diseases	0	0	0.008422020823	0										
16205110	3091	C535575	HIF-1alpha | hypoxia-inducible factor 1alpha	head and neck squamous cell carcinoma	0	1	0.9454239607	1	1	only							mbg	Previous reports have identified the existence of single nucleotide polymorphisms (SNPs) in the oxygen-dependent degradation domain of the HIF-1alpha gene in renal cell carcinoma, head and neck squamous cell carcinoma, and androgen-independent prostate cancer (AIPC). 
16205110	3091	D002292	HIF-1alpha | hypoxia-inducible factor 1alpha	renal cell carcinoma	0	1	0.9744796157	1	1	only							mbg	Previous reports have identified the existence of single nucleotide polymorphisms (SNPs) in the oxygen-dependent degradation domain of the HIF-1alpha gene in renal cell carcinoma, head and neck squamous cell carcinoma, and androgen-independent prostate cancer (AIPC). 
16205110	3091	D009369	HIF-1alpha | hypoxia-inducible factor 1alpha	cancer	0	1	0.8495688438	1	1	only							1bg	The hypoxia-inducible factor 1alpha (HIF-1alpha) plays a major role in cancer progression.
16205110	3091	D011471	HIF-1alpha | hypoxia-inducible factor 1alpha	prostate cancer	1	1	0.995182693	0	1			Di					e	These results suggest that the C1772T polymorphism in HIF-1alpha may confer susceptibility to AIPC and contribute to the progression or metastasis of this disease.
16224024	114798	D001523	SLITRK1	developmental neuropsychiatric disorder	0	0	0.008956562728	0										
16224024	114798	D005879	SLITRK1	TS | Tourette's syndrome	1	1	0.9939755797	0										
16224024	407012	D001523	miR-189	developmental neuropsychiatric disorder	0	0	0.003565408057	0										
16224024	407012	D005879	miR-189	TS | Tourette's syndrome	0	0	0.1882235259	0										
16239104	11200	D001943	CHEK2	breast cancer | familial breast cancer	1	1	0.9947295785	0										
16239104	11200	D030342	CHEK2	familial disease	0	0	0.01009925921	0										
16239104	672	D001943	BRCA1	breast cancer | familial breast cancer	0	0	0.008854704909	0										
16239104	672	D030342	BRCA1	familial disease	0	0	0.002505289158	0										
16239632	5444	D003324	PON1 | Paraoxonase 1 | paraoxonase 1	coronary artery disease	0	1	0.7406583428	1	1	only							mbg	Paraoxonase 1 (PON1) was implicated in susceptibility to coronary artery disease and stroke in previous studies.
16239632	5444	D003920	PON1 | Paraoxonase 1 | paraoxonase 1	diabetes	0	0	0.01280122902	0										
16239632	5444	D006973	PON1 | Paraoxonase 1 | paraoxonase 1	hypertension	0	0	0.04998633638	0										
16239632	5444	D020521	PON1 | Paraoxonase 1 | paraoxonase 1	stroke	1	1	0.9880290627	0										
16239632	5445	D003324	PON2	coronary artery disease	0	0	0.005329196807	0										
16239632	5445	D003920	PON2	diabetes	0	0	0.003283287166	0										
16239632	5445	D006973	PON2	hypertension	0	0	0.003273953218	0										
16239632	5445	D020521	PON2	stroke	0	1	0.9599288702	1	0					1			e	Polymorphisms in the PON2 and PON3 genes were not associated with stroke.
16239632	5446	D003324	PON3	coronary artery disease	0	0	0.005248858128	0										
16239632	5446	D003920	PON3	diabetes	0	0	0.003253242932	0										
16239632	5446	D006973	PON3	hypertension	0	0	0.003243841231	0										
16239632	5446	D020521	PON3	stroke	0	1	0.9583724141	1	0					1			e	Polymorphisms in the PON2 and PON3 genes were not associated with stroke.
16243804	2064	D001943	erbB2	breast cancer	0	0	0.01076401956	0										
16243804	2064	D009369	erbB2	tumor	0	0	0.003032962093	0										
16243804	7157	D001943	p53	breast cancer	1	1	0.9946447611	0										
16243804	7157	D009369	p53	tumor	0	0	0.01456781942	0										
16304445	3552	D001523	IL-1A	aggressive disease | aggressive periodontitis	0	0	0.003996245097	0	0.5			Dk	n				m	The results show statistically significant (p &lt;or= 0.05) differences between genotype frequencies in aggressive and controls (IL-1B +3954 &amp; IL-6 -174)
16304445	3552	D002908	IL-1A	chronic disease	0	0	0.004117172677	0	0.5				n				m	chronic and aggressive periodontitis (IL-1A -889)
16304445	3552	D010518	IL-1A	periodontitis	1	0	0.007491819095	1	0.5				n				m	chronic and aggressive periodontitis (IL-1A -889)
16304445	3553	D001523	IL-1B	aggressive disease | aggressive periodontitis	0	0	0.003314646194	0	0.5				n				m	The results show statistically significant (p &lt;or= 0.05) differences between genotype frequencies in aggressive and controls (IL-1B +3954 &amp; IL-6 -174)
16304445	3553	D002908	IL-1B	chronic disease	0	0	0.003987539094	0	0				n					
16304445	3553	D010518	IL-1B	periodontitis	1	0	0.005105955061	1	0.5				n				m	The results show statistically significant (p &lt;or= 0.05) differences between genotype frequencies in aggressive and controls (IL-1B +3954 &amp; IL-6 -174)
16304445	3569	D001523	IL-6	aggressive disease | aggressive periodontitis	0	0	0.008279812522	0	0.5				n				m	The results show statistically significant (p &lt;or= 0.05) differences between genotype frequencies in aggressive and controls (IL-1B +3954 &amp; IL-6 -174)
16304445	3569	D002908	IL-6	chronic disease	0	0	0.005778794177	0	0.5				n				m	chronic and controls (IL-6 -174 &amp; VDR -1056)
16304445	3569	D010518	IL-6	periodontitis	1	0	0.01641815715	1	0.5				n				m	The results show statistically significant (p &lt;or= 0.05) differences between genotype frequencies in aggressive and controls (IL-1B +3954 &amp; IL-6 -174)
16304445	7099	D001523	TLR-4	aggressive disease | aggressive periodontitis	0	0	0.003626530757	0	0				n					
16304445	7099	D002908	TLR-4	chronic disease	0	0	0.004127118271	0	0				n					
16304445	7099	D010518	TLR-4	periodontitis	1	0	0.005556389689	1	0.5				n				e	and periodontitis as a whole and controls (VDR -1056, TLR-4 399 &amp; IL-6 -174).
16304445	7421	D001523	VDR	aggressive disease | aggressive periodontitis	0	0	0.006545017008	0	0				n					
16304445	7421	D002908	VDR	chronic disease	0	0	0.005117437802	0	0.5				n				m	chronic and controls (IL-6 -174 &amp; VDR -1056)
16304445	7421	D010518	VDR	periodontitis	1	0	0.01208961662	1	0.5				n				e	and periodontitis as a whole and controls (VDR -1056, TLR-4 399 &amp; IL-6 -174).
16360962	270	D006333	AMPD | AMPD1 | adenosine monophosphate deaminase	ischemic heart failure | nonischemic heart failure	1	1	0.9897918701	0	0					1			e	Results of this study failed to confirm a reported survival benefit among HF patients carrying the AMPD1 T-allele.
16360962	270	D007511	AMPD | AMPD1 | adenosine monophosphate deaminase	ischemic | ischemic HF	0	1	0.9912984967	1	0					1			e	Results of this study failed to confirm a reported survival benefit among HF patients carrying the AMPD1 T-allele.
16380919	4763	C537393	NF1 | NFNS | Neurofibromatosis type 1	neurofibromatosis-Noonan syndrome	1	1	0.9861132503	0	1								e	These results support the view that NFNS represents a variant of NF1 and is caused by mutations of the NF1 gene, some of which have been demonstrated to cause classic NF1 in other individuals.
16380919	4763	D009404	NF1 | NFNS | Neurofibromatosis type 1	NS	0	1	0.9301255345	1	1								1bg	Neurofibromatosis type 1 (NF1) demonstrates phenotypic overlap with Noonan syndrome (NS) in some patients, which results in the so-called neurofibromatosis-Noonan syndrome (NFNS).
16380919	4763	D009634	NF1 | NFNS | Neurofibromatosis type 1	Noonan syndrome	0	1	0.8675539494	1	1								1bg	Neurofibromatosis type 1 (NF1) demonstrates phenotypic overlap with Noonan syndrome (NS) in some patients, which results in the so-called neurofibromatosis-Noonan syndrome (NFNS).
16380919	5781	C537393	PTPN11	neurofibromatosis-Noonan syndrome	0	0	0.0288354177	0										
16380919	5781	D009404	PTPN11	NS	0	0	0.01241342817	0										
16380919	5781	D009634	PTPN11	Noonan syndrome	0	0	0.006568550598	0										
16388712	7099	D001907	TLR)4 | TLR4	Boutonneuse fever	1	1	0.9866705537	0										
16388712	7099	D009203	TLR)4 | TLR4	myocardial infarction	0	0	0.4373424649	0										
16395129	207	D012559	AKT | AKT1 | akt	schizophrenia	1	1	0.9945867062	0										
16411416	4524	D013927	MTHFR | methylenetetrahydrofolate reductase	Splenic thrombosis	0	1	0.9698577523	1	1								0	Splenic thrombosis in three patients with moderate hyperhomocysteinemia, low folate and the C677T variant of the methylenetetrahydrofolate reductase (MTHFR) gene.
16411416	4524	D020138	MTHFR | methylenetetrahydrofolate reductase	hyperhomocysteinemia	1	1	0.9858283997	0										
16418737	351	D008180	A/A+A/G	SLE | systemic lupus erythematosus	0	0	0.06908052415	0										
16418737	7124	D008180	TNF-alpha | tumor necrosis factor-alpha	SLE | systemic lupus erythematosus	1	1	0.9939925075	0										
16424004	1586	D009369	CYP17A1	tumors	0	0	0.004117849283	0										
16424004	1586	D011471	CYP17A1	prostate cancer	1	1	0.9246277809	0										
16424004	1588	D009369	CYP19A1	tumors	0	0	0.005031384993	0										
16424004	1588	D011471	CYP19A1	prostate cancer	1	1	0.9910317659	0										
16424004	354	D009369	KLK3	tumors	0	0	0.003570161294	0										
16424004	354	D011471	KLK3	prostate cancer	1	0	0.418799758	1	1		1						m	Individuals carrying both the CYP19A1 and KLK3 -252A&gt;G variant alleles had a significantly increased risk for prostate cancer
16442598	4824	D010051	NKX3 | NKX3.1	Colorectal, and Ovarian Cancer	0	0	0.01532306522	0										
16442598	4824	D011470	NKX3 | NKX3.1	benign prostatic hyperplasia | prostatic hyperplasia	1	0	0.03734560311	1	0.5				m				e	The NKX3.1 nucleotide 154 C/T or T/T genotype increases the relative odds for prostatic enlargement. The group with prostatic enlargement also had increased clinical benign prostatic hyperplasia and nocturia.
16442598	4824	D011471	NKX3 | NKX3.1	prostate cancer	0	1	0.8265575171	1	0									
16442598	4824	D011472	NKX3 | NKX3.1	prostatic enlargement	0	1	0.9670809507	1	1		1						e	The NKX3.1 nucleotide 154 C/T or T/T genotype increases the relative odds for prostatic enlargement.
16442598	4824	D053158	NKX3 | NKX3.1	nocturia	0	0	0.0900984481	0	0.5				m				e	The NKX3.1 nucleotide 154 C/T or T/T genotype increases the relative odds for prostatic enlargement. The group with prostatic enlargement also had increased clinical benign prostatic hyperplasia and nocturia.
16459141	22796	D003324	LDL-C | low-density lipoprotein cholesterol	coronary artery disease	0	0	0.01187560987	0										
16459141	23443	D003324	AMRS	coronary artery disease	0	0	0.01276805159	0										
16459141	341	D003324	apoCI	coronary artery disease	1	0	0.02016819082	1	1		1						e	The results suggested that both apoE and apoCI on chromosome 19 were the susceptibility locus for CAD
16459141	344	D003324	apoCII	coronary artery disease	0	0	0.01293030474	0										
16459141	348	D003324	apoE	coronary artery disease	1	1	0.8439134955	0										
16459141	3949	D003324	LDL-R	coronary artery disease	0	0	0.3943001926	0										
16465465	6950	D012559	TCP1	schizophrenia	1	1	0.9925013781	0										
16476014	3458	D014376	IFNG	tuberculosis	0	0	0.4888677001	0										
16476014	3459	D014376	IFNGR1 | Interferon-gamma receptor-1 | interferon-gamma (IFN-gamma) receptor-1	tuberculosis	1	1	0.9920045733	0										
16476505	7124	D002289	TNF-alpha | tumor necrosis factor-alpha	NSCLC | non-small cell lung cancer	0	1	0.9900678396	1	1				n				m	We have investigated two polymorphisms in the promoter region of the TNF-alpha gene (-308 G/A and -238 G/A) for their role in the susceptibility to and severity of non-small cell lung cancer (NSCLC)
16476505	7124	D008175	TNF-alpha | tumor necrosis factor-alpha	lung cancer | lung cancers	1	1	0.9915599227	0										
16517595	25818	D011471	kallikrein 5	prostate cancer	1	0	0.2386074066	1	1		1						0	Human tissue kallikrein 5 is a member of a proteolytic cascade pathway involved in seminal clot liquefaction and potentially in prostate cancer progression.
16517595	3484	D011471	insulin-like growth factor-binding proteins 1, 2, 3, 4, and 5	prostate cancer	0	0	0.1896722466	0										
16517595	3850	D011471	hK3	prostate cancer	0	0	0.05617475882	0										
16517595	3852	D011471	hK5	prostate cancer	0	1	0.9147306681	1	1		1						0	Human tissue kallikrein 5 is a member of a proteolytic cascade pathway involved in seminal clot liquefaction and potentially in prostate cancer progression.
16517595	58164	D011471	hK2	prostate cancer	0	0	0.0980970636	0										
16534528	153	D009765	ADRB1 | beta1-adrenergic receptor	obesity	1	1	0.9910960197	0										
16534528	4023	D009765	LPL | lipoprotein lipase	obesity	1	1	0.9852677584	0										
16538175	3303	D004342	HSPA1A	hypersensitivity | hypersensitivity reactions	1	0	0.4442893565	1	1	only	1						m	Analyses revealed that alleles G, T and C at the SNPs HSPA1A +1911 C/G, HSPA1A +438 C/T and HSPA1L +2437 T/C, respectively, were associated with protection from serious hypersensitivity reactions to CBZ, with the associated alleles falling on a common haplotype.
16538175	3305	D004342	HSPA1L	hypersensitivity | hypersensitivity reactions	1	0	0.3502887189	1	1	only	1						m	Analyses revealed that alleles G, T and C at the SNPs HSPA1A +1911 C/G, HSPA1A +438 C/T and HSPA1L +2437 T/C, respectively, were associated with protection from serious hypersensitivity reactions to CBZ, with the associated alleles falling on a common haplotype.
16538175	3308	D004342	HSP70 | heat shock protein (HSP70	hypersensitivity | hypersensitivity reactions	0	1	0.9927734733	1	1		1						e	Our data show that HSP70 gene variants are associated with serious CBZ hypersensitivity reactions, but whether this is causal or reflects LD with another gene within the MHC requires further study.
16538185	4855	D012559	Notch4	schizophrenia | schizophrenic	1	1	0.9908047915	0										
16571646	100049783	D000013	Kir2.1	dysmorphic features	0	0	0.002804565243	0										
16571646	100049783	D006331	Kir2.1	cardiac dysarrhythmias	0	0	0.002897426719	0										
16571646	100049783	D010243	Kir2.1	paralysis	0	0	0.002834829735	0										
16571646	100049783	D013610	Kir2.1	tachycardia	0	0	0.003228339134	0										
16571646	100049783	D017180	Kir2.1	Ventricular tachyarrhythmias | ventricular tachycardia	0	0	0.007844750769	0										
16571646	100049783	D030342	Kir2.1	inherited disorder	0	0	0.002973400755	0										
16571646	100049783	D050030	Kir2.1	ATS | familial ATS	0	0	0.004988064989	0										
16571646	3759	D000013	KCNJ2 | Kir2.1	dysmorphic features	0	0	0.02016022615	0										
16571646	3759	D006331	KCNJ2 | Kir2.1	cardiac dysarrhythmias	0	0	0.1472698599	0										
16571646	3759	D010243	KCNJ2 | Kir2.1	paralysis	0	0	0.08448661864	0										
16571646	3759	D013610	KCNJ2 | Kir2.1	tachycardia	0	0	0.02064901777	0										
16571646	3759	D017180	KCNJ2 | Kir2.1	Ventricular tachyarrhythmias | ventricular tachycardia	0	0	0.2521086037	0										
16571646	3759	D030342	KCNJ2 | Kir2.1	inherited disorder	0	0	0.01855786331	0										
16571646	3759	D050030	KCNJ2 | Kir2.1	ATS | familial ATS	1	1	0.9866086841	0										
16600714	7421	D011471	vitamin D receptor	prostate cancer	1	1	0.994732976	0										
16618831	154	C536778	B2AR | Beta2-adrenergic receptor | beta2-adrenergic receptor	SCD	0	1	0.9945080876	1	1		1						e	Our findings suggest that B2AR plays a role in SCD in humans.
16618831	154	D001145	B2AR | Beta2-adrenergic receptor | beta2-adrenergic receptor	ventricular arrhythmias	0	0	0.0188670475	0										
16618831	154	D002318	B2AR | Beta2-adrenergic receptor | beta2-adrenergic receptor	black Cardiovascular	0	0	0.005949729122	0										
16618831	154	D002609	B2AR | Beta2-adrenergic receptor | beta2-adrenergic receptor	CHS	0	0	0.02545132861	0										
16618831	154	D006323	B2AR | Beta2-adrenergic receptor | beta2-adrenergic receptor	Cardiac Arrest	0	0	0.004842494614	0										
16618831	154	D016757	B2AR | Beta2-adrenergic receptor | beta2-adrenergic receptor	sudden cardiac death	1	1	0.9859502912	0										
16642438	100130889	D011565	PSORS1C3	psoriasis	0	0	0.009519477375	0										
16642438	1041	D011565	CDSN | CDSN* | CDSN*TTC	psoriasis	0	0	0.1533058584	0										
16642438	170679	D011565	SEEK1	psoriasis	0	0	0.00915244408	0										
16642438	170680	D011565	SPR1	psoriasis	0	0	0.009025276639	0										
16642438	253018	D011565	HCG27	psoriasis	0	0	0.009918398224	0										
16642438	285834	D011565	HCG22	psoriasis	0	0	0.0101520475	0										
16642438	3106	D011565	HLA-B	psoriasis	0	0	0.009300974198	0										
16642438	3107	D011565	HLA-C | PSORS1	psoriasis	1	1	0.9303931594	0										
16642438	54535	D011565	HCR	psoriasis	0	0	0.009385759942	0										
16642438	5460	D011565	OTF3	psoriasis	0	0	0.0113151148	0										
16642438	6941	D011565	TCF19	psoriasis	0	0	0.009190563112	0										
16741935	1636	D001927	ACE | Angiotensin-converting enzyme | angiotensin-converting enzyme	brain disorder	0	0	0.004905559123	0										
16741935	1636	D003711	ACE | Angiotensin-converting enzyme | angiotensin-converting enzyme	Autoimmune demyelination	0	0	0.01469086017	0										
16741935	1636	D013344	ACE | Angiotensin-converting enzyme | angiotensin-converting enzyme	sclerosing panencephalitis	0	0	0.03780129179	0										
16741935	1636	D014412	ACE | Angiotensin-converting enzyme | angiotensin-converting enzyme	virus infection	0	0	0.004760350101	0										
16741935	183	D001927	Ang II | angiotensin II	brain disorder	0	0	0.002987111686	0										
16741935	183	D003711	Ang II | angiotensin II	Autoimmune demyelination	0	0	0.004897735082	0										
16741935	183	D013344	Ang II | angiotensin II	sclerosing panencephalitis	0	0	0.004121153615	0										
16741935	183	D014412	Ang II | angiotensin II	virus infection	0	0	0.002936091973	0										
16741935	185	D001927	AT1R | Ang II type 1 receptor | angiotensin II type 1 receptor	brain disorder	0	0	0.009425599128	0										
16741935	185	D003711	AT1R | Ang II type 1 receptor | angiotensin II type 1 receptor	Autoimmune demyelination	0	0	0.05212714896	0										
16741935	185	D013344	AT1R | Ang II type 1 receptor | angiotensin II type 1 receptor	sclerosing panencephalitis	1	1	0.6971429586	0										
16741935	185	D014412	AT1R | Ang II type 1 receptor | angiotensin II type 1 receptor	virus infection	0	0	0.008967061527	0										
16786764	3123	D006689	HLA DRB1	Hodgkin's lymphoma	0	0	0.008968964219	0										
16786764	3123	D008223	HLA DRB1	lymphoma	0	0	0.09444569051	0										
16786764	3123	D008228	HLA DRB1	NHL | non-Hodgkin's lymphomas	1	1	0.9902544618	0										
16786764	4049	D006689	LTalpha | lymphotoxin alpha	Hodgkin's lymphoma	0	0	0.003076936118	0										
16786764	4049	D008223	LTalpha | lymphotoxin alpha	lymphoma	0	0	0.007548005786	0										
16786764	4049	D008228	LTalpha | lymphotoxin alpha	NHL | non-Hodgkin's lymphomas	0	0	0.09922252595	0										
16786764	7124	D006689	TNF | tumor necrosis factor	Hodgkin's lymphoma	0	0	0.02372104488	0										
16786764	7124	D008223	TNF | tumor necrosis factor	lymphoma	0	0	0.1743942201	0										
16786764	7124	D008228	TNF | tumor necrosis factor	NHL | non-Hodgkin's lymphomas	1	1	0.9913914204	0										
16786764	7132	D006689	p55	Hodgkin's lymphoma	0	0	0.003185169771	0										
16786764	7132	D008223	p55	lymphoma	0	0	0.004320710897	0										
16786764	7132	D008228	p55	NHL | non-Hodgkin's lymphomas	0	0	0.0109172808	0										
16786764	7133	D006689	p75	Hodgkin's lymphoma	0	0	0.00299239764	0										
16786764	7133	D008223	p75	lymphoma	0	0	0.004027648829	0										
16786764	7133	D008228	p75	NHL | non-Hodgkin's lymphomas	0	0	0.00960491132	0										
16800822	1544	D009369	CYP1A2 | cytochrome P450 1A2	cancer	0	0	0.1043204516	0										
16800822	1544	D015179	CYP1A2 | cytochrome P450 1A2	colorectal cancer	1	1	0.9906041026	0										
16800822	2328	D009369	FMO3 | flavin-containing monooxygenase 3	cancer	0	0	0.008829893544	0										
16800822	2328	D015179	FMO3 | flavin-containing monooxygenase 3	colorectal cancer	1	0	0.432913363	1	0						1		m	The genotypes and allele frequencies of the MDR1/C3435T, FMO3/G488A, FMO3/A923G and CYP1A2/G-3860 A polymorphisms were not significantly different in cancer-free subjects and CRC patients.
16800822	5243	D009369	MDR1 | P-glycoprotein | PGP	cancer	0	0	0.003429178614	0										
16800822	5243	D015179	MDR1 | P-glycoprotein | PGP	colorectal cancer	1	0	0.1148564741	1	0						1		m	The genotypes and allele frequencies of the MDR1/C3435T, FMO3/G488A, FMO3/A923G and CYP1A2/G-3860 A polymorphisms were not significantly different in cancer-free subjects and CRC patients.
16855521	3123	C580472	DRB1 | HLA | HLA-DRB1	arthro-pathy	0	0	0.008004580624	0										
16855521	3123	D002357	DRB1 | HLA | HLA-DRB1	cartilage loss	0	0	0.05074343458	0										
16855521	3123	D010003	DRB1 | HLA | HLA-DRB1	Osteoarthritis | osteoarthritis	1	1	0.8780516982	0										
16855521	3123	D020914	DRB1 | HLA | HLA-DRB1	structural defect	0	0	0.04166676849	0										
16859836	1586	D009369	CYP17	cancer	0	0	0.003861350939	0										
16859836	1586	D011471	CYP17	decrease prostate cancer | familial prostate cancer | prostate cancer	1	1	0.9896968603	0										
16859836	367	D009369	AR | androgen receptor	cancer	0	0	0.003660197603	0										
16859836	367	D011471	AR | androgen receptor	decrease prostate cancer | familial prostate cancer | prostate cancer	0	1	0.9826399684	1	0									
16859836	6716	D009369	SRD5A2	cancer	0	0	0.002875687322	0										
16859836	6716	D011471	SRD5A2	decrease prostate cancer | familial prostate cancer | prostate cancer	0	1	0.9476409554	1	0									
16859836	7366	D009369	UDG-glucuronosyltransferase (UGT) 2B15 | UGT2B15	cancer	0	0	0.003734609345	0										
16859836	7366	D011471	UDG-glucuronosyltransferase (UGT) 2B15 | UGT2B15	decrease prostate cancer | familial prostate cancer | prostate cancer	1	1	0.9896500111	0										
16909125	26136	D001932	TES | Testin	brain tumor	0	0	0.008334754035	0										
16909125	26136	D005909	TES | Testin	Glioblastoma | glioblastoma | glioblastoma tumorigenesis | glioblastomas	1	1	0.9901812673	0										
16909125	26136	D005910	TES | Testin	malignant glioma	0	0	0.06953892112	0										
16909125	26136	D009369	TES | Testin	tumor	0	0	0.007132954895	0										
16909125	864	D001932	RUNX3	brain tumor	0	0	0.00715351291	0										
16909125	864	D005909	RUNX3	Glioblastoma | glioblastoma | glioblastoma tumorigenesis | glioblastomas	1	1	0.985966146	0										
16909125	864	D005910	RUNX3	malignant glioma	0	0	0.05007009208	0										
16909125	864	D009369	RUNX3	tumor	0	0	0.006295059808	0										
16951497	4205	D003324	MEF2A	coronary artery disease	1	1	0.9939607382	0										
16970152	5428	D007246	Polg	idiopathic infertile	0	0	0.01447782572	0										
16970152	5428	D007248	Polg	idiopathic male infertility | male infertility	1	1	0.9918501377	0										
16970152	5428	D009845	Polg	oligospermia	0	0	0.01189154014	0										
16970152	5428	D053713	Polg	azoospermia	0	0	0.01305384282	0										
16973370	348	D000544	ApoE | apolipoprotein E	AD | Alzheimer's disease	1	1	0.9849898815	0										
16973370	348	D019636	ApoE | apolipoprotein E	neurodegeneration	0	0	0.008435211144	0										
16973370	348	D020258	ApoE | apolipoprotein E	neurotoxicity	0	0	0.009830673225	0										
16973370	348	D044882	ApoE | apolipoprotein E	cerebral glucose metabolism	0	0	0.028210802	0										
16973370	590	D000544	BuChE | Butyrylcholinesterase | butyrylcholinesterase	AD | Alzheimer's disease	0	1	0.9908518195	1	1								1bg	Butyrylcholinesterase (BuChE) is increased in the cerebral cortex of Alzheimer's disease (AD) patients, particularly those carrying epsilon4 allele of the apolipoprotein E gene (ApoE) and certain BuChE variants that predict increased AD risk and poor response to anticholinesterase therapy.
16973370	590	D019636	BuChE | Butyrylcholinesterase | butyrylcholinesterase	neurodegeneration	0	0	0.0844624266	0	1								e	Thus, low BuChE in a patient's CSF may predict extensive incorporation in neuritic plaques, increased neurotoxicity and greater central neurodegeneration.
16973370	590	D020258	BuChE | Butyrylcholinesterase | butyrylcholinesterase	neurotoxicity	0	1	0.5054892898	1	1								e	Thus, low BuChE in a patient's CSF may predict extensive incorporation in neuritic plaques, increased neurotoxicity and greater central neurodegeneration.
16973370	590	D044882	BuChE | Butyrylcholinesterase | butyrylcholinesterase	cerebral glucose metabolism	0	0	0.2432667464	0										
16988840	23205	D001172	LPD	RA | RA-LPD | rheumatoid arthritis	0	1	0.9289782643	1	0			Gi						
16988840	23205	D008228	LPD	non-Hodgkin's lymphoma	0	0	0.007252529729	0	0			Gi						
16988840	23205	D008232	LPD	lymphoproliferative disorders	0	0	0.003600926138	0	0			Gi						
16988840	4580	D001172	MTX	RA | RA-LPD | rheumatoid arthritis	0	1	0.7633360028	1	0			Gi						
16988840	4580	D008228	MTX	non-Hodgkin's lymphoma	0	0	0.0598648116	0	0			Gi						
16988840	4580	D008232	MTX	lymphoproliferative disorders	0	0	0.003884806763	0	0			Gi						
16988840	578	D001172	Bak	RA | RA-LPD | rheumatoid arthritis	0	1	0.6932176352	1	0					1			e	MTX-LPD and non-MTX-LPD show similar findings in clinical characteristics, histology, EBV positive rate, and frequency of Bak gene mutations.
16988840	578	D008228	Bak	non-Hodgkin's lymphoma	0	0	0.006369648967	0	0									
16988840	578	D008232	Bak	lymphoproliferative disorders	1	0	0.02622214891	1	0					1			e	MTX-LPD and non-MTX-LPD show similar findings in clinical characteristics, histology, EBV positive rate, and frequency of Bak gene mutations.
16988840	7157	D001172	p53	RA | RA-LPD | rheumatoid arthritis	0	1	0.9703642726	1	1			Dm	n				e	Whereas the non-MTX-LPD is distinct from the MTX-LPD in its significantly higher p53 mutation frequency.
16988840	7157	D008228	p53	non-Hodgkin's lymphoma	0	0	0.04288958758	0	1	only			n				m	Among the cases with non-Hodgkin's lymphoma (NHL), the largest category of RA-LPD, the frequency of p53 mutations in the non-MTX-NHL (47.6%) was significantly higher than that in the MTX-NHL (14.8%) (P &lt; 0.05).
16988840	7157	D008232	p53	lymphoproliferative disorders	1	0	0.01557936892	1	1			Dm	n				e	Whereas the non-MTX-LPD is distinct from the MTX-LPD in its significantly higher p53 mutation frequency.
17009404	2068	D013274	XPD | Xeroderma pigmentosum group D | xeroderma pigmentosum group D	gastric cancer	1	1	0.9932945371	0										
17027833	10242	D009765	beta2	obese | obesity	0	0	0.01069510449	0										
17027833	154	D009765	Beta2-adrenoceptor | beta2-adrenoceptor	obese | obesity	1	1	0.9726595283	0										
17027833	3952	D009765	leptin	obese | obesity	0	1	0.9899457097	1	1								0	Beta2-adrenoceptor polymorphisms relate to obesity through blunted leptin-mediated sympathetic activation.
17044851	2784	D006973	G-protein beta3	Hypertension | hypertension	1	1	0.9893855453	0										
17054409	5243	D012559	ABCB1 | ATP-binding cassette B1 | P-glycoprotein	schizophrenia	1	1	0.9859981537	0										
17063270	672	D001943	BRCA1	breast cancer | breast cancers	1	1	0.9914172292	0										
17063270	675	D001943	BRCA2	breast cancer | breast cancers	1	1	0.9919322133	0										
17074108	6532	D003248	SERT | Serotonin transporter | serotonin reuptake transporter	constipation	0	0	0.101547122	0										
17074108	6532	D043183	SERT | Serotonin transporter | serotonin reuptake transporter	IBS | irritable bowel syndrome	1	1	0.988217175	0										
17089069	1815	D001523	DRD4 | dopamine D4 receptor	psychiatric illnesses	0	0	0.4551190138	0										
17089069	1815	D012559	DRD4 | dopamine D4 receptor	schizophrenia | schizophrenic	1	1	0.9849536419	0										
17119036	1588	D001943	CYP19A1	breast cancer	1	1	0.9945762157	0										
17119036	1588	D009369	CYP19A1	cancer	0	0	0.01853522286	0										
17123692	7124	D014627	TNF | TNF-alpha | TNFA | tumor necrosis factor-alpha	abnormal vaginal flora	0	1	0.8504264951	1	1								m	The vaginal TNF-alpha concentration was elevated in TNFA-308A carriers only in the presence of abnormal vaginal flora.
17123692	7124	D016585	TNF | TNF-alpha | TNFA | tumor necrosis factor-alpha	bacterial vaginosis	1	1	0.9627907276	0	1		1						m	A median TNF-alpha level of 10.94 pg/ml in TNFA-308A carriers with bacterial vaginosis (BV) was significantly higher than that of 1.77 pg/ml in TNFA-308A carriers without BV (P=.02), and 1.72 pg/ml in TNF-308G homozygotes with BV (P=.01).
17130675	1906	D006973	endothelin-1	hypertension	1	0	0.3323053122	1	1								e	Our results indicated that endothelin-1 plays a key role in the FK506-induced change in vascular reactivity to noradrenaline in renal vascular beds and drug-induced hypertension in the rats.
17130675	1906	D014652	endothelin-1	vascular dysfunction	0	1	0.5177633762	1	0									
17173698	3155	C537358	3-Hydroxy-3-Methylglutaryl CoA lyase | HL | HMGCL	aciduria	0	0	0.1109348685	0										
17173698	3155	C538324	3-Hydroxy-3-Methylglutaryl CoA lyase | HL | HMGCL	CoA lyase deficiency	1	1	0.5651803017	0										
17173698	3155	D008375	3-Hydroxy-3-Methylglutaryl CoA lyase | HL | HMGCL	autosomal recessive branched chain organic aciduria	0	0	0.04500041902	0										
17182746	10063	D028361	Cox17	respiratory chain deficiency	0	0	0.006892209407	0										
17182746	6341	D028361	Sco1	respiratory chain deficiency	1	1	0.9016187787	0										
17184882	2908	D001284	Glucocorticoid receptor | glucocorticoid receptor	atrophy	0	0	0.008937751874	0										
17184882	2908	D001927	Glucocorticoid receptor | glucocorticoid receptor	brain abnormalities	0	0	0.00525549287	0										
17184882	2908	D003704	Glucocorticoid receptor | glucocorticoid receptor	dementia	1	0	0.1289717108	1	1		1		M				e	Our findings suggest a protective effect of the ER22/23EK allele on the risk of dementia and white matter lesions.
17184882	2908	D056784	Glucocorticoid receptor | glucocorticoid receptor	white matter lesions	0	1	0.7000422478	1	1		1		M				e	Our findings suggest a protective effect of the ER22/23EK allele on the risk of dementia and white matter lesions.
17187665	120892	D009127	LRRK2	rigidity	0	0	0.004790909123	0										
17187665	120892	D010300	LRRK2	PD | Parkinson disease | Parkinson's disease	1	1	0.990673244	0										
17187665	120892	D014202	LRRK2	tremor	0	0	0.004637921695	0										
17187665	120892	D018476	LRRK2	bradykinesia	0	0	0.004302348942	0										
17187665	120892	D019636	LRRK2	neurodegenerative movement disorder	0	0	0.004577298183	0										
17219962	1385	D004409	CREB | cAMP response element-binding protein	LID | abnormal involuntary movement | dyskinesias	0	1	0.6496278048	1	0.5				n				e	As compared with the control group, the expression of PDyn mRNA in striatum was decreased by antisense CREB-treated LID group (P&lt;0.01) and compared with sense CREB treated LID group
17219962	1385	D010300	CREB | cAMP response element-binding protein	PD | Parkinson disease	0	0	0.3524077237	0										
17219962	2354	D004409	FosB	LID | abnormal involuntary movement | dyskinesias	1	1	0.910703063	0										
17219962	2354	D010300	FosB	PD | Parkinson disease	0	0	0.4281928539	0										
17219962	5173	D004409	PDyn | prodynorphin	LID | abnormal involuntary movement | dyskinesias	0	1	0.9918631315	1	1				n				e	In conclusion, FosB protein, which replaced the CREG, could regulate the expression of PDyn mRNA and play critical role in the pathogenesis of LID.
17219962	5173	D010300	PDyn | prodynorphin	PD | Parkinson disease	0	1	0.9118393064	1	0									
17219962	8804	D004409	CREG	LID | abnormal involuntary movement | dyskinesias	0	0	0.01843584701	0										
17219962	8804	D010300	CREG	PD | Parkinson disease	0	0	0.008049832657	0										
17220914	1268	D004681	CB1	autoimmune encephalomyelitis	0	1	0.6327062845	1	0									
17220914	1268	D009103	CB1	multiple sclerosis	0	1	0.970610261	1	1		1						0	Control of spasticity in a multiple sclerosis model is mediated by CB1, not CB2, cannabinoid receptors.
17220914	1268	D009128	CB1	muscle-spasticity in multiple sclerosis | spasticity	1	1	0.9343436956	0	1		1						0	Control of spasticity in a multiple sclerosis model is mediated by CB1, not CB2, cannabinoid receptors.
17220914	1269	D004681	CB2	autoimmune encephalomyelitis	0	0	0.01439341903	0										
17220914	1269	D009103	CB2	multiple sclerosis	0	1	0.8973231912	1	0									
17220914	1269	D009128	CB2	muscle-spasticity in multiple sclerosis | spasticity	0	1	0.9646614194	1	1								m	As previously suggested, some CB2-selective agonists (RWJ400065) could inhibit spasticity.
17264841	4862	D001321	Npas2 | npas2	Autism | autism | autistic disorder	1	1	0.9922377467	0										
17264841	4862	D008569	Npas2 | npas2	memory and temporal deficits	0	0	0.01435489114	0										
17276496	4210	D010505	MEFV | familial Mediterranean fever	FMF	1	1	0.989459157	0										
17283289	150	D001289	ADRA2A | adrenergic alpha2A receptor	ADHD | attention-deficit/hyperactivity disorder	1	1	0.9909679294	0										
17283289	150	D007174	ADRA2A | adrenergic alpha2A receptor	hyperactivity-impulsivity	0	0	0.03404026851	0										
17283289	5580	D001289	May 1	ADHD | attention-deficit/hyperactivity disorder	0	0	0.02073905058	0										
17283289	5580	D007174	May 1	hyperactivity-impulsivity	0	0	0.00373077183	0										
17301827	3119	C535541	DQB1	IBD	0	0	0.01200374309	0										
17301827	3119	D003093	DQB1	ulcerative colitis	1	0	0.006639915053	1	0									
17301827	3119	D006086	DQB1	hepatobiliary versus intestinal pathology	0	1	0.6051458716	1	0									
17301827	3119	D015209	DQB1	primary sclerosing cholangitis | sclerosing cholangitis	0	1	0.6821038127	1	0									
17301827	3119	D015212	DQB1	inflammatory bowel disease	0	0	0.00722626783	0										
17301827	3123	C535541	DRB1	IBD	0	0	0.00963881705	0										
17301827	3123	D003093	DRB1	ulcerative colitis	1	0	0.005801701918	1	0									
17301827	3123	D006086	DRB1	hepatobiliary versus intestinal pathology	0	0	0.4734545946	0										
17301827	3123	D015209	DRB1	primary sclerosing cholangitis | sclerosing cholangitis	0	1	0.5678572059	1	0									
17301827	3123	D015212	DRB1	inflammatory bowel disease	0	0	0.006251737475	0										
17325735	1565	D012559	CYP2D6	schizophrenia | schizophrenic	1	1	0.9946125746	0										
17325735	6531	D012559	dopamine transporter	schizophrenia | schizophrenic	0	0	0.02704382129	0										
17334511	2811	D001791	GPIbalpha | Glycoprotein Ibalpha	platelet aggregation	0	0	0.0102198096	0										
17334511	2811	D012421	GPIbalpha | Glycoprotein Ibalpha	rupture	0	0	0.005636844318	0										
17334511	2811	D013927	GPIbalpha | Glycoprotein Ibalpha	intra-arterial thrombus | platelet thrombus | thrombus	1	1	0.9763917327	0										
17334511	2811	D050197	GPIbalpha | Glycoprotein Ibalpha	atherosclerotic | rupture of atherosclerotic	0	1	0.9692476988	1	1								0	Glycoprotein Ibalpha inhibition and ADP receptor antagonists, but not aspirin, reduce platelet thrombus formation in flowing blood exposed to atherosclerotic plaques.
17334511	5028	D001791	P2Y(1)	platelet aggregation	0	0	0.009038627148	0										
17334511	5028	D012421	P2Y(1)	rupture	0	0	0.00559587637	0										
17334511	5028	D013927	P2Y(1)	intra-arterial thrombus | platelet thrombus | thrombus	1	1	0.9277557731	0										
17334511	5028	D050197	P2Y(1)	atherosclerotic | rupture of atherosclerotic	0	1	0.7253346443	1	1				C				0	Glycoprotein Ibalpha inhibition and ADP receptor antagonists, but not aspirin, reduce platelet thrombus formation in flowing blood exposed to atherosclerotic plaques.
17343741	2288	D007021	FKBP4 | FKBP52 | fkbp52	hypospadias | isolated hypospadias | non-syndromic hypospadias | syndromic hypospadias	1	1	0.9943774343	0										
17343741	2288	D008661	FKBP4 | FKBP52 | fkbp52	inborn error	0	0	0.04622075707	0										
17343741	2288	D012734	FKBP4 | FKBP52 | fkbp52	male genitalia	0	0	0.04411012679	0										
17343741	367	D007021	androgen receptor	hypospadias | isolated hypospadias | non-syndromic hypospadias | syndromic hypospadias	0	0	0.07405989617	0										
17343741	367	D008661	androgen receptor	inborn error	0	0	0.007036919706	0										
17343741	367	D012734	androgen receptor	male genitalia	0	0	0.006803138647	0										
17344400	1385	D000544	CREB | cAMP response element-binding protein	AD | Alzheimer's disease | senile dementia	0	0	0.01234245766	0										
17344400	1385	D003072	CREB | cAMP response element-binding protein	cognitive decline | cognitive dysfunction	0	0	0.004129094537	0										
17344400	1385	D003704	CREB | cAMP response element-binding protein	dementia	0	0	0.002788781654	0										
17344400	1385	D008569	CREB | cAMP response element-binding protein	memory loss	0	0	0.003188855248	0										
17344400	1385	D009447	CREB | cAMP response element-binding protein	neuroblastoma	0	0	0.003524228698	0										
17344400	1385	D009461	CREB | cAMP response element-binding protein	neuronal dysfunction	0	0	0.002800173359	0										
17344400	1385	D064420	CREB | cAMP response element-binding protein	Abeta toxicity	0	0	0.00253333454	0										
17344400	351	D000544	Abeta	AD | Alzheimer's disease | senile dementia	0	1	0.8420273066	1	1								e	Thus, oligomeric Abeta(1-42) could compromise neuronal function, causing memory loss and cognitive dysfunction by downregulation of BDNF in AD.
17344400	351	D003072	Abeta	cognitive decline | cognitive dysfunction	0	0	0.005581066012	0	1								e	Thus, oligomeric Abeta(1-42) could compromise neuronal function, causing memory loss and cognitive dysfunction by downregulation of BDNF in AD.
17344400	351	D003704	Abeta	dementia	0	0	0.002723491518	0										
17344400	351	D008569	Abeta	memory loss	0	0	0.004024518654	0	1								e	Thus, oligomeric Abeta(1-42) could compromise neuronal function, causing memory loss and cognitive dysfunction by downregulation of BDNF in AD.
17344400	351	D009447	Abeta	neuroblastoma	0	0	0.002955840435	0										
17344400	351	D009461	Abeta	neuronal dysfunction	0	0	0.002694552299	0										
17344400	351	D064420	Abeta	Abeta toxicity	0	0	0.002719577868	0										
17344400	627	D000544	BDNF | Brain-derived neurotrophic factor | brain-derived neurotrophic factor	AD | Alzheimer's disease | senile dementia	1	1	0.9920933843	0	1								e	Thus, oligomeric Abeta(1-42) could compromise neuronal function, causing memory loss and cognitive dysfunction by downregulation of BDNF in AD.
17344400	627	D003072	BDNF | Brain-derived neurotrophic factor | brain-derived neurotrophic factor	cognitive decline | cognitive dysfunction	0	1	0.636970222	1	1								e	Thus, oligomeric Abeta(1-42) could compromise neuronal function, causing memory loss and cognitive dysfunction by downregulation of BDNF in AD.
17344400	627	D003704	BDNF | Brain-derived neurotrophic factor | brain-derived neurotrophic factor	dementia	0	0	0.006381378509	0										
17344400	627	D008569	BDNF | Brain-derived neurotrophic factor | brain-derived neurotrophic factor	memory loss	0	0	0.01749326661	0	1								e	Thus, oligomeric Abeta(1-42) could compromise neuronal function, causing memory loss and cognitive dysfunction by downregulation of BDNF in AD.
17344400	627	D009447	BDNF | Brain-derived neurotrophic factor | brain-derived neurotrophic factor	neuroblastoma	0	0	0.3244110048	0										
17344400	627	D009461	BDNF | Brain-derived neurotrophic factor | brain-derived neurotrophic factor	neuronal dysfunction	0	0	0.06979157031	0	1	only							m	We previously demonstrated that BDNF reduction occurs early in the course of AD, suggesting that decreased BDNF may promote neuronal dysfunction in AD.
17344400	627	D064420	BDNF | Brain-derived neurotrophic factor | brain-derived neurotrophic factor	Abeta toxicity	0	0	0.004927121103	0										
17353161	2717	D000795	alpha-galactosidase A	Fabry disease	0	0	0.1689314842	0										
17353161	2717	D007249	alpha-galactosidase A	inflammation	0	0	0.01021891274	0										
17353161	2717	D009202	alpha-galactosidase A	cardiomyopathy	0	0	0.002918018727	0										
17353161	2717	D020521	alpha-galactosidase A	stroke	0	0	0.002816254273	0										
17353161	2717	D040181	alpha-galactosidase A	X-linked disorder	0	0	0.002776820678	0										
17353161	2717	D051437	alpha-galactosidase A	renal failure	0	0	0.002775401808	0										
17353161	3552	D000795	IL-1 alpha | IL-1alpha	Fabry disease	1	1	0.614130199	0										
17353161	3552	D007249	IL-1 alpha | IL-1alpha	inflammation	0	0	0.02771883085	0										
17353161	3552	D009202	IL-1 alpha | IL-1alpha	cardiomyopathy	0	0	0.003924016375	0										
17353161	3552	D020521	IL-1 alpha | IL-1alpha	stroke	0	0	0.003726788098	0										
17353161	3552	D040181	IL-1 alpha | IL-1alpha	X-linked disorder	0	0	0.003638789756	0										
17353161	3552	D051437	IL-1 alpha | IL-1alpha	renal failure	0	0	0.003635823028	0										
17353161	3553	D000795	IL-1beta	Fabry disease	1	0	0.1908932924	1	1								m	Statistically significant differences were found in the ratio between the two polymorphisms of IL-10 (p &lt; 0.0001), between the two polymorphisms of IL-1beta (p = 0.001); between IL-1alpha
17353161	3553	D007249	IL-1beta	inflammation	0	0	0.01041802857	0										
17353161	3553	D009202	IL-1beta	cardiomyopathy	0	0	0.002989784116	0										
17353161	3553	D020521	IL-1beta	stroke	0	0	0.002888028976	0										
17353161	3553	D040181	IL-1beta	X-linked disorder	0	0	0.002845981158	0										
17353161	3553	D051437	IL-1beta	renal failure	0	0	0.002845444018	0										
17353161	3586	D000795	IL-10	Fabry disease	1	0	0.1781056374	1	1								m	Statistically significant differences were found in the ratio between the two polymorphisms of IL-10 (p &lt; 0.0001), between the two polymorphisms of IL-1beta (p = 0.001); between IL-1alpha
17353161	3586	D007249	IL-10	inflammation	0	0	0.009963748045	0										
17353161	3586	D009202	IL-10	cardiomyopathy	0	0	0.002932300093	0										
17353161	3586	D020521	IL-10	stroke	0	0	0.002835723571	0										
17353161	3586	D040181	IL-10	X-linked disorder	0	0	0.002796488814	0										
17353161	3586	D051437	IL-10	renal failure	0	0	0.002795818727	0										
17353161	7124	D000795	TNF-alpha	Fabry disease	1	1	0.7759164572	0										
17353161	7124	D007249	TNF-alpha	inflammation	0	0	0.04340922832	0										
17353161	7124	D009202	TNF-alpha	cardiomyopathy	0	0	0.004642236046	0										
17353161	7124	D020521	TNF-alpha	stroke	0	0	0.004375530407	0										
17353161	7124	D040181	TNF-alpha	X-linked disorder	0	0	0.004257502966	0										
17353161	7124	D051437	TNF-alpha	renal failure	0	0	0.004250571132	0										
17388667	7421	D000309	VDR | vitamin D receptor	insufficiency	0	0	0.2359468043	0										
17388667	7421	D001523	VDR | vitamin D receptor	aggressive disease	0	0	0.005070162471	0										
17388667	7421	D009369	VDR | vitamin D receptor	cancer	0	0	0.005825254135	0										
17388667	7421	D011471	VDR | vitamin D receptor	aggressive prostate cancer | prostate cancer	1	1	0.9932258725	0										
17392301	7012	D000741	hTR	aplastic anemia	0	0	0.007416611072	0										
17392301	7012	D003643	hTR	premature death	0	0	0.006672988646	0										
17392301	7012	D011658	hTR	Familial Pulmonary Fibrosis | pulmonary fibrosis	0	0	0.007522650529	0										
17392301	7012	D019871	hTR	autosomal dominant dyskeratosis congenita | dyskeratosis congenita	0	0	0.03357118368	0										
17392301	7012	D030342	hTR	hereditary disorder	0	0	0.007387227844	0										
17392301	7012	D054990	hTR	Idiopathic pulmonary fibrosis | familial idiopathic pulmonary fibrosis | idiopathic pulmonary fibrosis	1	1	0.9909052849	0										
17392301	7015	D000741	hTERT	aplastic anemia	0	0	0.007746617775	0										
17392301	7015	D003643	hTERT	premature death	0	0	0.006987791974	0										
17392301	7015	D011658	hTERT	Familial Pulmonary Fibrosis | pulmonary fibrosis	0	0	0.007958319969	0										
17392301	7015	D019871	hTERT	autosomal dominant dyskeratosis congenita | dyskeratosis congenita	0	0	0.03404005617	0										
17392301	7015	D030342	hTERT	hereditary disorder	0	0	0.00777054159	0										
17392301	7015	D054990	hTERT	Idiopathic pulmonary fibrosis | familial idiopathic pulmonary fibrosis | idiopathic pulmonary fibrosis	1	1	0.9909589291	0										
17397031	1029	D004416	CDKN2A	dysplastic	0	0	0.120993875	0										
17397031	1029	D008545	CDKN2A	melanoma | primary-melanoma	0	1	0.8678817153	1	1								0	Cutaneous phenotype and MC1R variants as modifying factors for the development of melanoma in CDKN2A G101W mutation carriers from 4 countries.
17397031	4157	D004416	MC1R	dysplastic	0	0	0.01315113436	0										
17397031	4157	D008545	MC1R	melanoma | primary-melanoma	1	1	0.9910491705	0										
17426996	1401	D002318	C-reactive protein | CRP	cardiovascular disease	0	0	0.005235221703	0										
17426996	1401	D003920	C-reactive protein | CRP	diabetes	0	0	0.003092197003	0										
17426996	1401	D006973	C-reactive protein | CRP	hypertension	0	0	0.003624322591	0										
17426996	1401	D007249	C-reactive protein | CRP	inflammation	0	0	0.00505931396	0										
17426996	348	D002318	Apo E | Apolipoprotein E | apolipoprotein E	cardiovascular disease	1	1	0.9694325924	0										
17426996	348	D003920	Apo E | Apolipoprotein E | apolipoprotein E	diabetes	0	0	0.04746423289	0										
17426996	348	D006973	Apo E | Apolipoprotein E | apolipoprotein E	hypertension	0	0	0.1434366256	0										
17426996	348	D007249	Apo E | Apolipoprotein E | apolipoprotein E	inflammation	0	1	0.966835916	1	1	only							1	Polymorphisms in the apolipoprotein E (Apo E) gene have been associated with lipid levels, carotid intima media thickness (CCA-IMT), inflammation and cardiovascular disease (CVD).
17439326	246	D001168	ALOX15	arthritis	0	0	0.03860135376	0	1	only							1	Reticulocyte-type 15-lipoxygenase-1 (ALOX15) has anti-inflammatory and inflammatory effects and is implicated in the development of asthma, arthritis and atherosclerosis.
17439326	246	D001249	ALOX15	asthma	0	0	0.0608411245	0	1	only							1	Reticulocyte-type 15-lipoxygenase-1 (ALOX15) has anti-inflammatory and inflammatory effects and is implicated in the development of asthma, arthritis and atherosclerosis.
17439326	246	D003324	ALOX15	coronary artery disease	1	0	0.4143844545	1	0									
17439326	246	D007249	ALOX15	inflammation	0	0	0.01204461232	0	1								e	These results suggest that increased ALOX15 activity may attenuate inflammation
17439326	246	D050197	ALOX15	atherosclerosis	0	1	0.6500795484	1	1	only							1	Reticulocyte-type 15-lipoxygenase-1 (ALOX15) has anti-inflammatory and inflammatory effects and is implicated in the development of asthma, arthritis and atherosclerosis.
17439326	6688	D001168	SPI1	arthritis	0	0	0.007202988956	0										
17439326	6688	D001249	SPI1	asthma	0	0	0.0079879798	0										
17439326	6688	D003324	SPI1	coronary artery disease	0	0	0.2349976003	0										
17439326	6688	D007249	SPI1	inflammation	0	0	0.005660627503	0										
17439326	6688	D050197	SPI1	atherosclerosis	0	0	0.05130057037	0										
17440943	1045	D011471	Cdx2	prostate cancer	0	0	0.1303094029	0										
17440943	7421	D011471	VDR | Vitamin D receptor | vitamin D receptor	prostate cancer	1	1	0.9923325777	0										
17444587	3552	D012595	IL1A	systemic sclerosis	0	0	0.006142576691	0										
17444587	3553	D012595	IL1B	systemic sclerosis	1	0	0.02256337926	1	1		1	Dk					e	IL1B and IL2 gene polymorphisms may be involved in susceptibility to SSc. Moreover, the IL2-384-G allele may be a marker for the limited phenotype of SSc.
17444587	3557	D012595	IL1RN	systemic sclerosis	0	0	0.005965237971	0										
17444587	3558	D012595	IL2	systemic sclerosis	1	0	0.05833034962	1	1		1	Dk					e	IL1B and IL2 gene polymorphisms may be involved in susceptibility to SSc. Moreover, the IL2-384-G allele may be a marker for the limited phenotype of SSc.
17444587	3569	D012595	IL6	systemic sclerosis	0	0	0.00551584363	0										
17444587	3586	D012595	IL10	systemic sclerosis	0	0	0.00409995066	0										
17446335	260431	D029424	COPD	Chronic obstructive pulmonary disease | chronic obstructive pulmonary disease	0	1	0.9057583809	1	0			Gm						
17446335	5270	D029424	SERPINE2 | Serpin peptidase inhibitor, clade E [nexin, plasminogen activator inhibitor type 1], member 2	Chronic obstructive pulmonary disease | chronic obstructive pulmonary disease	1	1	0.9719112515	0										
17470137	4771	D009369	NF2	tumour	0	0	0.249512434	0										
17470137	4771	D009442	NF2	schwannoma	0	1	0.9840647578	1	0			Di						
17470137	4771	D009464	NF2	vestibular schwannoma	1	1	0.9682982564	0										
17470137	4771	D016518	NF2	inherited condition neurofibromatosis type 2	0	1	0.9667651057	1	0			Dm						
17504528	571	D001943	BACH1	breast cancer | familial breast cancer	1	0	0.136798352	1	0					1			e	No significant differences in genotype frequencies between BC cases and controls for BRIP1 -64G>A and Pro919Ser were observed.
17504528	571	D005199	BACH1	Fanconi anaemia	0	0	0.008449241519	0	1	only							1	Inactivating and truncating mutations of the nuclear BRCA1-interacting protein 1 (BRIP1) have been shown to be the major cause of Fanconi anaemia and, due to subsequent alterations of BRCA1 function, predispose to breast cancer (BC).
17504528	64979	D001943	BRCA1-interacting protein 1 | BRIP1	breast cancer | familial breast cancer	0	1	0.9925784469	1	0					1			e	No significant differences in genotype frequencies between BC cases and controls for BRIP1 -64G>A and Pro919Ser were observed.
17504528	64979	D005199	BRCA1-interacting protein 1 | BRIP1	Fanconi anaemia	0	1	0.9447943568	1	1	only							1	Inactivating and truncating mutations of the nuclear BRCA1-interacting protein 1 (BRIP1) have been shown to be the major cause of Fanconi anaemia and, due to subsequent alterations of BRCA1 function, predispose to breast cancer (BC).
17504528	672	D001943	BRCA1	breast cancer | familial breast cancer	0	0	0.4131207168	0										
17504528	672	D005199	BRCA1	Fanconi anaemia	0	0	0.04159228876	0										
17504528	675	D001943	BRCA2	breast cancer | familial breast cancer	0	0	0.01818854734	0										
17504528	675	D005199	BRCA2	Fanconi anaemia	0	0	0.00726613123	0										
17531924	154	D001281	Beta2-adrenergic receptor | Beta2-adrenergic receptors | beta2-AR	atrial fibrillation	0	0	0.01534918323	0										
17531924	154	D002544	Beta2-adrenergic receptor | Beta2-adrenergic receptors | beta2-AR	ischemic stroke | ischemic strokes	0	0	0.08336369693	0										
17531924	154	D006973	Beta2-adrenergic receptor | Beta2-adrenergic receptors | beta2-AR	hypertension	0	0	0.01427947823	0										
17531924	154	D020521	Beta2-adrenergic receptor | Beta2-adrenergic receptors | beta2-AR	cerebrovascular accidents | stroke	1	1	0.8585418463	0										
17531924	154	D050171	Beta2-adrenergic receptor | Beta2-adrenergic receptors | beta2-AR	dyslipidemia	0	0	0.0154407518	0										
17532232	3552	D010003	IL-1alpha | IL1A | interleukin-1 (IL-1	hip OA | osteoarthritis	1	1	0.9859149456	0										
17532232	3553	D010003	IL-1beta | IL1B	hip OA | osteoarthritis	1	1	0.9801476002	0										
17532232	3557	D010003	IL-1 receptor antagonist | IL1RN	hip OA | osteoarthritis	1	1	0.9736888409	0										
17532232	389090	D010003	odds ratio (OR) 2.1	hip OA | osteoarthritis	0	0	0.03676339611	0										
17547583	1312	D001714	COMT | catechol-O-methyl transferase	Bipolar disorder | bipolar | bipolar I | bipolar I disorder | mania	1	1	0.9935436249	0										
17547583	1312	D003072	COMT | catechol-O-methyl transferase	Cognitive impairment | cognitive impairment	0	0	0.02450404689	0										
17547583	1312	D003866	COMT | catechol-O-methyl transferase	depression	0	0	0.02332392521	0										
17547583	1312	D012559	COMT | catechol-O-methyl transferase	schizophrenia	0	0	0.09663277864	0										
17579611	6531	D001289	DAT1 | dopamine transporter	ADHD | attention-deficit/hyperactivity disorder	1	1	0.9915476441	0										
17603749	54829	D010003	ASPN | asporin	osteoarthritis	1	1	0.9923366904	0										
17614770	4513	D007249	COX-2 and SCD	inflammation	0	0	0.09819233418	0										
17614770	4513	D049970	COX-2 and SCD	Graves' ophthalmopathy | endocrine ophthalmopathy | ophthalmopathy	0	0	0.3846151233	0										
17614770	5468	D007249	PPAR-gamma | peroxisome proliferator-activated receptor-gamma	inflammation	0	0	0.1526933759	0										
17614770	5468	D049970	PPAR-gamma | peroxisome proliferator-activated receptor-gamma	Graves' ophthalmopathy | endocrine ophthalmopathy | ophthalmopathy	0	1	0.6937172413	1	0									
17614770	5743	D007249	COX-2 | cyclooxygenase-2	inflammation	0	0	0.03884380311	0										
17614770	5743	D049970	COX-2 | cyclooxygenase-2	Graves' ophthalmopathy | endocrine ophthalmopathy | ophthalmopathy	1	1	0.7945180535	0										
17614770	6319	D007249	SCD | stearoyl-coenzyme A desaturase	inflammation	0	0	0.0630948171	0										
17614770	6319	D049970	SCD | stearoyl-coenzyme A desaturase	Graves' ophthalmopathy | endocrine ophthalmopathy | ophthalmopathy	1	1	0.8208919168	0										
17615072	3685	D001172	ITGAV | integrin alpha(v)beta3	RA | rheumatoid arthritis	1	1	0.9952043295	0										
17617023	3356	D012559	5-HT2A | 5-HT2A receptor	schizophrenia	1	1	0.9896416068	0										
17652883	1401	C564969	C-reactive protein	multi-vessel disease	0	0	0.003507932881	0										
17652883	1401	D000787	C-reactive protein	angina pectoris	0	0	0.002853911137	0										
17652883	1401	D002637	C-reactive protein	chest pain	0	0	0.002996578813	0										
17652883	1401	D003920	C-reactive protein	diabetes mellitus	0	0	0.002760013798	0										
17652883	1401	D006333	C-reactive protein	congestive heart failure	0	0	0.009986422025	0										
17652883	1401	D006937	C-reactive protein	hypercholesterolemia	0	0	0.003056861926	0										
17652883	1401	D006973	C-reactive protein	hypertension	0	0	0.002741592471	0										
17652883	1401	D009203	C-reactive protein	myocardial infarction	0	0	0.007552011404	0										
17652883	1493	C564969	CTLA-4 | Cytotoxic T lymphocyte antigen 4	multi-vessel disease	0	0	0.0280271098	0										
17652883	1493	D000787	CTLA-4 | Cytotoxic T lymphocyte antigen 4	angina pectoris	0	0	0.03335183114	0										
17652883	1493	D002637	CTLA-4 | Cytotoxic T lymphocyte antigen 4	chest pain	0	0	0.04851827398	0										
17652883	1493	D003920	CTLA-4 | Cytotoxic T lymphocyte antigen 4	diabetes mellitus	0	0	0.02834958211	0										
17652883	1493	D006333	CTLA-4 | Cytotoxic T lymphocyte antigen 4	congestive heart failure	0	0	0.1742537022	0										
17652883	1493	D006937	CTLA-4 | Cytotoxic T lymphocyte antigen 4	hypercholesterolemia	0	0	0.04697590694	0										
17652883	1493	D006973	CTLA-4 | Cytotoxic T lymphocyte antigen 4	hypertension	0	0	0.02662593499	0										
17652883	1493	D009203	CTLA-4 | Cytotoxic T lymphocyte antigen 4	myocardial infarction	1	1	0.9929484129	0										
17661168	11200	D001943	CHEK2	MBC | breast cancer	1	1	0.9929401875	0										
17661168	11200	D011471	CHEK2	prostate cancer	0	1	0.8251346946	1	1								mbg	Intriguingly, two other CHEK2 mutations (IVS2+1G&gt;A and I157T) and a CHEK2 large genomic deletion (del9-10) have been associated with an elevated risk for prostate cancer.
17661168	11200	D018567	CHEK2	Male breast cancer | male breast cancer	0	1	0.6296179891	1	1				C	1	1		mbg	The CHEK2 1100delC mutation has been shown to increase the risk of breast cancer in men lacking BRCA1/BRCA2 mutations.
17661168	11200	D061325	CHEK2	breast/ovarian cancer	0	0	0.01537253521	0										
17661168	672	D001943	BRCA1 | BRCA1/2	MBC | breast cancer	0	1	0.9837745428	1	1								1bg	Germ-line mutations of BRCA2 and, to lesser extent, BRCA1 genes are the highest risk factors associated with MBC.
17661168	672	D011471	BRCA1 | BRCA1/2	prostate cancer	0	0	0.00479387911	0										
17661168	672	D018567	BRCA1 | BRCA1/2	Male breast cancer | male breast cancer	0	0	0.005553997587	0										
17661168	672	D061325	BRCA1 | BRCA1/2	breast/ovarian cancer	0	0	0.003052826039	0										
17661168	675	D001943	BRCA2	MBC | breast cancer	0	0	0.3732646406	0	1								1bg	Germ-line mutations of BRCA2 and, to lesser extent, BRCA1 genes are the highest risk factors associated with MBC.
17661168	675	D011471	BRCA2	prostate cancer	0	0	0.004448776599	0										
17661168	675	D018567	BRCA2	Male breast cancer | male breast cancer	0	0	0.007503070869	0										
17661168	675	D061325	BRCA2	breast/ovarian cancer	0	0	0.004325834103	0										
17850436	3553	D005929	IL-1B | IL-1beta | IL1-B	Benign migratory glossitis | benign migratory glossitis	1	1	0.8720007539	0										
17850436	3569	D005929	IL-6	Benign migratory glossitis | benign migratory glossitis	1	1	0.929099381	0										
17850436	7124	D005929	TNFA	Benign migratory glossitis | benign migratory glossitis	1	1	0.9537351727	0										
17850927	5465	D000544	PPAR-alpha | peroxisome proliferator-activated receptor alpha	AD | Alzheimer's disease	1	1	0.9938930273	0										
17854273	3553	D009369	IL-1 beta | interleukin (IL)-1 beta | interleukin-1 beta	cancer	0	0	0.01290118508	0										
17854273	3553	D013274	IL-1 beta | interleukin (IL)-1 beta | interleukin-1 beta	tuberculosis or gastric cancer	1	0	0.07267940789	1	1			Di					e	In the case control study, our genotyping data supported the reported association between gastric cancer and the genotypes of IL-1 beta -31 TT and -511 CC (p &lt; 0.05).
17854273	3553	D014376	IL-1 beta | interleukin (IL)-1 beta | interleukin-1 beta	tuberculosis	1	0	0.01313496754	1	1		1						e	We also found that there is a significant difference of IL-1 beta -31 genotypes between 98 tuberculosis
17899368	4683	D001943	NBS | NBS1	breast cancer	1	1	0.9945230484	0										
17899368	4683	D008223	NBS | NBS1	lymphoid malignancies	0	0	0.1460922211	0										
17899368	4683	D009369	NBS | NBS1	tumors	0	0	0.01763563044	0										
17899368	4683	D019337	NBS | NBS1	hematological malignancies	0	0	0.01141593326	0										
17899368	4683	D030342	NBS | NBS1	recessive disease	0	0	0.05970874056	0										
17905480	2020	D010300	Engrailed 1/2	PD | Parkinson's disease	0	0	0.142346248	0										
17905480	2020	D019636	Engrailed 1/2	neurodegenerative disease	0	0	0.003134470899	0										
17905480	4010	D010300	LMX1B	PD | Parkinson's disease	1	0	0.1663209945	1	0									
17905480	4010	D019636	LMX1B	neurodegenerative disease	0	0	0.003228408052	0										
17905480	5015	D010300	OTX2	PD | Parkinson's disease	1	0	0.1302061528	1	0									
17905480	5015	D019636	OTX2	neurodegenerative disease	0	0	0.003064322984	0										
17905480	5309	D010300	PITX3	PD | Parkinson's disease	1	1	0.9938400388	0										
17905480	5309	D019636	PITX3	neurodegenerative disease	0	0	0.0101280259	0										
17908086	3106	D013167	HLA-B | HLA-B27 | leucocyte antigen (HLA)-B27	ankylosing spondylitis	1	1	0.984141767	0										
17940864	1950	D001943	EGF | Epidermal growth factor	breast cancer	1	1	0.9916036725	0										
17940864	1950	D009369	EGF | Epidermal growth factor	cancer | cancers	0	0	0.2843849659	0										
17974962	4317	D001943	MMP8 | matrix metalloproteinase-8	breast cancer | breast cancer metastasis	1	1	0.9949191213	0										
17974962	4317	D009369	MMP8 | matrix metalloproteinase-8	cancer | tumor	0	0	0.01073760353	0										
17981213	4193	D015451	MDM2	CLL disease | chronic lymphocytic leukemia	1	1	0.5335887671	0										
17981213	581	D015451	BAX	CLL disease | chronic lymphocytic leukemia	1	1	0.8163858056	0										
17981213	7157	D015451	p53	CLL disease | chronic lymphocytic leukemia	1	1	0.991542697	0										
17987108	2864	D003924	FFAR1	Type 2 diabetes	1	1	0.9857062697	0										
17987108	3630	D003924	insulin	Type 2 diabetes	0	0	0.006283479277	0										
17999359	5888	D001943	RAD51	breast cancer	1	1	0.989454627	0										
17999359	672	D001943	BRCA1	breast cancer	1	0	0.08372393996	1	1								m	A single-nucleotide polymorphism (SNP) in the 5' untranslated region (UTR) of RAD51, 135G--&gt;C, has been suggested as a possible modifier of breast cancer risk in BRCA1 and BRCA2 mutation carriers.
17999359	675	D001943	BRCA2	breast cancer	1	1	0.7594840527	0										
18003940	196	D000544	aHR	AD | Alzheimer disease	0	0	0.2051851898	0	0			Gi						
18003940	196	D002318	aHR	Cardiovascular | Cardiovascular Health	0	0	0.003343628021	0	0			Gi						
18003940	196	D003704	aHR	dementia	0	0	0.002699229401	0	0			Gi						
18003940	196	D015140	aHR	vascular dementia	0	0	0.003324645571	0	0			Gi						
18003940	348	D000544	APOE	AD | Alzheimer disease	0	1	0.9845803976	1	1								m	Closer examination suggested AD risk reduction with NSAIDs only in participants having an APOE epsilon 4 allele
18003940	348	D002318	APOE	Cardiovascular | Cardiovascular Health	0	0	0.02098879404	0										
18003940	348	D003704	APOE	dementia	1	0	0.003486661939	1	0									
18003940	348	D015140	APOE	vascular dementia	0	0	0.005310548004	0										
18003940	351	D000544	A beta	AD | Alzheimer disease	0	1	0.8221390843	1	0					1			e	There was no advantage in AD risk reduction with NSAIDs reported to selectively reduce A beta(42).
18003940	351	D002318	A beta	Cardiovascular | Cardiovascular Health	0	0	0.002894101664	0										
18003940	351	D003704	A beta	dementia	0	0	0.002233174164	0										
18003940	351	D015140	A beta	vascular dementia	0	0	0.00284943264	0										
18068431	154	D006333	beta2-adrenoceptor	heart failure	1	1	0.9935594797	0										
18093316	2052	C563924	EPHX1	colorectal adenomas	0	0	0.02900244854	0										
18093316	2052	D000236	EPHX1	adenoma | adenomas	1	1	0.7225334048	0										
18093316	2052	D002277	EPHX1	carcinomas	0	0	0.008058521897	0										
18093316	2052	D015179	EPHX1	CRC | colorectal carcinoma | colorectal carcinomas | sporadic colorectal cancer	1	1	0.9866853952	0										
18093316	2052	D063646	EPHX1	colorectal carcinogenesis	0	0	0.03673681244	0										
18093316	2944	C563924	GSTM1	colorectal adenomas	0	0	0.03210975975	0										
18093316	2944	D000236	GSTM1	adenoma | adenomas	1	0	0.2197826505	1	1		1						e	In addition the study supports the notion that the biotransformation enzymes GSTM1, GSTP1 and EPHX1 may modify the effect of dietary factors on the risk of developing colorectal carcinoma and adenoma.
18093316	2944	D002277	GSTM1	carcinomas	0	0	0.009334109724	0										
18093316	2944	D015179	GSTM1	CRC | colorectal carcinoma | colorectal carcinomas | sporadic colorectal cancer	1	1	0.9848998785	0										
18093316	2944	D063646	GSTM1	colorectal carcinogenesis	0	0	0.0540096201	0										
18093316	2950	C563924	GSTP1	colorectal adenomas	0	0	0.03151027858	0										
18093316	2950	D000236	GSTP1	adenoma | adenomas	1	0	0.2453261018	1	1		1						e	In addition the study supports the notion that the biotransformation enzymes GSTM1, GSTP1 and EPHX1 may modify the effect of dietary factors on the risk of developing colorectal carcinoma and adenoma.
18093316	2950	D002277	GSTP1	carcinomas	0	0	0.008734667674	0										
18093316	2950	D015179	GSTP1	CRC | colorectal carcinoma | colorectal carcinomas | sporadic colorectal cancer	1	1	0.9884896874	0										
18093316	2950	D063646	GSTP1	colorectal carcinogenesis	0	0	0.05436211824	0										
18093316	2952	C563924	GSTT1	colorectal adenomas	0	0	0.009009982459	0										
18093316	2952	D000236	GSTT1	adenoma | adenomas	1	0	0.02151385136	1	0									
18093316	2952	D002277	GSTT1	carcinomas	0	0	0.005126588512	0										
18093316	2952	D015179	GSTT1	CRC | colorectal carcinoma | colorectal carcinomas | sporadic colorectal cancer	1	1	0.5445184112	0										
18093316	2952	D063646	GSTT1	colorectal carcinogenesis	0	0	0.01356848516	0										
18159160	7157	D013274	p53	gastric cancer	1	1	0.9920409322	0										
18172074	4658	D009216	MYP2	myopia	0	1	0.6851858497	1	0.5						1	1	e	Future studies should focus on other genes in the MYP2 linkage region or other linked regions to identify myopia-causing genes.
18172074	7050	D009216	TGIF | Transforming growth beta-induced factor	myopia	1	1	0.9898394346	0										
18189189	1234	D001168	CC chemokine receptor 5 | CCR5	arthritis	0	0	0.4808934927	0										
18189189	1234	D001171	CC chemokine receptor 5 | CCR5	Juvenile idiopathic arthritis | juvenile idiopathic arthritis	1	1	0.8550620675	0										
18189189	1234	D001172	CC chemokine receptor 5 | CCR5	RA | rheumatoid arthritis	1	1	0.9829409719	0										
18189189	1234	D012216	CC chemokine receptor 5 | CCR5	rheumatic disease | rheumatological diseases	1	0	0.02413263917	1	1		1						mbg	The CC chemokine receptor 5 (CCR5)Delta32 polymorphism has been associated with rheumatoid arthritis (RA), conferring a protective effect.
18194124	4524	D006086	Methylenetetrahydrofolate reductase | methylenetetrahydrofolate reductase	graft-versus-host disease	1	1	0.9930105805	0										
18194124	4524	D064420	Methylenetetrahydrofolate reductase | methylenetetrahydrofolate reductase	toxicity	0	0	0.302796483	0										
18199088	2214	C566404	FcgammaRIIIa	atopic diseases	0	1	0.9781091213	1	1		1						e	Our study shows that the V158V genotype in FcgammaRIIIa gene polymorphism may be a genetic risk factor for the development of atopic diseases.
18199088	2214	D001249	FcgammaRIIIa	asthma | asthma bronchiale | bronchial asthma	1	1	0.9290103912	0										
18199088	2214	D004342	FcgammaRIIIa	allergy	0	0	0.1833645403	0										
18199088	2214	D012220	FcgammaRIIIa	allergic rhinitis	0	1	0.9762643576	1	1								m	Distribution of 158 V allele was significantly different among asthmatic children (OR: 2.20, 95% CI: 1.65-2.92, p &lt; 0.001) and allergic rhinitis patients (OR: 1.77, 95% CI: 1.32-2.35, p &lt; 0.001) compared to healthy controls.
18247401	2346	D011471	PSMA | Prostate specific membrane antigen | prostate specific membrane antigen	prostate cancer	1	1	0.9878835082	0										
18247401	367	D011471	AR | androgen receptor	prostate cancer	0	0	0.04625138268	0										
18247401	7421	D011471	VDR | vitamin D receptor	prostate cancer	0	0	0.01335083228	0										
18252210	26281	D010300	FGF20 | fibroblast growth factor 20	PD | Parkinson disease	1	1	0.9918923378	0										
18252210	26281	D019636	FGF20 | fibroblast growth factor 20	neurodegenerative disorder	0	0	0.02732722275	0										
18252210	6622	D010300	alpha-synuclein	PD | Parkinson disease	0	1	0.9845383167	1	1								m	In a cell-based system and in PD brains, this increase in translation of FGF20 is correlated with increased alpha-synuclein expression, which has previously been shown to cause PD through both overexpression and point mutations.
18252210	6622	D019636	alpha-synuclein	neurodegenerative disorder	0	0	0.004633811768	0										
18273801	6010	D001766	rhodopsin	blindness	0	0	0.05643858761	0										
18273801	6010	D009223	rhodopsin	dystrophy	0	0	0.09335795045	0										
18273801	6010	D012162	rhodopsin	inherited retinal degeneration	0	0	0.03809082508	0										
18273801	6010	D012174	rhodopsin	Retinitis pigmentosa | retinitis pigmentosa	1	0	0.008866258897	1	1		1	DkGk					mbg	P is in most cases associated with missense mutations in the rhodopsin gene (RHO). RHO plays an important role in phototransduction pathways.
18285424	3663	D001172	IRF5 | Interferon regulatory factor 5	rheumatoid arthritis	0	0	0.008504428901	0										
18285424	3663	D001327	IRF5 | Interferon regulatory factor 5	autoimmune diseases | autoimmunity	0	0	0.006829421967	0										
18285424	3663	D008180	IRF5 | Interferon regulatory factor 5	systemic lupus erythematosus	0	0	0.01391634345	0										
18285424	3663	D009103	IRF5 | Interferon regulatory factor 5	MS | multiple sclerosis	1	1	0.9923787117	0										
18285424	3663	D015212	IRF5 | Interferon regulatory factor 5	inflammatory bowel diseases	0	0	0.03807867318	0										
18289755	2900	D001523	GRIK4	chronic psychiatric disorder	0	0	0.02122355066	0										
18289755	2900	D012559	GRIK4	Schizophrenia | schizophrenia	1	1	0.9945874214	0										
18295974	2166	C564092	FAAH	obese BED	0	0	0.03845559806	0										
18295974	2166	D001068	FAAH	eating disorder	0	1	0.95558393	1	0									
18295974	2166	D009765	FAAH	obese | obesity	1	1	0.9948564768	0										
18304461	1543	D009369	CYP1A1 | cytochrome P-450 CYP1A1	cancer	0	0	0.005557009019	0										
18304461	1543	D011471	CYP1A1 | cytochrome P-450 CYP1A1	linked to prostate cancer | prostate cancer	0	1	0.8197497129	1	0		1			1			e	No significant differences in the frequency distributions of CYP1A1 polymorphisms were observed between prostate cancer patients and controls.
18304461	2944	D009369	GSTM1 | glutathione S-transferase M1	cancer	0	0	0.02091174386	0										
18304461	2944	D011471	GSTM1 | glutathione S-transferase M1	linked to prostate cancer | prostate cancer	1	1	0.9937386513	0										
18304461	354	D009369	prostate specific antigen	cancer	0	0	0.003377231769	0										
18304461	354	D011471	prostate specific antigen	linked to prostate cancer | prostate cancer	0	0	0.01662337966	0										
18305461	135	D001008	ADORA2A	anxiety	1	1	0.992415905	0										
18305461	1813	D001008	DRD(2) | DRD2	anxiety	1	1	0.9492587447	0										
18306451	3552	D009765	IL-1 | IL-1alpha | Interleukin-1 | Interleukin-1alpha	obese | obesity	1	1	0.9943051934	0										
18317464	27185	D001321	DISC1 | Disrupted in schizophrenia 1	autism	0	0	0.1425601542	0	1	only							1bg	Disrupted in schizophrenia 1 (DISC1) has been associated with risk of schizophrenia, schizoaffective disorder, bipolar disorder, major depression, autism and Asperger syndrome
18317464	27185	D001523	DISC1 | Disrupted in schizophrenia 1	psychiatric illness	0	0	0.03307994083	0	1								e	These findings provide further support for the role of DISC1 in psychiatric illness and demonstrate the presence of locus heterogeneity,
18317464	27185	D001714	DISC1 | Disrupted in schizophrenia 1	bipolar disorder | schizophrenia and bipolar disorder	1	1	0.9936653376	0										
18317464	27185	D003866	DISC1 | Disrupted in schizophrenia 1	depression	0	0	0.2156001776	0	1	only							1bg	Disrupted in schizophrenia 1 (DISC1) has been associated with risk of schizophrenia, schizoaffective disorder, bipolar disorder, major depression, autism and Asperger syndrome
18317464	27185	D011618	DISC1 | Disrupted in schizophrenia 1	schizoaffective disorder	0	0	0.009318433702	0	1	only							1bg	Disrupted in schizophrenia 1 (DISC1) has been associated with risk of schizophrenia, schizoaffective disorder, bipolar disorder, major depression, autism and Asperger syndrome
18317464	27185	D012559	DISC1 | Disrupted in schizophrenia 1	schizophrenia	1	0	0.02102353424	1	1	only							1bg	Disrupted in schizophrenia 1 (DISC1) has been associated with risk of schizophrenia, schizoaffective disorder, bipolar disorder, major depression, autism and Asperger syndrome
18317464	27185	D020817	DISC1 | Disrupted in schizophrenia 1	Asperger syndrome	0	1	0.6529903412	1	1	only							1bg	Disrupted in schizophrenia 1 (DISC1) has been associated with risk of schizophrenia, schizoaffective disorder, bipolar disorder, major depression, autism and Asperger syndrome
18317470	79068	D009765	FTO	dichotomous obesity | obese | obesity	0	1	0.817185998	1	1		1						0	NYD-SP18 is associated with obesity in the NHLBI Family Heart Study.
18317470	84691	D009765	NYD-SP18	dichotomous obesity | obese | obesity	1	1	0.9939301014	0										
18347838	4905	D002493	N-ethylmaleimide-sensitive fusion protein | NSF	neurocognitive impairment	0	0	0.005116243381	0										
18347838	4905	D003072	N-ethylmaleimide-sensitive fusion protein | NSF	cognitive domains verbal memory | cognitive dysfunctions | cognitive dysfunctions of schizophrenic	0	0	0.031382218	0										
18347838	4905	D012559	N-ethylmaleimide-sensitive fusion protein | NSF	neurocognitive dysfunctions in schizophrenia | schizophrenia | schizophrenic	0	0	0.02809230052	0										
18347838	4905	D014786	N-ethylmaleimide-sensitive fusion protein | NSF	visual memory	0	0	0.0133854663	0										
18347838	6616	D002493	SNAP-25 | synaptosomal-associated protein of 25 kDa	neurocognitive impairment	0	0	0.05470563099	0										
18347838	6616	D003072	SNAP-25 | synaptosomal-associated protein of 25 kDa	cognitive domains verbal memory | cognitive dysfunctions | cognitive dysfunctions of schizophrenic	0	1	0.9940633178	1	1		1						e	As we observed an association between the DdeI polymorphism of the SNAP-25 gene and cognitive dysfunctions of schizophrenic patients our finding suggests that the SNAP-25 gene could play a role in the pathophysiology of neurocognitive dysfunctions in schizophrenia but is not predictive for treatment response with atypical antipsychotics.
18347838	6616	D012559	SNAP-25 | synaptosomal-associated protein of 25 kDa	neurocognitive dysfunctions in schizophrenia | schizophrenia | schizophrenic	1	1	0.9938767552	0										
18347838	6616	D014786	SNAP-25 | synaptosomal-associated protein of 25 kDa	visual memory	0	0	0.1256041378	0										
18357393	142	D001943	PARP1	breast cancer	0	0	0.01200080197	0										
18357393	142	D061325	PARP1	breast tumor	0	0	0.003519657068	0										
18357393	328	D001943	APE1	breast cancer	0	0	0.01360778511	0										
18357393	328	D061325	APE1	breast tumor	0	0	0.003521084087	0										
18357393	7515	D001943	XRCC1	breast cancer	1	1	0.9947564602	0										
18357393	7515	D061325	XRCC1	breast tumor	0	0	0.06794057041	0										
18384956	22854	D012559	NTNG1 | netrin G1	schizophrenia	1	1	0.9948219061	0										
18387595	6091	D009765	ROBO1	obesity	1	0	0.1813742667	1	1	only							m	we identified an age-varying association between a SNP in ROBO1 and obesity and hypothesized an age-gene interaction.
18406176	152100	D006226	CMC1	radiographic osteoarthritic	0	0	0.004079209641	0										
18406176	152100	D010003	CMC1	osteoarthritis	0	0	0.02437549643	0										
18406176	2487	D006226	FRZB	radiographic osteoarthritic	0	0	0.05345794186	0										
18406176	2487	D010003	FRZB	osteoarthritis	1	1	0.8826652765	0										
18406176	4040	D006226	LRP6 | Low-density lipoprotein receptor-related protein 6	radiographic osteoarthritic	0	0	0.126200974	0										
18406176	4040	D010003	LRP6 | Low-density lipoprotein receptor-related protein 6	osteoarthritis	1	1	0.9308567047	0										
18406176	4041	D006226	LRP5 | Low-density lipoprotein receptor-related protein 5	radiographic osteoarthritic	0	0	0.02496440709	0										
18406176	4041	D010003	LRP5 | Low-density lipoprotein receptor-related protein 5	osteoarthritis	1	1	0.7557123303	0										
18410260	1520	D011656	Cathepsin S | cathepsin S	pulmonary emphysema	0	1	0.9735799432	1	1		1						e	Novel functional polymorphisms were identified in the cathepsin S gene, which has a possible association with pulmonary emphysema in the Japanese population.
18410260	3458	D011656	IFN-gamma | interferon (IFN)-gamma	pulmonary emphysema	1	0	0.03024145588	1										
18410260	3596	D011656	IL-13	pulmonary emphysema	0	0	0.008946583606	0										
18429752	153	D006973	ADRB1	hypertension	1	0	0.2345167547	1	0					1			m	No significant differences were revealed in dynamics of systolic and diastolic BP both at rest and at effort between patients with different genotypes of polymorphic marker Gly389Arg of ADRB1 gene.
18429752	153	D007022	ADRB1	Hypotensive	0	0	0.004701227415	0										
18429752	1565	D006973	CYP2D6 | Cyp2D6	hypertension	0	1	0.8572426438	1	1		1						m	Thus efficacy of betaxolol in patients with hypertension was associated solely with genotype of polymorphic marker Ser34Pro of CYP2D6 gene.
18429752	1565	D007022	CYP2D6 | Cyp2D6	Hypotensive	0	0	0.004101395607	0										
18449420	2157	D013927	FVIII | factor VIII	thrombosis | thrombotic	0	0	0.170379445	0										
18449420	2157	D054556	FVIII | factor VIII	venous thromboembolism	0	1	0.7035153508	1	1								1bg	A suggestive locus on chromosome 8 could be shown to be associated with familial high factor VIII (FVIII) levels in venous thromboembolism.
18449420	27299	D013927	ADAMDEC 1 | ADAMDEC1	thrombosis | thrombotic	0	0	0.02507445589	0										
18449420	27299	D054556	ADAMDEC 1 | ADAMDEC1	venous thromboembolism	1	0	0.1866813898	1	0.5				n		1	1	m	Interestingly, the ADAMDEC1 haplotype (rs12674766, rs10087305, rs2291577, rs2291578, rs3765124) differed between cases and controls (p = 0.04).
18449420	4023	D013927	LPL | lipoprotein lipase	thrombosis | thrombotic	0	0	0.01016056538	0										
18449420	4023	D054556	LPL | lipoprotein lipase	venous thromboembolism	1	0	0.01201515459	1	0									
18449420	4035	D013927	LRP	thrombosis | thrombotic	0	0	0.007162297145	0										
18449420	4035	D054556	LRP	venous thromboembolism	0	0	0.009765492752	0										
18449420	5327	D013927	t-PA	thrombosis | thrombotic	0	0	0.008672250435	0										
18449420	5327	D054556	t-PA	venous thromboembolism	1	0	0.01087310351	1	0.5				n		1	1	m	A new polymorphism in intron 7 of the t-PA gene with a minor allele frequency of 2.2% was identified.
18455228	4041	D010024	LRP5	Osteoporosis | osteoporosis	1	0	0.02073732764	1	1			Dk					m	A non-synonymous SNP in the LRP5 gene was associated with decreased bone mineral density (rs3736228, p=6 3x10-12 for lumbar spine and p=1 9x10-4 for femoral neck) and an increased risk of both osteoporotic fractures (odds ratio [OR] 1 3, 95% CI 1 09-1 52, p=0 002) and osteoporosis (OR 1 3, 1 08-1 63, p=0 008).
18455228	4041	D050723	LRP5	fractures	0	0	0.0110144075	0										
18455228	4041	D058866	LRP5	osteoporotic fracture | osteoporotic fractures	0	0	0.3320343494	0	1			Dk					m	A non-synonymous SNP in the LRP5 gene was associated with decreased bone mineral density (rs3736228, p=6 3x10-12 for lumbar spine and p=1 9x10-4 for femoral neck) and an increased risk of both osteoporotic fractures (odds ratio [OR] 1 3, 95% CI 1 09-1 52, p=0 002) and osteoporosis (OR 1 3, 1 08-1 63, p=0 008).
18455228	4982	D010024	TNFRSF11B | osteoprotegerin	Osteoporosis | osteoporosis	1	0	0.08378078789	1	1		1						m	Three SNPs near the TNFRSF11B gene were associated with decreased bone mineral density (top SNP, rs4355801: p=7 6x10-10 for lumbar spine and p=3 3x10-8 for femoral neck) and increased risk of osteoporosis
18455228	4982	D050723	TNFRSF11B | osteoprotegerin	fractures	0	0	0.02899152786	0										
18455228	4982	D058866	TNFRSF11B | osteoprotegerin	osteoporotic fracture | osteoporotic fractures	0	0	0.2415318489	0										
18461507	1392	D004827	CRH | corticotrophin-releasing hormone	epileptic encephalopathy	0	0	0.004342887085	0										
18461507	1392	D013035	CRH | corticotrophin-releasing hormone	spasms	0	0	0.01000464521	0										
18461507	1392	D013036	CRH | corticotrophin-releasing hormone	infantile spasms	0	0	0.1308611929	0										
18461507	4160	D004827	MC4R | melanocortin-4 receptor	epileptic encephalopathy	0	0	0.01082465611	0										
18461507	4160	D013035	MC4R | melanocortin-4 receptor	spasms	0	0	0.06492676586	0										
18461507	4160	D013036	MC4R | melanocortin-4 receptor	infantile spasms	1	1	0.9912176728	0										
18466515	26191	D001172	PTPN22	RA | Rheumatoid arthritis | rheumatoid arthritis	1	1	0.9886371493	0										
18466515	26191	D001327	PTPN22	autoimmune disease	0	0	0.00856108591	0										
18466515	3123	D001172	HLA-DRB1	RA | Rheumatoid arthritis | rheumatoid arthritis	1	1	0.9875829816	0										
18466515	3123	D001327	HLA-DRB1	autoimmune disease	0	0	0.007395344786	0										
18472644	2944	D003643	GSTM1 | Glutathione S-transferase M1, T1 and P1	deaths	0	0	0.00750563154	0										
18472644	2944	D008175	GSTM1 | Glutathione S-transferase M1, T1 and P1	GSTs and lung cancer | lung cancer	1	1	0.6049038768	0										
18472644	2950	D003643	GSTP1	deaths	0	0	0.01967846043	0										
18472644	2950	D008175	GSTP1	GSTs and lung cancer | lung cancer	1	1	0.8687525988	0										
18472644	2952	D003643	GSTT1	deaths	0	0	0.02611705847	0										
18472644	2952	D008175	GSTT1	GSTs and lung cancer | lung cancer	1	1	0.992244184	0										
18472644	373156	D003643	GSTs | glutathione S-transferases	deaths	0	0	0.002642870415	0										
18472644	373156	D008175	GSTs | glutathione S-transferases	GSTs and lung cancer | lung cancer	0	0	0.01024130546	0										
18486767	4846	D001249	endothelial nitric oxide synthase	asthma	1	1	0.9889008999	0										
18497072	174	D001943	AFP | alpha-fetoprotein | alphaFP	breast cancer	1	1	0.9854121804	0										
18497072	174	D009369	AFP | alpha-fetoprotein | alphaFP	tumor	0	0	0.01069087256	0										
18497072	3342	D001943	hCG	breast cancer	0	1	0.9239370227	1	0									
18497072	3342	D009369	hCG	tumor	0	0	0.005224958993	0										
18497072	5199	D001943	cFP	breast cancer	0	0	0.2702406943	0										
18497072	5199	D009369	cFP	tumor	0	0	0.002733853878	0										
18497072	6043	D001943	E3, E2 + P, E3 + P, hCG	breast cancer	0	0	0.1336816996	0										
18497072	6043	D009369	E3, E2 + P, E3 + P, hCG	tumor	0	0	0.002680081874	0										
18513846	4524	D001714	MTHFR | methylenetetrahydrofolate reductase	bipolar | bipolar disorder	1	1	0.9120599031	0										
18513846	4709	D001714	B12	bipolar | bipolar disorder	0	1	0.9788137674	1	1		1						e	High tHcy but low folate and vitamin B12 levels may be a risk factor for development of bipolar disorder.
18533279	9047	D009103	SH2D2A	multiple sclerosis	0	1	0.966201961	1	1								mbg	The genotype GA13-16 homozygote of the SH2D2A gene promoter has been associated with the susceptibility to develop multiple sclerosis.
18533279	9047	D009422	SH2D2A	neuropathy	0	0	0.006650174968	0										
18533279	9047	D020277	SH2D2A	CIDP | Chronic inflammatory demyelinating polyradiculoneuropathy | inflammatory demyelinating polyradiculoneuropathy	1	1	0.9645804763	0										
18550062	1636	D017544	ACE	abdominal aortic aneurysm	1	1	0.9484211802	0										
18550062	183	D017544	Angiotensin II | angiotensin II	abdominal aortic aneurysm	0	0	0.00758307334	0										
18550062	185	D017544	AT1R	abdominal aortic aneurysm	1	0	0.05484467372	1	0					1			m	A significant difference in genotype distribution and allele frequency between patients and controls was found for ACE, but not for AT1R and TGFBR1 polymorphisms.
18550062	7046	D017544	TGFBR1	abdominal aortic aneurysm	1	1	0.746533215	0										
18550062	7048	D017544	TGFBR2	abdominal aortic aneurysm	1	0	0.006802358665	1	0									
18551041	5739	D006965	PTGIR | prostacyclin receptor	hyperplasia	1	1	0.9777401686	0										
18551041	5739	D007249	PTGIR | prostacyclin receptor	inflammation	0	1	0.6387636065	1	0									
18551041	5739	D012735	PTGIR | prostacyclin receptor	dysfunctional	0	0	0.07364362478	0										
18551041	5739	D014652	PTGIR | prostacyclin receptor	vascular disease | vascular dysfunction	0	1	0.9701018929	1	0	eg many ann, using PTC to visualize								
18551041	5739	D014842	PTGIR | prostacyclin receptor	von Willebrand	0	0	0.009556627832	0										
18551041	5739	D020246	PTGIR | prostacyclin receptor	deep vein thrombosis | venous thrombosis	1	1	0.9911523461	0										
18551041	6403	D006965	P-selectin	hyperplasia	0	0	0.004245609045	0										
18551041	6403	D007249	P-selectin	inflammation	0	0	0.003582005389	0										
18551041	6403	D012735	P-selectin	dysfunctional	0	0	0.002990442328	0										
18551041	6403	D014652	P-selectin	vascular disease | vascular dysfunction	0	0	0.01158978883	0										
18551041	6403	D014842	P-selectin	von Willebrand	0	0	0.0053291535	0										
18551041	6403	D020246	P-selectin	deep vein thrombosis | venous thrombosis	0	0	0.01324917842	0										
18580587	348	D000544	APOE | apolipoprotein E	AD | AD neuropathologic | AD neuropathologic criteria | Alzheimer disease	1	1	0.9940027595	0										
18580587	348	D003704	APOE | apolipoprotein E	dementia	0	0	0.004685385618	0										
18580587	348	D017887	APOE | apolipoprotein E	longitudinal	0	0	0.00424103532	0										
18580587	348	D018288	APOE | apolipoprotein E	Small HC	0	0	0.004487779457	0										
18583877	7422	D015179	VEGF | vascular endothelial growth factor	colorectal cancer	1	1	0.9939012527	0										
18590468	1543	D006258	CYP1A1	head and neck cancer | head and neck cancers | neck cancer	1	1	0.7874614596	0										
18590468	1543	D009369	CYP1A1	cancer | neoplasms	0	0	0.003221822903	0										
18590468	2944	D006258	GSTM1 | glutathione S-transferase M1 and cytochrome P450 1A1	head and neck cancer | head and neck cancers | neck cancer	1	1	0.9862530828	0										
18590468	2944	D009369	GSTM1 | glutathione S-transferase M1 and cytochrome P450 1A1	cancer | neoplasms	0	0	0.01422820892	0										
18590468	2950	D006258	GSTP1	head and neck cancer | head and neck cancers | neck cancer	1	0	0.3546320498	1	1				C				m	The estimated head and neck cancer risk for the combination of either CYP1A1 Ile462Val or CYP1A1 Val462Val genotype with either GSTP1 Ile105Val or Val105Val genotype
18590468	2950	D009369	GSTP1	cancer | neoplasms	0	0	0.01448054705	0										
18590468	2952	D006258	GSTT1	head and neck cancer | head and neck cancers | neck cancer	1	1	0.7474917173	0										
18590468	2952	D009369	GSTT1	cancer | neoplasms	0	0	0.008597061038	0										
18590468	373156	D006258	GST | glutathione S-transferase	head and neck cancer | head and neck cancers | neck cancer	0	0	0.008099060506	0										
18590468	373156	D009369	GST | glutathione S-transferase	cancer | neoplasms	0	0	0.003088520141	0										
18590468	4051	D006258	CYP | Cytochrome P450	head and neck cancer | head and neck cancers | neck cancer	0	0	0.007912814617	0										
18590468	4051	D009369	CYP | Cytochrome P450	cancer | neoplasms	0	0	0.002746101702	0										
18604206	1857	D052177	Dishevelled	cystic diseases | cystic kidney disease	0	0	0.01090887003	0										
18604206	1857	D058495	Dishevelled	Drosophila PCP proteins	0	0	0.007864262909	0										
18604206	24147	D052177	Four-jointed	cystic diseases | cystic kidney disease	0	0	0.006572815124	0										
18604206	24147	D058495	Four-jointed	Drosophila PCP proteins	0	0	0.01884939894	0										
18604206	45343	D052177	Prickle	cystic diseases | cystic kidney disease	0	0	0.007527868729	0										
18604206	45343	D058495	Prickle	Drosophila PCP proteins	0	0	0.005551885813	0										
18604206	79633	D052177	Fat4	cystic diseases | cystic kidney disease	1	1	0.9901757836	0										
18604206	79633	D058495	Fat4	Drosophila PCP proteins	0	0	0.01713837869	0										
18604206	81839	D052177	Van Gogh	cystic diseases | cystic kidney disease	0	0	0.008692220785	0										
18604206	81839	D058495	Van Gogh	Drosophila PCP proteins	0	0	0.006383737084	0										
18604206	8642	D052177	Dachsous	cystic diseases | cystic kidney disease	0	0	0.006506297272	0										
18604206	8642	D058495	Dachsous	Drosophila PCP proteins	0	0	0.01245286036	0										
18645269	1027	D011471	CDKN1B	localized prostate cancer | prostate cancer	1	1	0.9946799874	0										
18645269	10534	D011471	p27	localized prostate cancer | prostate cancer	0	0	0.02883563749	0										
18660546	406938	D001943	miR-146a	Breast cancer | familial breast cancer	0	0	0.03687464818	0										
18660546	406938	D010051	miR-146a	familial ovarian cancer | ovarian cancer	1	1	0.5918899775	0										
18660546	406938	D061325	miR-146a	breast and ovarian cancer | breast and/or ovarian cancer | breast/ovarian cancer | familial breast and ovarian cancers | familial breast/ovarian cancer	0	1	0.9937728047	1	1		1	Di					e	our data suggest that breast/ovarian cancer patients with variant C allele miR-146a may have high levels of mature miR-146 and that these variants predispose them to an earlier age of onset of familial breast and ovarian cancers.
18660546	672	D001943	BRCA1	Breast cancer | familial breast cancer	0	0	0.004544029478	0										
18660546	672	D010051	BRCA1	familial ovarian cancer | ovarian cancer	0	0	0.004419003613	0										
18660546	672	D061325	BRCA1	breast and ovarian cancer | breast and/or ovarian cancer | breast/ovarian cancer | familial breast and ovarian cancers | familial breast/ovarian cancer	0	0	0.2033165097	0										
18660546	675	D001943	BRCA2	Breast cancer | familial breast cancer	0	0	0.003142574336	0										
18660546	675	D010051	BRCA2	familial ovarian cancer | ovarian cancer	0	0	0.003129473189	0										
18660546	675	D061325	BRCA2	breast and ovarian cancer | breast and/or ovarian cancer | breast/ovarian cancer | familial breast and ovarian cancers | familial breast/ovarian cancer	0	0	0.04319871217	0										
18722801	11315	D010300	DJ-1	Parkinson's disease | parkinsonian	1	1	0.9725044966	0	1		1						e	DJ-1 are a cause, even if rare, of early-onset Parkinson's disease.
18722801	11315	D010302	DJ-1	parkinsonism	0	1	0.9620099068	1	1		1						e	DJ-1 are a cause, even if rare, of early-onset Parkinson's disease.
18728071	6925	C537403	TCF4 | transcription factor 4	Pitt-Hopkins syndrome	0	1	0.972540617	1	1								1bg	Haploinsufficiency of the gene encoding for transcription factor 4 (TCF4) was recently identified as the underlying cause of Pitt-Hopkins syndrome (PTHS)
18728071	6925	D004417	TCF4 | transcription factor 4	breathing anomalies	0	0	0.03233809397	0	1				M			1	m	In total, 16 novel mutations were identified. All of these proven patients were severely mentally retarded and showed a distinct facial gestalt. In addition, 56% had breathing anomalies, 56% had microcephaly, 38% had seizures and 44% had MRI anomalies.
18728071	6925	D008607	TCF4 | transcription factor 4	mental retardation | mental-retardation syndrome | mentally retarded	0	1	0.9809609652	1	1				M			1	m	In total, 16 novel mutations were identified. All of these proven patients were severely mentally retarded and showed a distinct facial gestalt. In addition, 56% had breathing anomalies, 56% had microcephaly, 38% had seizures and 44% had MRI anomalies.
18728071	6925	D008831	TCF4 | transcription factor 4	microcephaly	1	0	0.006551459432	1	1				M			1	m	In total, 16 novel mutations were identified. All of these proven patients were severely mentally retarded and showed a distinct facial gestalt. In addition, 56% had breathing anomalies, 56% had microcephaly, 38% had seizures and 44% had MRI anomalies.
18728071	6925	D012640	TCF4 | transcription factor 4	seizures	1	0	0.006795136724	1	1				M			1	m	In total, 16 novel mutations were identified. All of these proven patients were severely mentally retarded and showed a distinct facial gestalt. In addition, 56% had breathing anomalies, 56% had microcephaly, 38% had seizures and 44% had MRI anomalies.
18728071	6925	D058495	TCF4 | transcription factor 4	Haploinsufficiency	0	0	0.01049660612	0										
18761744	3356	D001791	serotonin 2A receptor | serotonin 5-HT2A receptor	Platelet aggregation | platelet aggregation	0	0	0.06542814523	0										
18761744	3356	D005355	serotonin 2A receptor | serotonin 5-HT2A receptor	fibrosis	0	0	0.01194965839	0										
18761744	3356	D012595	serotonin 2A receptor | serotonin 5-HT2A receptor	scleroderma | systemic sclerosis	1	1	0.9747505784	0										
18762705	23171	D030342	GPD1L	inherited arrhythmic disorder	0	0	0.02028211579	0										
18762705	23171	D053840	GPD1L	Brugada syndrome	1	1	0.974709928	0										
18762705	2819	D030342	glycerol-3 phosphate dehydrogenase-1	inherited arrhythmic disorder	0	0	0.01546388678	0										
18762705	2819	D053840	glycerol-3 phosphate dehydrogenase-1	Brugada syndrome	0	1	0.6913690567	1	0.5				n			1	m	1 synonymous mutation was identified, as well as 1 intronic variant, both of which were absent in 220 control alleles.
18762705	6331	D030342	SCN5A	inherited arrhythmic disorder	0	0	0.003970624879	0										
18762705	6331	D053840	SCN5A	Brugada syndrome	0	0	0.01565586589	0	1	only							1bg	Brugada syndrome is an inherited arrhythmic disorder, and mutations in the SCN5A gene, encoding cardiac sodium channels, are identified in approximately 15% of cases.
18763293	125	D015179	ADH2 | alcohol dehydrogenase 2	colorectal cancer	1	1	0.9697681665	0										
18763293	217	D015179	ALDH2 | aldehyde dehydrogenase 2	colorectal cancer	1	1	0.987603128	0										
18799289	4762	D003072	NEUROG1 | Neurod3 | Neurogenin1 | Ngn1	cognitive abilities | cognitive deficits	0	1	0.9903684855	1	1				M				e	rs2344484-C-allele may affect NEUROG1's role in transcription regulation such that brain morphology and cognitive abilities are altered resulting in increased susceptibility to develop schizophrenia.
18799289	4762	D011618	NEUROG1 | Neurod3 | Neurogenin1 | Ngn1	schizophrenia or schizoaffective disorder	0	0	0.02574066631	0										
18799289	4762	D012559	NEUROG1 | Neurod3 | Neurogenin1 | Ngn1	schizophrenia	1	1	0.9926149845	0										
18801688	3119	D001172	DQB1	RA | Rheumatoid arthritis | rheumatoid arthritis	1	1	0.8445150852	0										
18801688	3119	D001327	DQB1	autoimmune multifactorial disease	0	0	0.00429309113	0										
18801688	3123	D001172	DRB1	RA | Rheumatoid arthritis | rheumatoid arthritis	1	1	0.9892705679	0										
18801688	3123	D001327	DRB1	autoimmune multifactorial disease	0	0	0.005879384931	0										
18827005	5251	D001847	PHEX	bone deformities	0	0	0.01381805725	0										
18827005	5251	D006130	PHEX	growth defects	0	0	0.00508428039	0										
18827005	5251	D053098	PHEX	X-linked hypophosphatemic rickets	0	0	0.003950424492	0										
18827005	5251	D063730	PHEX	hypophosphatemic rickets	0	0	0.00962021295	0										
18827005	7421	D001847	VDR | Vitamin D receptor | vitamin D receptor	bone deformities	0	1	0.6453126669	1	0									
18827005	7421	D006130	VDR | Vitamin D receptor | vitamin D receptor	growth defects	0	0	0.03779921308	0										
18827005	7421	D053098	VDR | Vitamin D receptor | vitamin D receptor	X-linked hypophosphatemic rickets	1	0	0.01750466041	1	0									
18827005	7421	D063730	VDR | Vitamin D receptor | vitamin D receptor	hypophosphatemic rickets	0	1	0.9815143943	1	1		1						0	Vitamin D receptor genotype in hypophosphatemic rickets as a predictor of growth and response to treatment.
18827005	8074	D001847	FGF23	bone deformities	0	0	0.01456167363	0										
18827005	8074	D006130	FGF23	growth defects	0	0	0.005120550748	0										
18827005	8074	D053098	FGF23	X-linked hypophosphatemic rickets	0	0	0.003944496159	0										
18827005	8074	D063730	FGF23	hypophosphatemic rickets	0	0	0.008288862184	0										
18827005	9001	D001847	Hap1	bone deformities	0	0	0.09829355776	0										
18827005	9001	D006130	Hap1	growth defects	0	0	0.1518009007	0										
18827005	9001	D053098	Hap1	X-linked hypophosphatemic rickets	0	0	0.007137687877	0										
18827005	9001	D063730	Hap1	hypophosphatemic rickets	0	0	0.01627646759	0										
18827765	1565	D001480	CYP 2D6 | CYP2D6 | cytochrome P450 2D6	extrapyramidal symptoms	1	1	0.9870157242	0										
18827765	1565	D011618	CYP 2D6 | CYP2D6 | cytochrome P450 2D6	schizophrenia or schizoaffective disorder	0	0	0.07670902461	0										
18827765	1565	D012559	CYP 2D6 | CYP2D6 | cytochrome P450 2D6	schizophrenia	0	1	0.8881087303	1	1				n			1	e	The aim of the presentation was to evaluate the impact of CYP2D6 genotype on psychopathological and extrapyramidal symptoms in a group of Slovenian outpatients with schizophrenia or schizoaffective disorder in stable remission, who were receiving long-term maintenance therapy.
18832463	54658	D003414	UDP-glucuronosyltransferase 1A1 | UGT1A1	unconjugated hyperbilirubinemia	0	1	0.5952212811	1	0									
18832463	54658	D005878	UDP-glucuronosyltransferase 1A1 | UGT1A1	Gilbert's syndrome	1	1	0.9824565649	0										
18832463	54658	D007565	UDP-glucuronosyltransferase 1A1 | UGT1A1	jaundice	0	0	0.1442522407	0										
18832463	54658	D064420	UDP-glucuronosyltransferase 1A1 | UGT1A1	toxicity	0	0	0.04307828099	0										
18832463	7361	D003414	UGT1A	unconjugated hyperbilirubinemia	0	0	0.005758848507	0										
18832463	7361	D005878	UGT1A	Gilbert's syndrome	0	0	0.0214366056	0										
18832463	7361	D007565	UGT1A	jaundice	0	0	0.003275475465	0										
18832463	7361	D064420	UGT1A	toxicity	0	0	0.002797438297	0										
18838388	3123	C538347	HLA-DRB1	RF	0	0	0.01820327714	0										
18838388	3123	D001172	HLA-DRB1	RA | rheumatoid arthritis	1	0	0.01431110408	1	0									
18838388	3123	D007249	HLA-DRB1	inflammation	0	0	0.02724902332	0										
18838388	3552	C538347	IL-1 | IL-1A | Interleukin-1	RF	0	0	0.08958101273	0										
18838388	3552	D001172	IL-1 | IL-1A | Interleukin-1	RA | rheumatoid arthritis	1	1	0.8692640662	0										
18838388	3552	D007249	IL-1 | IL-1A | Interleukin-1	inflammation	0	1	0.9401473999	1	1	only							1bg	IL-1 has a central role mediating inflammation and joint destruction in RA.
18838388	3553	C538347	IL-1B	RF	0	0	0.007091034669	0										
18838388	3553	D001172	IL-1B	RA | rheumatoid arthritis	1	1	0.9926958084	0										
18838388	3553	D007249	IL-1B	inflammation	0	0	0.1769887805	0										
18855532	1812	D009459	DRD1	neuroleptic-naive schizophrenia	0	0	0.005409733858	0										
18855532	1812	D012559	DRD1	schizophrenia	1	0	0.05984340981	1	0									
18855532	1813	D009459	DRD2	neuroleptic-naive schizophrenia	0	0	0.006533180363	0										
18855532	1813	D012559	DRD2	schizophrenia	0	0	0.08822464943	0	1		1				1		e	These data suggest that the SNPs in DRD2 and AKT1 may influence the treatment response to risperidone in schizophrenia patients.
18855532	1816	D009459	DRD5	neuroleptic-naive schizophrenia	0	0	0.005205818452	0										
18855532	1816	D012559	DRD5	schizophrenia	1	0	0.04361004755	1	0									
18855532	207	D009459	AKT1	neuroleptic-naive schizophrenia	0	0	0.01454988867	0										
18855532	207	D012559	AKT1	schizophrenia	1	1	0.9163728356	0	1		1				1		e	These data suggest that the SNPs in DRD2 and AKT1 may influence the treatment response to risperidone in schizophrenia patients.
18855532	2932	D009459	GSK3beta	neuroleptic-naive schizophrenia	0	0	0.005631402601	0										
18855532	2932	D012559	GSK3beta	schizophrenia	1	0	0.1619657725	1	0									
18855532	3350	D009459	HTR1A	neuroleptic-naive schizophrenia	0	0	0.005770042073	0										
18855532	3350	D012559	HTR1A	schizophrenia	1	0	0.3601952791	1	0									
18855532	3351	D009459	HTR1B	neuroleptic-naive schizophrenia	0	0	0.005318404175	0										
18855532	3351	D012559	HTR1B	schizophrenia	1	0	0.1319264024	1	0									
18855532	3352	D009459	HTR1D	neuroleptic-naive schizophrenia	0	0	0.005429885816	0										
18855532	3352	D012559	HTR1D	schizophrenia	1	0	0.1757227331	1	0									
18855532	3356	D009459	HTR2A	neuroleptic-naive schizophrenia	0	0	0.005437402986	0										
18855532	3356	D012559	HTR2A	schizophrenia	1	0	0.0785921216	1	0									
18855532	3358	D009459	HTR2C	neuroleptic-naive schizophrenia	0	0	0.005271058064	0										
18855532	3358	D012559	HTR2C	schizophrenia	1	0	0.04880143702	1	0									
18855532	3362	D009459	HTR6	neuroleptic-naive schizophrenia	0	0	0.005732316989	0										
18855532	3362	D012559	HTR6	schizophrenia	1	0	0.1883410513	1	0									
18855532	3363	D009459	HTR7	neuroleptic-naive schizophrenia	0	0	0.005782356951	0										
18855532	3363	D012559	HTR7	schizophrenia	1	0	0.2220320255	1	0									
18923807	120892	D010300	LRRK2	PD | Parkinson's disease	1	1	0.9950974584	0										
18923807	120892	D019636	LRRK2	neurodegenerative disorder	0	0	0.01098669879	0										
18973462	1589	C535979	CYP21A2	steroid 21-hydroxylase deficiency	0	0	0.01370375883	0										
18973462	1589	D000312	CYP21A2	Congenital adrenal hyperplasia	1	0	0.01153107267	1	1			Dk					e	Genotyping for the four common mutations (IVS2-13A/C&gt;G, p.Q318X, large lesions of the CYP21A2 gene and p.I172N) should allow identifying the diseased alleles and providing genetic counseling in 94% of CAH Moroccan cases.
18973462	1589	D030342	CYP21A2	autosomal recessive disease	0	0	0.01047794707	0										
18973462	389549	C535979	Fez	steroid 21-hydroxylase deficiency	0	0	0.003745981026	0										
18973462	389549	D000312	Fez	Congenital adrenal hyperplasia	0	0	0.003519435879	0										
18973462	389549	D030342	Fez	autosomal recessive disease	0	0	0.003414250212	0										
18979915	7054	D001523	TH | tyrosine hydroxylase	mental disorder | mental disorders	1	1	0.9831590652	0										
18979915	7054	D003866	TH | tyrosine hydroxylase	depression	0	0	0.125017941	0										
18979915	7054	D012559	TH | tyrosine hydroxylase	schizophrenia	0	0	0.007647060789	0										
19026700	3553	D001172	IL-1beta	RA | rheumatoid arthritis	0	0	0.007063113153	0										
19026700	3553	D011111	IL-1beta	polymyalgia rheumatica	0	0	0.01756577939	0										
19026700	3553	D012216	IL-1beta	rheumatic	0	0	0.003515802557	0										
19026700	3553	D013700	IL-1beta	giant cell arteritis	0	0	0.003461246612	0										
19026700	3557	D001172	IL-1RN | IL1RN	RA | rheumatoid arthritis	1	1	0.9866847396	0										
19026700	3557	D011111	IL-1RN | IL1RN	polymyalgia rheumatica	1	1	0.9933692813	0										
19026700	3557	D012216	IL-1RN | IL1RN	rheumatic	0	0	0.1494889706	0										
19026700	3557	D013700	IL-1RN | IL1RN	giant cell arteritis	1	0	0.1473455578	1	0					1	1	1	e	The presence of IL1RN*1 or IL1RN*2 allele was not associated with severity of the disease in PMR and GCA
19072763	7157	D000230	p53	adenocarcinomas	0	0	0.008061023429	0										
19072763	7157	D002289	p53	non-small cell lung cancer	0	1	0.9048784971	1	0.5			Dr	n			1	e	Therefore, p53 mutations are frequent in tumor-surrounding histologically normal tissue, and some of them might be involved in lung carcinogenesis.
19072763	7157	D002294	p53	squamous cell carcinomas	0	0	0.007603674196	0										
19072763	7157	D008175	p53	lung cancer | lung tumor | lung tumors	1	1	0.9935224652	0										
19072763	7157	D009369	p53	tumor	0	0	0.006605488714	0										
19072763	7157	D063646	p53	lung carcinogenesis	0	0	0.03641550615	0										
19075277	1956	D001523	EGFR	tumor aggressiveness	0	0	0.002852588426	0										
19075277	1956	D001943	EGFR	breast cancer | tumor aggressiveness in breast cancer	1	0	0.1830463558	1	0.5				n				m	For the evaluation of tumor aggressiveness, AKT2, EGFR, and TRERF1 mRNA levels were all significantly associated with MFS,
19075277	1956	D008382	EGFR	MFS	0	0	0.2311730534	0										
19075277	1956	D061325	EGFR	breast tumors	0	0	0.006527098827	0										
19075277	2064	D001523	ERBB2	tumor aggressiveness	0	0	0.002491093241	0										
19075277	2064	D001943	ERBB2	breast cancer | tumor aggressiveness in breast cancer	1	0	0.09661375731	1	0.5				n				m	For the evaluation of tumor aggressiveness, AKT2, EGFR, and TRERF1 mRNA levels were all significantly associated with MFS,
19075277	2064	D008382	ERBB2	MFS	0	0	0.01242937427	0										
19075277	2064	D061325	ERBB2	breast tumors	0	0	0.005276368465	0										
19075277	207	D001523	AKT1	tumor aggressiveness	0	0	0.002550302073	0										
19075277	207	D001943	AKT1	breast cancer | tumor aggressiveness in breast cancer	0	0	0.1124748439	0	0									
19075277	207	D008382	AKT1	MFS	0	0	0.01272937655	0										
19075277	207	D061325	AKT1	breast tumors	0	0	0.006940024905	0										
19075277	208	D001523	AKT2	tumor aggressiveness	0	0	0.002787642647	0										
19075277	208	D001943	AKT2	breast cancer | tumor aggressiveness in breast cancer	1	0	0.2283959091	1	0.5				n				m	For the evaluation of tumor aggressiveness, AKT2, EGFR, and TRERF1 mRNA levels were all significantly associated with MFS,
19075277	208	D008382	AKT2	MFS	0	0	0.2079545259	0										
19075277	208	D061325	AKT2	breast tumors	0	0	0.008438996971	0										
19075277	2886	D001523	GRB7	tumor aggressiveness	0	0	0.002645017812	0										
19075277	2886	D001943	GRB7	breast cancer | tumor aggressiveness in breast cancer	1	0	0.3895487487	1	0.5				b				m	Concerning tamoxifen resistance, BCAR3, ERBB2, GRB7, and TLE3 mRNA levels were predictive for PFS, independent of traditional predictive factors.
19075277	2886	D008382	GRB7	MFS	0	0	0.01390064042	0										
19075277	2886	D061325	GRB7	breast tumors	0	0	0.009499787353	0										
19075277	55809	D001523	TRERF1	tumor aggressiveness	0	0	0.002889747266	0										
19075277	55809	D001943	TRERF1	breast cancer | tumor aggressiveness in breast cancer	1	0	0.1991235912	1	0.5				n				m	For the evaluation of tumor aggressiveness, AKT2, EGFR, and TRERF1 mRNA levels were all significantly associated with MFS,
19075277	55809	D008382	TRERF1	MFS	0	0	0.0247257594	0										
19075277	55809	D061325	TRERF1	breast tumors	0	0	0.008128952235	0										
19075277	6714	D001523	SRC	tumor aggressiveness	0	0	0.002534174593	0										
19075277	6714	D001943	SRC	breast cancer | tumor aggressiveness in breast cancer	0	0	0.09418376535	0	0									
19075277	6714	D008382	SRC	MFS	0	0	0.01262012869	0										
19075277	6714	D061325	SRC	breast tumors	0	0	0.005794653203	0										
19075277	7090	D001523	TLE3	tumor aggressiveness	0	0	0.002807037439	0										
19075277	7090	D001943	TLE3	breast cancer | tumor aggressiveness in breast cancer	1	1	0.7557144761	0	0.5				b				m	Concerning tamoxifen resistance, BCAR3, ERBB2, GRB7, and TLE3 mRNA levels were predictive for PFS, independent of traditional predictive factors.
19075277	7090	D008382	TLE3	MFS	0	0	0.0160339009	0										
19075277	7090	D061325	TLE3	breast tumors	0	0	0.01998662762	0										
19075277	8412	D001523	BCAR3	tumor aggressiveness	0	0	0.002572438447	0										
19075277	8412	D001943	BCAR3	breast cancer | tumor aggressiveness in breast cancer	1	0	0.1606923938	1	0.5				b				m	Concerning tamoxifen resistance, BCAR3, ERBB2, GRB7, and TLE3 mRNA levels were predictive for PFS, independent of traditional predictive factors.
19075277	8412	D008382	BCAR3	MFS	0	0	0.01289120503	0										
19075277	8412	D061325	BCAR3	breast tumors	0	0	0.007866406813	0										
19075277	9564	D001523	BCAR1	tumor aggressiveness	0	0	0.002549289493	0										
19075277	9564	D001943	BCAR1	breast cancer | tumor aggressiveness in breast cancer	0	0	0.108533822	0										
19075277	9564	D008382	BCAR1	MFS	0	0	0.01271842699	0										
19075277	9564	D061325	BCAR1	breast tumors	0	0	0.006830221042	0										
19076285	1636	C538250	ACE | Angiotensin-converting enzyme	idiopathic FSGS	0	0	0.0721668303	0										
19076285	1636	D003643	ACE | Angiotensin-converting enzyme	Renal death | renal death	0	0	0.007058472838	0										
19076285	1636	D005921	ACE | Angiotensin-converting enzyme	glomerulonephritis | glomerulosclerosis	0	1	0.9817064404	1	0					1	1		e	Our study revealed no correlation between ACE I/D gene polymorphism and rapidity of progression of FSGS to ESRD in Iranian children.
19076285	1636	D007674	ACE | Angiotensin-converting enzyme	renal disease	0	0	0.006196439732	0										
19076285	1636	D007676	ACE | Angiotensin-converting enzyme	ESRD	1	0	0.06910660863	1	0					1			e	Our study revealed no correlation between ACE I/D gene polymorphism and rapidity of progression of FSGS to ESRD in Iranian children.
19087273	7139	D002312	TNNT2	hypertrophic cardiomyopathy	1	1	0.9770107865	0										
19087273	7139	D006331	TNNT2	cardiac troponin T	0	0	0.00875051599	0										
19087273	7139	D009202	TNNT2	cardiomyopathy	0	0	0.0165999569	0										
19102423	3356	D004402	5-HT 2A receptor | Serotonin-2A receptor	FD	0	0	0.009765806608	0										
19102423	3356	D004415	5-HT 2A receptor | Serotonin-2A receptor	dyspepsia	1	0	0.04789852723	1	0			Di						
19102423	3356	D016481	5-HT 2A receptor | Serotonin-2A receptor	pylori infection	0	0	0.004532881547	0										
19102423	3356	D051271	5-HT 2A receptor | Serotonin-2A receptor	dyspeptic symptoms	0	1	0.7030566931	1	0				M	1			e	Our results suggest that 5HTR2A polymorphism is unlikely to be associated with susceptibility of dyspeptic symptoms.
19116909	3559	D001171	CD25 | IL2RA | interleukin-2 receptor alpha	juvenile idiopathic arthritis	1	1	0.984832108	0										
19116909	3559	D001172	CD25 | IL2RA | interleukin-2 receptor alpha	RA | rheumatoid arthritis	0	1	0.9782029986	1	1								1bg	IL2RA/CD25, the gene for interleukin-2 receptor alpha, is emerging as a general susceptibility gene for autoimmune diseases because of its role in the development and function of regulatory T cells and the association of single-nucleotide polymorphisms (SNPs) within this gene with type 1 diabetes mellitus (DM), Graves' disease, rheumatoid arthritis (RA), and multiple sclerosis (MS).
19116909	3559	D003920	CD25 | IL2RA | interleukin-2 receptor alpha	diabetes mellitus	0	0	0.008945091628	0										
19116909	3559	D006111	CD25 | IL2RA | interleukin-2 receptor alpha	Graves' disease	0	0	0.0114727756	0	1								1bg	IL2RA/CD25, the gene for interleukin-2 receptor alpha, is emerging as a general susceptibility gene for autoimmune diseases because of its role in the development and function of regulatory T cells and the association of single-nucleotide polymorphisms (SNPs) within this gene with type 1 diabetes mellitus (DM), Graves' disease, rheumatoid arthritis (RA), and multiple sclerosis (MS).
19116909	3559	D009103	CD25 | IL2RA | interleukin-2 receptor alpha	MS | multiple sclerosis	0	1	0.9879569411	1	1								1bg	IL2RA/CD25, the gene for interleukin-2 receptor alpha, is emerging as a general susceptibility gene for autoimmune diseases because of its role in the development and function of regulatory T cells and the association of single-nucleotide polymorphisms (SNPs) within this gene with type 1 diabetes mellitus (DM), Graves' disease, rheumatoid arthritis (RA), and multiple sclerosis (MS).
19121298	4582	D001943	CA 15-3 | MUC1	breast cancer	1	1	0.9935998917	0										
19121298	4582	D009369	CA 15-3 | MUC1	benign disease | cancer | tumor	0	0	0.01985661313	0										
19121298	4582	D061325	CA 15-3 | MUC1	benign breast disease | breast tumors | malignant breast tumors	0	1	0.9835657477	1	1		1						1bg	CA 15-3 is a widely used tumor marker for breast cancer.
19124501	328	D008175	APE1 | Apurinic/apyrimidinic endonuclease 1	lung cancer	1	1	0.9942631125	0										
19124501	328	D009369	APE1 | Apurinic/apyrimidinic endonuclease 1	cancer	0	0	0.008636773564	0										
19154219	4897	D012559	NRCAM | neuronal cell adhesion molecule	schizophrenia	1	1	0.9760074019	0										
19164858	102641031	D003643	pyrin domain-containing protein 3	death	0	0	0.002784235403	0										
19164858	102641031	D017695	pyrin domain-containing protein 3	increases overall tissue injury	0	0	0.00562763121	0										
19164858	102641031	D056486	pyrin domain-containing protein 3	hepatotoxicity | liver injury	0	0	0.002506221179	0										
19164858	102641031	D064420	pyrin domain-containing protein 3	toxic injury	0	0	0.002968554851	0										
19164858	114548	D003643	Nalp3	death	0	0	0.004177002702	0										
19164858	114548	D017695	Nalp3	increases overall tissue injury	0	0	0.0168964006	0										
19164858	114548	D056486	Nalp3	hepatotoxicity | liver injury	0	0	0.006451396272	0										
19164858	114548	D064420	Nalp3	toxic injury	0	0	0.004797739442	0										
19164858	29108	D003643	ASC | apoptosis-associated speck-like protein containing a CARD	death	0	0	0.003603982972	0										
19164858	29108	D017695	ASC | apoptosis-associated speck-like protein containing a CARD	increases overall tissue injury	0	0	0.01030992996	0										
19164858	29108	D056486	ASC | apoptosis-associated speck-like protein containing a CARD	hepatotoxicity | liver injury	0	0	0.003222207539	0										
19164858	29108	D064420	ASC | apoptosis-associated speck-like protein containing a CARD	toxic injury	0	0	0.004053337034	0										
19164858	3553	D003643	IL-1beta	death	0	0	0.002795867855	0										
19164858	3553	D017695	IL-1beta	increases overall tissue injury	0	0	0.005672306754	0										
19164858	3553	D056486	IL-1beta	hepatotoxicity | liver injury	1	0	0.002475872403	1	0									
19164858	3553	D064420	IL-1beta	toxic injury	0	0	0.002958732657	0										
19164858	3606	D003643	IL-18	death	0	0	0.003465018468	0										
19164858	3606	D017695	IL-18	increases overall tissue injury	0	0	0.009280644357	0										
19164858	3606	D056486	IL-18	hepatotoxicity | liver injury	1	0	0.002969229128	1	0									
19164858	3606	D064420	IL-18	toxic injury	0	0	0.003731027246	0										
19164858	4512	D003643	COX-1	death	0	0	0.002727544401	0										
19164858	4512	D017695	COX-1	increases overall tissue injury	0	0	0.005169549957	0										
19164858	4512	D056486	COX-1	hepatotoxicity | liver injury	0	0	0.002454400528	0										
19164858	4512	D064420	COX-1	toxic injury	0	0	0.002869089367	0										
19164858	54106	D003643	Tlr9	death	0	0	0.0075075645	0										
19164858	54106	D017695	Tlr9	increases overall tissue injury	0	0	0.02433996461	0										
19164858	54106	D056486	Tlr9	hepatotoxicity | liver injury	0	0	0.008738711476	0										
19164858	54106	D064420	Tlr9	toxic injury	0	0	0.005859699566	0										
19164858	834	D003643	caspase-1	death	0	0	0.002837914042	0										
19164858	834	D017695	caspase-1	increases overall tissue injury	0	0	0.005929053761	0										
19164858	834	D056486	caspase-1	hepatotoxicity | liver injury	0	0	0.002629265655	0										
19164858	834	D064420	caspase-1	toxic injury	0	0	0.003040862037	0										
19181484	1139	D012559	CHRNA7 | alpha7 neuronal nicotinic acetylcholine receptor	Schizophrenia | schizophrenia | schizophrenic	1	1	0.9947795868	0										
19181484	4790	D012559	P50	Schizophrenia | schizophrenia | schizophrenic	0	0	0.03513842076	0										
19184136	3359	D001321	HTR3A	Autism | autism | increases autism	1	1	0.9941776991	0										
19184136	3359	D002658	HTR3A	developmental disorders	0	0	0.005216783844	0										
19184136	3359	D003072	HTR3A	cognitive disturbances	0	0	0.008042669855	0										
19184136	4544	D001321	MTNR1B	Autism | autism | increases autism	0	1	0.9752667546	1	1							1	e	a significant 2-way interaction (p-value = 0.01) was found between rs10830962, near MTNR1B (Chromosome11; 92,338,075 bp) and rs1007631, near SLC7A5 (Chromosome16; 86,413,596 bp).
19184136	4544	D002658	MTNR1B	developmental disorders	0	0	0.004737609532	0										
19184136	4544	D003072	MTNR1B	cognitive disturbances	0	0	0.006840676535	0										
19184136	8140	D001321	SLC7A5	Autism | autism | increases autism	0	1	0.9748016596	1	1							1	e	a significant 2-way interaction (p-value = 0.01) was found between rs10830962, near MTNR1B (Chromosome11; 92,338,075 bp) and rs1007631, near SLC7A5 (Chromosome16; 86,413,596 bp).
19184136	8140	D002658	SLC7A5	developmental disorders	0	0	0.004655046389	0										
19184136	8140	D003072	SLC7A5	cognitive disturbances	0	0	0.006687067915	0										
19208741	4118	D001932	MAL | myelin and lymphocyte protein	primary tumors	0	0	0.1704452187	0										
19208741	4118	D001943	MAL | myelin and lymphocyte protein	breast cancer	1	1	0.9941182137	0										
19208741	4118	D002583	MAL | myelin and lymphocyte protein	cervical cancers	0	1	0.9705399871	1	1								1bg	Dis-regulation of MAL (myelin and lymphocyte protein) has been implicated in several malignancies including esophageal, ovarian, and cervical cancers.
19208741	4118	D009369	MAL | myelin and lymphocyte protein	cancer | malignancies	0	0	0.01987425238	0	0									
19208741	4118	D010049	MAL | myelin and lymphocyte protein	ovarian	0	1	0.5956556797	1	0			Di						
19208741	4118	D018250	MAL | myelin and lymphocyte protein	solid malignancies	0	1	0.7548652291	1	1	only							mbg	The MAL protein functions in apical transport in polarized-epithelial cells, therefore its disruption may lead to loss of organized polarity characteristic of most solid malignancies.
19212639	2056	D000740	EPO	anemia	1	1	0.9632506371	0										
19212639	2056	D001943	EPO	breast cancer | primary breast cancer	0	1	0.9935597181	1	1				L				e	In conclusion, there is potential for improved anemia management using EPO during pre-operative chemotherapy, which not only benefits quality of life but could also influence long-term survival in breast cancer through improved tumor oxygenation.
19212639	2056	D009369	EPO	tumor	0	0	0.01559583191	0										
19223177	4524	D011471	5,10-methylenetetrahydrofolate reductase | MTHFR	prostate cancer	1	1	0.9949582219	0										
19273450	4153	D001172	MBL | MBL2 | Mannose-binding lectin | mannose-binding lectin	rheumatoid arthritis	1	1	0.9923421741	0										
19273450	79841	D001172	CCP2	rheumatoid arthritis	0	0	0.01110173017	0										
19290788	11251	D000799	CRTH2	angioedema	0	0	0.2751312852	0										
19290788	11251	D004342	CRTH2	Allergy	0	1	0.8676843047	1	0									
19290788	11251	D014581	CRTH2	urticaria	1	1	0.9006735682	0										
19290788	2625	D000799	GATA-3	angioedema	0	0	0.007114419714	0										
19290788	2625	D004342	GATA-3	Allergy	0	0	0.0148671614	0										
19290788	2625	D014581	GATA-3	urticaria	0	0	0.003997702617	0										
19295411	4313	D006333	MMP-2 | MMPs	congestive heart failure	1	1	0.980830431	0										
19295411	4313	D054143	MMP-2 | MMPs	systolic heart failure	0	1	0.9810339212	1	1		1						0	Polymorphisms of MMP-2 gene are associated with systolic heart failure risk in Han Chinese.
19295411	4313	D054160	MMP-2 | MMPs	systolic HF	0	1	0.9941506982	1	1		1						e	The findings of the current study suggest that MMP-2 rs243866 A allele was associated with lower risk of systolic HF in Han Chinese.
19317738	4282	D001249	MIF | Macrophage migration inhibitory factor	asthma | childhood asthma	1	1	0.9952270985	0										
19322213	55350	D003092	vanin-3	colitis	0	0	0.008957804181	0	0									
19322213	55350	D003876	vanin-3	atopic dermatitis lesions	0	0	0.03232568502	0	1								m	In a microarray analysis of epidermal gene expression of psoriasis and atopic dermatitis lesions, we identified vanin-3 as the gene showing the highest differential expression of all annotated genes that we studied
19322213	55350	D007249	vanin-3	inflammatory diseases	0	0	0.01695687138	0	0									
19322213	55350	D011565	vanin-3	psoriasis	1	0	0.1184415445	1	1								m	In a microarray analysis of epidermal gene expression of psoriasis and atopic dermatitis lesions, we identified vanin-3 as the gene showing the highest differential expression of all annotated genes that we studied
19322213	55350	D015535	vanin-3	psoriatic epidermis	0	0	0.02508052997	0	1								m	Quantitative real-time PCR analysis confirmed the microarray data on vanin-3 and showed similar induction of vanin-1, but not of vanin-2, in psoriatic epidermis.
19322213	8875	D003092	vanin-2	colitis	0	0	0.004894678015	0	0									
19322213	8875	D003876	vanin-2	atopic dermatitis lesions	1	0	0.004084771033	1	0									
19322213	8875	D007249	vanin-2	inflammatory diseases	0	0	0.007414967753	0	0									
19322213	8875	D011565	vanin-2	psoriasis	1	0	0.004149550572	1	0									
19322213	8875	D015535	vanin-2	psoriatic epidermis	0	0	0.007974022999	0	0									
19322213	8876	D003092	pantetheinase | vanin-1	colitis	0	1	0.5132389665	1	0.5				n				mbg	Recent studies in a mouse colitis model indicated that vanin-1 has proinflammatory activity and suggest that pantetheinases are potential therapeutic targets in inflammatory diseases.
19322213	8876	D003876	pantetheinase | vanin-1	atopic dermatitis lesions	1	0	0.00962136779	1	0									
19322213	8876	D007249	pantetheinase | vanin-1	inflammatory diseases	0	1	0.6873431802	1	1								mbg	suggest that pantetheinases are potential therapeutic targets in inflammatory diseases.
19322213	8876	D011565	pantetheinase | vanin-1	psoriasis	1	0	0.1671934128	1	1								e	We hypothesize that increased levels of pantetheinase activity are part of the inflammatory-regenerative epidermal differentiation program, and may contribute to the phenotype observed in psoriasis.
19322213	8876	D015535	pantetheinase | vanin-1	psoriatic epidermis	0	0	0.0294594001	0	1								m	Quantitative real-time PCR analysis confirmed the microarray data on vanin-3 and showed similar induction of vanin-1, but not of vanin-2, in psoriatic epidermis.
19326438	4842	D010300	NOS1 | nitric oxide synthase 1	PD | Parkinson's disease	1	1	0.9947808385	0										
19327158	10392	D003092	NOD1 | Nod1 | Nucleotide-binding oligomerization domain containing 1 | nucleotide-binding oligomerization domain containing 1	colitis	0	0	0.09212624282	0										
19327158	10392	D003093	NOD1 | Nod1 | Nucleotide-binding oligomerization domain containing 1 | nucleotide-binding oligomerization domain containing 1	ulcerative colitis	0	0	0.04557392001	0										
19327158	10392	D003424	NOD1 | Nod1 | Nucleotide-binding oligomerization domain containing 1 | nucleotide-binding oligomerization domain containing 1	Crohn's disease	0	1	0.968265295	1	1			Dk	M				m	Carrying the rs2075818 G allele decreased the risk of CD
19327158	10392	D015212	NOD1 | Nod1 | Nucleotide-binding oligomerization domain containing 1 | nucleotide-binding oligomerization domain containing 1	inflammatory bowel diseases	1	1	0.974445641	0										
19343045	3741	C538250	KCNA5	idiopathic AF	0	0	0.07344085723	0										
19343045	3741	D001281	KCNA5	AF | atrial fibrillation | familial atrial fibrillation	1	1	0.995034337	0										
19368828	1437	D000544	CSF	AD | Alzheimer's disease	0	1	0.6242278814	1	0									
19368828	1437	D003704	CSF	Dementias	0	0	0.003306628205	0										
19368828	348	D000544	APOE4	AD | Alzheimer's disease	1	0	0.4964752197	1	1						1	1	m	The SNP21G-allele and a SORL1 haplotype consisting of the SNP19 T-allele, SNP21 G-allele and SNP23 A-allele (T/G/A) were associated with increased hazard ratios and an earlier age at onset of AD (SNP21: p=0.002; T/G/A haplotype: p=0.007). This effect was most pronounced in carriers of an additional APOE4 allele
19368828	348	D003704	APOE4	Dementias	0	0	0.002696946962	0										
19368828	6653	D000544	SORL1	AD | Alzheimer's disease	1	1	0.9941852689	0										
19368828	6653	D003704	SORL1	Dementias	0	0	0.01198135037	0										
19379721	1636	D006973	ACE	hypertension	1	1	0.9219705462	0										
19379721	183	D006973	AGT	hypertension	1	0	0.09431426227	1	1			Dk					e	Within gene and between genes interactions of variants influence ACE activity and NO(x) levels and associate with EH.
19379721	4846	D006973	NOS3	hypertension	1	1	0.8972136974	0										
19383811	4193	D000230	MDM2	adenocarcinoma	0	0	0.02137022279	0										
19383811	4193	D002294	MDM2	adenocarcinoma versus squamous cell carcinoma | squamous cell carcinoma	0	0	0.01374870073	0										
19383811	4193	D003643	MDM2	death	0	0	0.005661537871	0										
19383811	4193	D004938	MDM2	esophageal cancer | esophageal cancers | esophageal carcinoma	1	1	0.9880002141	0										
19383811	7157	D000230	p53	adenocarcinoma	0	0	0.006042760797	0										
19383811	7157	D002294	p53	adenocarcinoma versus squamous cell carcinoma | squamous cell carcinoma	0	0	0.005716500338	0										
19383811	7157	D003643	p53	death	0	0	0.004952547606	0										
19383811	7157	D004938	p53	esophageal cancer | esophageal cancers | esophageal carcinoma	1	1	0.9861603975	0										
19384346	85358	D001321	SHANK3	ASD | Autism | autism	1	1	0.9944652915	0	0					1			e	Our data suggest that SHANK3 deletions may be limited to lower functioning individuals with autism.
19384346	85358	D002659	SHANK3	autism spectrum disorders	0	1	0.9511938691	1	0									
19396436	1813	D010300	DRD2	PD | Parkinson Disease | Parkinson's disease	1	1	0.9702765346	0										
19396436	1814	D010300	DRD3	PD | Parkinson Disease | Parkinson's disease	1	1	0.9914076924	0										
19401164	150	D003865	ADRA2A	MDD	0	1	0.9883153439	1	0			Dr		1			m	No relationship was observed between the ADRA2A -1291C/G polymorphism and MDD.
19401164	150	D003866	ADRA2A	Depression | depressive disorder	0	1	0.9839850068	1	0			Di						
19401164	150	D015430	ADRA2A	weight gain	1	1	0.9873837829	0										
19443940	3553	D001172	IL-1beta | IL1B | IL1beta	RA | rheumatoid arthritis	1	0	0.1116244048	1	0					1			0	IL-1beta, IL-6, and TNF gene polymorphisms do not affect the treatment outcome of rheumatoid arthritis patients with leflunomide.
19443940	3569	D001172	IL-6 | IL6	RA | rheumatoid arthritis	0	1	0.9580616951	1	0					1			0	IL-1beta, IL-6, and TNF gene polymorphisms do not affect the treatment outcome of rheumatoid arthritis patients with leflunomide.
19443940	7124	D001172	TNF | TNF-alpha	RA | rheumatoid arthritis	1	1	0.984000504	0	0					1			0	IL-1beta, IL-6, and TNF gene polymorphisms do not affect the treatment outcome of rheumatoid arthritis patients with leflunomide.
19466271	4153	D003550	MBL2	CF | cystic fibrosis	1	1	0.9659810066	0										
19466271	4153	D008171	MBL2	lung disease | pulmonary disease	1	1	0.9765639305	0										
19466271	7040	D003550	TGF-beta1	CF | cystic fibrosis	1	1	0.986921072	0										
19466271	7040	D008171	TGF-beta1	lung disease | pulmonary disease	1	1	0.9891848564	0										
19466271	929	D003550	CD14	CF | cystic fibrosis	1	1	0.9146882892	0										
19466271	929	D008171	CD14	lung disease | pulmonary disease	1	1	0.9883103371	0										
19480854	3458	D006521	IFNgamma	chronic hepatitis	0	0	0.007373639382	0										
19480854	3458	D006526	IFNgamma	chronic HCV infection | hepatitis C pathogenesis	0	0	0.1684485525	0										
19480854	3458	D006528	IFNgamma	hepatocellular carcinoma	1	0	0.007721346337	1	1				Di				m	the combination of IFNgamma(low producer) and IL-10(high producer) genotypes was significantly associated with a lower risk of LC and HCC
19480854	3458	D008103	IFNgamma	liver cirrhosis	1	0	0.02359386347	1	1				Di				m	the combination of IFNgamma(low producer) and IL-10(high producer) genotypes was significantly associated with a lower risk of LC and HCC
19480854	3458	D019698	IFNgamma	chronic hepatitis C	1	1	0.9708423615	0										
19480854	3586	D006521	IL-10	chronic hepatitis	0	0	0.003796649864	0										
19480854	3586	D006526	IL-10	chronic HCV infection | hepatitis C pathogenesis	0	0	0.02375354432	0										
19480854	3586	D006528	IL-10	hepatocellular carcinoma	1	0	0.003957472742	1	1				Di				m	the combination of IFNgamma(low producer) and IL-10(high producer) genotypes was significantly associated with a lower risk of LC and HCC
19480854	3586	D008103	IL-10	liver cirrhosis	1	0	0.009411527775	1	1				Di				m	the combination of IFNgamma(low producer) and IL-10(high producer) genotypes was significantly associated with a lower risk of LC and HCC
19480854	3586	D019698	IL-10	chronic hepatitis C	1	1	0.859461844	0										
19499246	672	D001943	BRCA1 | BRCA1 and 2	breast cancer	0	0	0.008453905582	0										
19499246	672	D009369	BRCA1 | BRCA1 and 2	Cancer	0	0	0.006929854397	0										
19499246	672	D010049	BRCA1 | BRCA1 and 2	ovarian	0	0	0.006868898869	0										
19499246	672	D010051	BRCA1 | BRCA1 and 2	(2) ovarian cancer | Korean ovarian cancer | ovarian cancer	1	1	0.9792044759	0										
19499246	672	D061325	BRCA1 | BRCA1 and 2	breast or ovarian cancer	0	0	0.01005154289	0										
19499246	675	D001943	BRCA2	breast cancer	0	0	0.006777309347	0										
19499246	675	D009369	BRCA2	Cancer	0	0	0.00568679627	0										
19499246	675	D010049	BRCA2	ovarian	0	0	0.005641798954	0										
19499246	675	D010051	BRCA2	(2) ovarian cancer | Korean ovarian cancer | ovarian cancer	1	1	0.9812307954	0										
19499246	675	D061325	BRCA2	breast or ovarian cancer	0	0	0.007874267176	0										
19512960	1813	D001523	DRD2 | dopamine D2 receptor	psychiatric	0	0	0.01348428242	0										
19512960	1813	D009422	DRD2 | dopamine D2 receptor	neurologic disorders	1	0	0.01724386774	1	0									
19512960	1813	D010300	DRD2 | dopamine D2 receptor	Parkinson's disease	0	0	0.1440050751	0										
19512960	1813	D012559	DRD2 | dopamine D2 receptor	schizophrenia	0	0	0.07385268807	0										
19512960	1813	D020271	DRD2 | dopamine D2 receptor	neurologic diseases	0	0	0.052817408	0										
19512960	255239	D001523	ANKK1 | ankyrin repeat and kinase domain containing 1	psychiatric	0	0	0.008012521081	0										
19512960	255239	D009422	ANKK1 | ankyrin repeat and kinase domain containing 1	neurologic disorders	1	0	0.01499557775	1	0									
19512960	255239	D010300	ANKK1 | ankyrin repeat and kinase domain containing 1	Parkinson's disease	0	0	0.009686738253	0										
19512960	255239	D012559	ANKK1 | ankyrin repeat and kinase domain containing 1	schizophrenia	0	0	0.008179658093	0										
19512960	255239	D020271	ANKK1 | ankyrin repeat and kinase domain containing 1	neurologic diseases	0	0	0.009482873604	0										
19547755	1312	D000699	COMT | Catechol-O-methyltransferase	analgesia	0	0	0.01719235629	0										
19547755	1312	D006930	COMT | Catechol-O-methyltransferase	hyperalgesia	0	1	0.8369053602	1	0									
19547755	1312	D010146	COMT | Catechol-O-methyltransferase	pain | sustained pain	1	1	0.9672856927	0										
19550076	2492	D007246	FSH receptor | FSHR | follicle-stimulating hormone (FSH) receptor	idiopathic infertile | infertile	0	0	0.01675723866	0										
19550076	2492	D007248	FSH receptor | FSHR | follicle-stimulating hormone (FSH) receptor	idiopathic male infertility | male infertility	1	1	0.9943515062	0										
19550076	2492	D009845	FSH receptor | FSHR | follicle-stimulating hormone (FSH) receptor	oligozoospermia	0	1	0.5745100379	1	1						1	1	e	Dysfunction of the FSH receptor (FSHR) may be involved in some form of male infertility with azoospermia or oligozoospermia.
19550076	2492	D053713	FSH receptor | FSHR | follicle-stimulating hormone (FSH) receptor	azoospermia	0	1	0.8645628691	1	1						1	1	e	Dysfunction of the FSH receptor (FSHR) may be involved in some form of male infertility with azoospermia or oligozoospermia.
19571519	4350	D001172	MPG	RA | rheumatoid arthritis	0	0	0.06388803571	0										
19571519	4524	D001172	5,10-methylenetetrahydrofolate reductase | MTHFR	RA | rheumatoid arthritis	1	0	0.4163841307	1	0									
19571519	7298	D001172	TYMS | thymidylate synthase	RA | rheumatoid arthritis	1	1	0.9834321141	0										
19579695	3458	D002006	IFN gamma | IFN-gamma	brucellosis	1	1	0.6399453878	0										
19579695	3458	D003141	IFN gamma | IFN-gamma	infectious diseases	0	0	0.00458255643	0										
19579695	3569	D002006	IL-6	brucellosis	1	1	0.9892655611	0										
19579695	3569	D003141	IL-6	infectious diseases	0	0	0.01478579547	0										
19579695	3586	D002006	IL-10	brucellosis	1	0	0.02891299501	1	1		1						m	Our results showed that polymorphisms of IL-10 (-819) and TGF beta 1 codons 10 and 25 were associated with susceptibility or resistance to brucellosis.
19579695	3586	D003141	IL-10	infectious diseases	0	0	0.002912013559	0										
19579695	7040	D002006	TGF beta | TGF beta 1 | TGF-beta | TGF-beta 1	brucellosis	1	1	0.904826045	0										
19579695	7040	D003141	TGF beta | TGF beta 1 | TGF-beta | TGF-beta 1	infectious diseases	0	0	0.02329213545	0										
19579695	7124	D002006	TNF alpha | TNF-alpha	brucellosis	1	0	0.2335725576	1	0									
19579695	7124	D003141	TNF alpha | TNF-alpha	infectious diseases	0	0	0.003581760684	0										
19586533	1610	D001714	D-amino acid oxidase | DAO	bipolar disorder | schizophrenia and bipolar disorder	1	0	0.1529316157	1	0									
19586533	1610	D012559	D-amino acid oxidase | DAO	schizophrenia	1	1	0.9413699508	0	0					1			e	No evidence was found to confirm the association of genetic markers at the DAO gene with schizophrenia.
19586533	267012	D001714	D-amino acid oxidase activator | DAOA	bipolar disorder | schizophrenia and bipolar disorder	0	1	0.9943342209	1	1								e	Allelic association was detected between the marker rs3918342 (M23), 3' to the DAOA gene and both schizophrenia (chi2 = 5.824 p = 0.016) and bipolar disorder
19586533	267012	D012559	D-amino acid oxidase activator | DAOA	schizophrenia	0	1	0.960401535	1	1						1		e	Our results provide some support for a role for DAOA in susceptibility to schizophrenia and bipolar disorder.
19586841	3586	D004715	IL-10	endometriosis	1	1	0.9891152382	0										
19606693	7124	D003093	TNF-alpha	ulcerative colitis | ulcerative colitis macroscopic lesions	1	1	0.9933500886	0										
19606693	7124	D009336	TNF-alpha	necrosis	0	0	0.1463957876	0										
19606693	7124	D009369	TNF-alpha	tumor	0	1	0.7650271058	1	0									
19606693	7124	D015212	TNF-alpha	bowel diseases	0	0	0.016577553	0										
19608186	2099	D003327	ESR1	Coronary heart disease | coronary heart disease	1	1	0.9098886251	0										
19608186	2099	D009203	ESR1	myocardial infarction	1	1	0.5393345356	0										
19661039	5243	D001943	MDR1 | P-glycoprotein	breast cancer | breast carcinoma	1	1	0.991669178	0										
19665066	4292	D003123	MLH1	hereditary nonpolyposis colorectal cancer	0	0	0.004795640707	0										
19665066	4292	D009369	MLH1	cancer | tumors	0	0	0.006101470441	0										
19665066	4292	D015179	MLH1	colorectal cancer | sporadic colorectal cancer	1	1	0.976649642	0										
19671143	4780	D004646	NFE2L2 | NRF2 | Nfe2l2	emphysema	0	1	0.9152557254	1	1								mbg	Nfe2l2-deficient mice develop tobacco-induced emphysema.
19671143	4780	D008171	NFE2L2 | NRF2 | Nfe2l2	lung function loss	0	0	0.02479814179	0										
19671143	4780	D029424	NFE2L2 | NRF2 | Nfe2l2	Chronic Obstructive Pulmonary Disease	1	0	0.1860224903	1										
19671143	9817	D004646	KEAP1	emphysema	0	1	0.5650222301	1										
19671143	9817	D008171	KEAP1	lung function loss	0	0	0.02177619934	0										
19671143	9817	D029424	KEAP1	Chronic Obstructive Pulmonary Disease	1	0	0.1477303207	1	0									
19728081	1647	D001943	GADD45A	breast cancer | familial breast cancer | familial breast cancers	1	1	0.9948199391	0										
19728081	1647	D006323	GADD45A	Growth arrest	0	0	0.01291098911	0										
19728081	672	D001943	BRCA1	breast cancer | familial breast cancer | familial breast cancers	0	1	0.5739528537	1	1				C		1	1	1bg	Growth arrest and DNA damage-induced 45, alpha (GADD45A) is a candidate breast cancer susceptibility gene because its product participates in DNA repair and it is a downstream gene of p53 and BRCA1, both of which are breast cancer susceptibility genes.
19728081	672	D006323	BRCA1	Growth arrest	0	0	0.005166618619	0										
19728081	7157	D001943	p53	breast cancer | familial breast cancer | familial breast cancers	0	0	0.02623460256	0	1				C		1	1	1bg	Growth arrest and DNA damage-induced 45, alpha (GADD45A) is a candidate breast cancer susceptibility gene because its product participates in DNA repair and it is a downstream gene of p53 and BRCA1, both of which are breast cancer susceptibility genes.
19728081	7157	D006323	p53	Growth arrest	0	0	0.003744570306	0										
19739106	1813	D001523	DRD2	neuropsychiatric syndrome	0	0	0.002476514317	0										
19739106	1813	D003072	DRD2	cognitive impairment	0	0	0.003873318667	0										
19739106	1813	D003693	DRD2	Delirium | delirium	1	0	0.2782633901	1	1		1						e	In independent cohorts, a variation in the SLC6A3 gene and possibly the DRD2 gene were found to protect for delirium.
19739106	6531	D001523	SLC6A3 | dopamine transporter | solute carrier family 6, member 3	neuropsychiatric syndrome	0	0	0.006051235367	0										
19739106	6531	D003072	SLC6A3 | dopamine transporter | solute carrier family 6, member 3	cognitive impairment	0	0	0.0221968554	0										
19739106	6531	D003693	SLC6A3 | dopamine transporter | solute carrier family 6, member 3	Delirium | delirium	1	1	0.9845024943	0										
19744146	3575	D001171	IL7RA | interleukin-7 receptor alpha chain	juvenile idiopathic arthritis	1	1	0.9156010747	0										
19744146	3575	D001172	IL7RA | interleukin-7 receptor alpha chain	rheumatoid arthritis	1	0	0.02669856697	1	0									
19744146	3575	D002908	IL7RA | interleukin-7 receptor alpha chain	chronic inflammatory arthropathies	0	0	0.01552557759	0										
19744146	3575	D003922	IL7RA | interleukin-7 receptor alpha chain	multiple sclerosis and Type I diabetes	0	1	0.9553188682	1	1								1bg	The C allele of a single nucleotide polymorphism (SNP), rs6897932, located in the interleukin-7 receptor alpha chain (IL7RA) was recently found to be associated with multiple sclerosis and Type I diabetes.
19744146	3575	D007592	IL7RA | interleukin-7 receptor alpha chain	inflammatory arthropathies	0	1	0.9282847047	1	1		1		M				e	Our data are suggestive for a role of rs6897932 in predisposition to chronic inflammatory arthropathies.
19744146	3575	D015535	IL7RA | interleukin-7 receptor alpha chain	arthritic	0	0	0.07734981924	0										
19767079	114548	D000707	NLRP3	anaphylaxis	1	1	0.9943226576	0	1		1						e	Our results indicate that the NLRP3 SNPs might play an important role in the development of food-induced anaphylaxis and AIA in a gain-of-function manner.
19767079	114548	D001249	NLRP3	asthma	0	1	0.9892386198	1	0									
19767079	114548	D004342	NLRP3	allergic diseases | hypersensitivity	1	1	0.8890528083	0										
19767079	114548	D005512	NLRP3	food allergy	1	1	0.9769644141	0										
19767079	114548	D007249	NLRP3	inflammatory diseases	0	1	0.9180790782	1	1		1						mbg	Recent studies have shown associations of human NLRP3 polymorphisms with susceptibility to various inflammatory diseases
19767079	3553	D000707	IL-1beta	anaphylaxis	0	0	0.008055577055	0										
19767079	3553	D001249	IL-1beta	asthma	0	0	0.007754693273	0										
19767079	3553	D004342	IL-1beta	allergic diseases | hypersensitivity	0	0	0.005860219244	0										
19767079	3553	D005512	IL-1beta	food allergy	0	0	0.00584723521	0										
19767079	3553	D007249	IL-1beta	inflammatory diseases	0	0	0.005762134213	0										
19767079	3606	D000707	IL-18	anaphylaxis	0	0	0.01036925241	0										
19767079	3606	D001249	IL-18	asthma	0	0	0.01059133559	0										
19767079	3606	D004342	IL-18	allergic diseases | hypersensitivity	0	0	0.008406937122	0										
19767079	3606	D005512	IL-18	food allergy	0	0	0.007554345299	0										
19767079	3606	D007249	IL-18	inflammatory diseases	0	0	0.008019133471	0										
19767079	834	D000707	caspase-1	anaphylaxis	0	0	0.008092230186	0										
19767079	834	D001249	caspase-1	asthma	0	0	0.007826927118	0										
19767079	834	D004342	caspase-1	allergic diseases | hypersensitivity	0	0	0.005925196223	0										
19767079	834	D005512	caspase-1	food allergy	0	0	0.005915612914	0										
19767079	834	D007249	caspase-1	inflammatory diseases	0	0	0.005822319072	0										
19800201	84062	D011618	DTNBP1 | dystrobrevin binding protein 1	psychotic illness	0	0	0.0256616734	0										
19800201	84062	D012559	DTNBP1 | dystrobrevin binding protein 1	Schizophrenia | schizophrenia	1	1	0.9947650433	0										
19803376	10392	D007918	NOD1	leprosy	1	0	0.4651080072	1	0									
19803376	10392	D009164	NOD1	Mycobacterium leprae infection	0	0	0.004856884945	0										
19803376	10392	D015440	NOD1	lepromatous	0	0	0.007406739518	0										
19803376	30835	D007918	DC-SIGN	leprosy	1	1	0.9310142398	0										
19803376	30835	D009164	DC-SIGN	Mycobacterium leprae infection	0	0	0.004531691782	0										
19803376	30835	D015440	DC-SIGN	lepromatous	0	0	0.006889661308	0										
19803376	64127	D007918	NOD2	leprosy	1	0	0.1667832881	1	0									
19803376	64127	D009164	NOD2	Mycobacterium leprae infection	0	0	0.003883264493	0										
19803376	64127	D015440	NOD2	lepromatous	0	0	0.005203675013	0										
19803376	7097	D007918	TLR2	leprosy	1	1	0.9729641676	0										
19803376	7097	D009164	TLR2	Mycobacterium leprae infection	0	0	0.02686232515	0										
19803376	7097	D015440	TLR2	lepromatous	0	0	0.08083250374	0										
19820032	2260	C562785	FGFR1 | fibroblast growth factor receptor 1	idiopathic hypogonadotropic hypogonadism	0	1	0.9830985665	1	1								0	Impaired fibroblast growth factor receptor 1 signaling as a cause of normosmic idiopathic hypogonadotropic hypogonadism.
19820032	2260	D017436	FGFR1 | fibroblast growth factor receptor 1	Kallmann syndrome	1	1	0.9032221437	0										
19854534	3845	C538231	KRAS	lung adenocarcinoma	0	1	0.7738822699	1	1								mbg	One downstream target of let-7 is the RAS gene family, including KRAS, an important oncogene in the etiology and clinical outcome of lung adenocarcinoma.
19854534	3845	D002289	KRAS	NSCLC | non-small cell lung cancer	0	1	0.9935269356	1	1					1	1	1	e	These unexpected findings imply that this newly reported KRAS-LCS6 polymorphism will have limited clinical utility for NSCLC.
19854534	3845	D008175	KRAS	lung cancer	1	1	0.9937857389	0										
19881467	1312	D002869	COMT | catechol-O-methyltransferase	SPEM abnormality	0	1	0.9219545126	1	0					1			e	In analysis of SPEM abnormality, no significant associations were detected with COMT polymorphisms.
19881467	1312	D009358	COMT | catechol-O-methyltransferase	multifactorial disorder	0	0	0.01839230955	0										
19881467	1312	D012559	COMT | catechol-O-methyltransferase	Schizophrenia | schizophrenia | schizophrenia and SPEM abnormality | schizophrenic	1	1	0.9937866926	0										
19881467	1312	D020820	COMT | catechol-O-methyltransferase	eye movement abnormality	0	1	0.9602991939	1	0									
19891529	4846	D001791	eNOS	platelet aggregation	0	1	0.9602358341	1	1								m	eNOS 4a allele significantly and independently influenced AA-induced platelet aggregation (p = 0.01).
19891529	4846	D054058	eNOS	coronary syndrome	1	1	0.9931353331	0										
19921975	2899	D012559	GRIK3	schizophrenia | schizophrenic	1	1	0.9948010445	0										
19923858	6347	D001714	MCP-1 | SCYA2 | monocyte chemoattractant protein 1	bipolar disorder I	0	0	0.02581050433	0										
19923858	6347	D003866	MCP-1 | SCYA2 | monocyte chemoattractant protein 1	depressive disorder	0	0	0.1607226133	0										
19923858	6347	D019964	MCP-1 | SCYA2 | monocyte chemoattractant protein 1	mood disorder | mood disorders	1	1	0.9934123158	0										
19930869	1508	D009361	CTSB | Cathepsin B | cathepsin B	tumour cell invasion	0	0	0.4787595272	0										
19930869	1508	D009369	CTSB | Cathepsin B | cathepsin B	cancer | tumour | tumours	0	0	0.1166536883	0										
19930869	1508	D011471	CTSB | Cathepsin B | cathepsin B	prostate adenocarcinoma | prostate cancer	1	1	0.9927506447	0										
19935662	55997	D006086	cryptic	GVHD | graft-versus-host disease	0	1	0.7478303909	1	0									
19935662	7367	D006086	UGT2B17	GVHD | graft-versus-host disease	1	1	0.9814655781	0										
19949855	6817	D001943	SULT1A1	breast cancer	1	1	0.9943339825	0										
19949855	6817	D006432	SULT1A1	HH	0	0	0.4706530869	0										
20008645	672	D001943	BRCA1	BRCA1-positive breast cancers | breast cancer	1	1	0.9912400842	0										
20031581	4205	C536271	MEF2A	premature MI	0	1	0.6214237809	1	0									
20031581	4205	D003324	MEF2A	coronary artery disease	0	1	0.9945979118	1	0		1			1			e	All together, our data do not support MEF2A as a susceptibility gene for coronary artery disease/MI in the Italian population.
20031581	4205	D009203	MEF2A	myocardial infarction | premature myocardial infarction	1	1	0.9914826155	0										
20054510	1543	C566250	CYP1A1	AHH	0	0	0.03283417597	0										
20054510	1543	D008175	CYP1A1	lung cancer	1	1	0.9920599461	0										
20054510	1543	D009369	CYP1A1	cancer | non-cancer	0	0	0.003971862607	0										
20056627	4524	D009369	MTHFR	cancers | tumors	0	0	0.01322239917	0										
20056627	4524	D012004	MTHFR	rectal cancers	0	0	0.01169274002	0										
20056627	4524	D015179	MTHFR	Colon Cancer | colorectal cancer	1	1	0.9949570298	0										
20056627	4524	D053842	MTHFR	microsatellite-high tumors	0	0	0.0116667375	0										
20058152	4221	D000236	MEN1 | MEN1 and 2	adenomas	0	0	0.01197072119	0										
20058152	4221	D006934	MEN1 | MEN1 and 2	hypercalcemia	0	0	0.01308905333	0										
20058152	4221	D006961	MEN1 | MEN1 and 2	Familial hyperparathyroidism | hyperparathyroidism	1	1	0.7094712853	0										
20058152	4221	D018761	MEN1 | MEN1 and 2	Multiple Endocrine Neoplasia Type 1	0	0	0.02130527608	0										
20058152	4221	D049950	MEN1 | MEN1 and 2	primary hyperparathyroidism	0	0	0.00908625219	0										
20058152	5979	D000236	MEN2A	adenomas	0	0	0.003008888336	0										
20058152	5979	D006934	MEN2A	hypercalcemia	0	0	0.003124722512	0										
20058152	5979	D006961	MEN2A	Familial hyperparathyroidism | hyperparathyroidism	0	0	0.004770603962	0										
20058152	5979	D018761	MEN2A	Multiple Endocrine Neoplasia Type 1	0	0	0.003587639891	0										
20058152	5979	D049950	MEN2A	primary hyperparathyroidism	0	0	0.002940648934	0										
20087403	2672	D009103	GFI1	International Multiple Sclerosis Genetic Consortium | multiple sclerosis	1	1	0.9717622995	0										
20087403	388650	D009103	FAM69A	International Multiple Sclerosis Genetic Consortium | multiple sclerosis	1	1	0.8787463903	0										
20087403	6125	D009103	RPL5	International Multiple Sclerosis Genetic Consortium | multiple sclerosis	1	1	0.9813827872	0										
20087403	7813	D009103	EVI5	International Multiple Sclerosis Genetic Consortium | multiple sclerosis	1	1	0.992452085	0										
20090668	2289	D007029	FKBP5	hypothalamic-pituitary-adrenal (HPA) axis dysregulation	0	1	0.744120419	1	0									
20090668	2289	D014947	FKBP5	Trauma | childhood trauma | trauma | trauma increases	0	1	0.9863638282	1	1		1						e	These data suggest that childhood trauma and variants of the FKBP5 gene may interact to increase the risk for attempting suicide.
20090668	2289	D019966	FKBP5	substance dependence	1	0	0.07715780288	1	0									
20116409	3552	D005776	IL-1alpha | interleukin-1alpha	GD	0	1	0.9902680516	1	1		1	Dk					e	The results confirmed that the rs1800587 (IL-alpha, T-889 C) and rs16944 (IL-1beta, A-511 G) polymorphisms may confer susceptibility to GD and GO in Asian population.
20116409	3552	D006111	IL-1alpha | interleukin-1alpha	Graves' disease	1	1	0.9855136275	0										
20116409	3552	D007249	IL-1alpha | interleukin-1alpha	inflammation	0	0	0.1788729429	0										
20116409	3552	D049970	IL-1alpha | interleukin-1alpha	Graves' ophthalmopathy	1	1	0.7535863519	0										
20116409	3553	D005776	IL-1beta | interleukin-1beta	GD	0	1	0.9937307835	1	1		1						e	The results confirmed that the rs1800587 (IL-alpha, T-889 C) and rs16944 (IL-1beta, A-511 G) polymorphisms may confer susceptibility to GD and GO in Asian population.
20116409	3553	D006111	IL-1beta | interleukin-1beta	Graves' disease	1	1	0.9887951612	0										
20116409	3553	D007249	IL-1beta | interleukin-1beta	inflammation	0	0	0.1123957336	0										
20116409	3553	D049970	IL-1beta | interleukin-1beta	Graves' ophthalmopathy	1	1	0.5215414166	0										
20156772	27306	D008175	GSTs	lung cancer	0	1	0.913143158	1	0									
20156772	2944	D008175	GSTM1	lung cancer	1	1	0.9902855754	0										
20156772	2950	D008175	GSTP1	lung cancer	1	1	0.9813324213	0										
20156772	2952	D008175	GSTT1	lung cancer	1	1	0.9826900959	0										
20172040	2322	D015470	FLT3	AML | acute myelogenous leukemia	1	1	0.9211272001	0										
20172040	4869	D015470	NPM | NPM1 | nucleophosmin	AML | acute myelogenous leukemia	1	1	0.993010819	0										
20191019	4524	D020138	MTHFR | Methylenetetrahydrofolate reductase | methylenetetrahydrofolate reductase	hyperhomocysteinemia	0	1	0.9613761902	1	1		1						m	Despite a significant association between the MTHFR 677TT genotype and hyperhomocysteinemia, the MTHFR 677C>T genotypes did not appear to influence susceptibility to SBI.
20191019	4524	D020520	MTHFR | Methylenetetrahydrofolate reductase | methylenetetrahydrofolate reductase	silent brain infarction	1	1	0.9028095007	0										
20196860	3123	D001172	HLA-DRB1	RA | rheumatoid arthritis	1	1	0.5143839717	0										
20196860	3123	D012216	HLA-DRB1	rheumatic diseases	0	0	0.009503210895	0										
20196860	3123	D014717	HLA-DRB1	SE-positive	0	0	0.01061945874	0										
20196860	3123	D017098	HLA-DRB1	IgA rheumatoid factors	0	0	0.01030671038	0										
20196860	340351	D001172	CCP3	RA | rheumatoid arthritis	0	0	0.009940415621	0										
20196860	340351	D012216	CCP3	rheumatic diseases	0	0	0.002784200944	0										
20196860	340351	D014717	CCP3	SE-positive	0	0	0.0031961801	0										
20196860	340351	D017098	CCP3	IgA rheumatoid factors	0	0	0.00757790124	0										
20196860	5657	D001172	ACPA	RA | rheumatoid arthritis	0	1	0.7590620518	1	1				n				e	other genetic factors control the development of ACPA in African RA patients.
20196860	5657	D012216	ACPA	rheumatic diseases	0	0	0.006887501106	0										
20196860	5657	D014717	ACPA	SE-positive	0	0	0.1639543176	0										
20196860	5657	D017098	ACPA	IgA rheumatoid factors	0	0	0.008580510505	0										
20196860	79841	D001172	CCP2	RA | rheumatoid arthritis	0	0	0.03894754499	0										
20196860	79841	D012216	CCP2	rheumatic diseases	0	0	0.003154259874	0										
20196860	79841	D014717	CCP2	SE-positive	0	0	0.003614579095	0										
20196860	79841	D017098	CCP2	IgA rheumatoid factors	0	0	0.01118785888	0										
20198651	2300	C537296	FOXL1	granulosa cell tumour of ovary	0	0	0.005169285461	0										
20198651	2300	D006106	FOXL1	granulosa cell tumour	1	0	0.0037955679	1	0		1							
20198651	2300	D009369	FOXL1	cancers | tumour | tumours	0	0	0.002478689887	0										
20198651	2300	D010051	FOXL1	ovarian sex cord-stromal tumours | ovarian tumours	1	0	0.004809960257	1	0		1							
20198651	2300	D013798	FOXL1	thecoma of the ovary	1	0	0.004618685227	1	0		1							
20198651	668	C537296	FOXL2	granulosa cell tumour of ovary	0	1	0.9440439939	1	0									
20198651	668	D006106	FOXL2	granulosa cell tumour	1	1	0.8688293099	0										
20198651	668	D009369	FOXL2	cancers | tumour | tumours	0	0	0.05427898467	0										
20198651	668	D010051	FOXL2	ovarian sex cord-stromal tumours | ovarian tumours	1	1	0.9837099314	0										
20198651	668	D013798	FOXL2	thecoma of the ovary	1	1	0.9365752935	0										
20212137	6335	C537181	Nav1.7 | SCN9A	paroxysmal extreme pain disorder	0	0	0.01031388156	0										
20212137	6335	D004916	Nav1.7 | SCN9A	primary erythermalgia	0	0	0.01658683084	0										
20212137	6335	D010003	Nav1.7 | SCN9A	osteoarthritis	0	0	0.02863400243	0										
20212137	6335	D010146	Nav1.7 | SCN9A	Pain | absence of pain | episodic pain | pain	1	1	0.9941732287	0										
20212137	6335	D010195	Nav1.7 | SCN9A	pancreatitis	0	0	0.01194914617	0										
20212137	6335	D013001	Nav1.7 | SCN9A	pain disorders	0	1	0.8942122459	1	1	only	1						1bg	The gene SCN9A is responsible for three human pain disorders.
20235791	3105	D013262	HLA-A, B	Stevens-Johnson syndrome | toxic epidermal necrolysis	0	1	0.9421460032	1	0			Gi						
20235791	3106	D013262	HLA-B	Stevens-Johnson syndrome | toxic epidermal necrolysis	1	1	0.9879187942	0										
20235791	3123	D013262	DRB1	Stevens-Johnson syndrome | toxic epidermal necrolysis	0	1	0.9758576751	1	1			Di					m	In addition, HLA-B*1301, Cw*0801 and DRB1*1602 also showed an association with PHT-SJS/TEN (p = 0.0128-0.0281; OR: 3.0-4.3).
20299531	260431	D001991	COPD	bronchitis	0	0	0.004902038723	0										
20299531	260431	D007249	COPD	inflammation | neutrophilic inflammation	0	0	0.04434014484	0										
20299531	260431	D029424	COPD	COPD disease | Chronic obstructive pulmonary disease | chronic obstructive pulmonary disease	0	1	0.8033136725	1	0			Gm						
20299531	3576	D001991	IL-8 | IL-8 and myeloperoxidase	bronchitis	0	0	0.002796377055	0										
20299531	3576	D007249	IL-8 | IL-8 and myeloperoxidase	inflammation | neutrophilic inflammation	0	0	0.1224856526	0										
20299531	3576	D029424	IL-8 | IL-8 and myeloperoxidase	COPD disease | Chronic obstructive pulmonary disease | chronic obstructive pulmonary disease	0	0	0.07889734209	0										
20299531	7124	D001991	TNF-alpha | Tumor necrosis factor (TNF)-alpha | Tumor necrosis factor-{alpha	bronchitis	0	0	0.006545906421	0										
20299531	7124	D007249	TNF-alpha | Tumor necrosis factor (TNF)-alpha | Tumor necrosis factor-{alpha	inflammation | neutrophilic inflammation	0	1	0.9764223099	1	1								0	Tumor necrosis factor-{alpha} rs361525 polymorphism is associated with increased local production and downstream inflammation in chronic obstructive pulmonary disease.
20299531	7124	D029424	TNF-alpha | Tumor necrosis factor (TNF)-alpha | Tumor necrosis factor-{alpha	COPD disease | Chronic obstructive pulmonary disease | chronic obstructive pulmonary disease	1	1	0.9637040496	0										
20300826	2263	D001943	FGFR2 | fibroblast growth factor receptor 2	breast cancer	1	1	0.9917885661	0										
20346235	64127	D015535	NOD2	Psoriatic arthritis | psoriatic arthritis	1	1	0.9883819222	0										
20354455	1956	D002289	EGFR | epidermal growth factor receptor	non-small cell lung cancer	0	0	0.02374570444	0										
20354455	1956	D008175	EGFR | epidermal growth factor receptor	lung cancer | lung cancers	0	0	0.009591756389	0										
20354455	208	D002289	AKT2	non-small cell lung cancer	0	1	0.8819457889	1	1								mbg	MEK1 gene mutation at exon 2 and mutation of the AKT2 (v-akt murine thymoma viral oncogene homologue 2) gene at kinase domain have been reported in non-small cell lung cancer.
20354455	208	D008175	AKT2	lung cancer | lung cancers	1	1	0.9880103469	0										
20354455	3845	D002289	K-ras	non-small cell lung cancer	0	0	0.007138465066	0										
20354455	3845	D008175	K-ras	lung cancer | lung cancers	0	0	0.007686679717	0										
20354455	5290	D002289	PIK3CA	non-small cell lung cancer	0	0	0.007363684941	0										
20354455	5290	D008175	PIK3CA	lung cancer | lung cancers	0	0	0.007636571303	0										
20354455	5604	D002289	MEK1	non-small cell lung cancer	0	1	0.896892786	1	1								mbg	MEK1 gene mutation at exon 2 and mutation of the AKT2 (v-akt murine thymoma viral oncogene homologue 2) gene at kinase domain have been reported in non-small cell lung cancer.
20354455	5604	D008175	MEK1	lung cancer | lung cancers	1	1	0.9831409454	0										
20354455	673	D002289	B-raf	non-small cell lung cancer	0	0	0.007355154492	0										
20354455	673	D008175	B-raf	lung cancer | lung cancers	0	0	0.008015219122	0										
20362651	24903	D007249	thiostatin	inflammation	0	0	0.4784570634	0										
20362651	24903	D014947	thiostatin	hepatobiliary injury	0	0	0.3005344272	0										
20362651	24903	D056486	thiostatin	hepatotoxicity | liver injury	0	0	0.00492163701	0										
20362651	24903	D064420	thiostatin	toxicity	0	0	0.004712434486	0										
20362651	27295	D007249	ALP	inflammation	0	0	0.00500743743	0										
20362651	27295	D014947	ALP	hepatobiliary injury	0	0	0.008216906339	0										
20362651	27295	D056486	ALP	hepatotoxicity | liver injury	0	0	0.002517648041	0										
20362651	27295	D064420	ALP	toxicity	0	0	0.002796080429	0										
20362651	3934	D007249	NGAL | lipocalin-2	inflammation	0	0	0.009371685795	0										
20362651	3934	D014947	NGAL | lipocalin-2	hepatobiliary injury	0	0	0.1049094051	0										
20362651	3934	D056486	NGAL | lipocalin-2	hepatotoxicity | liver injury	1	0	0.004181704018	1	0						1		e	Receiver-operating characteristics (ROC) analyses supported serum thiostatin, but not NGAL, as a better indicator of drug-induced hepatobiliary injury
20362651	3934	D064420	NGAL | lipocalin-2	toxicity	0	0	0.004025820643	0										
20362651	5444	D007249	PON1	inflammation	0	0	0.005058795679	0										
20362651	5444	D014947	PON1	hepatobiliary injury	0	0	0.008484994061	0										
20362651	5444	D056486	PON1	hepatotoxicity | liver injury	0	0	0.003224460641	0										
20362651	5444	D064420	PON1	toxicity	0	0	0.00281255669	0										
20411324	4552	D001943	MTRR | Methionine synthase reductase	breast cancer	1	1	0.9947813153	0										
20418489	3630	D003920	insulin	diabetes	0	0	0.004707210232	0										
20418489	3630	D003924	insulin	type 2 diabetes	0	1	0.7559161186	1	0									
20418489	3630	D044882	insulin	glucose metabolism	0	0	0.009039831348	0										
20418489	3694	D003920	ITGB6	diabetes	0	0	0.009634826332	0										
20418489	3694	D003924	ITGB6	type 2 diabetes	0	1	0.9480816126	1	1						1	1	m	We identified significantly associated variants near RBMS1 and ITGB6 genes at 2q24, best-represented by SNP rs7593730 (combined OR=0.90, 95% CI=0.86-0.93; P=3.7x10(-8)).
20418489	3694	D044882	ITGB6	glucose metabolism	0	0	0.01389382407	0										
20418489	5937	D003920	RBMS1	diabetes	0	0	0.01048611756	0										
20418489	5937	D003924	RBMS1	type 2 diabetes	1	1	0.951983273	0										
20418489	5937	D044882	RBMS1	glucose metabolism	0	0	0.01532133203	0										
20479152	7941	D003324	Lp-PLA2 | PLA2G7 | lipoprotein-associated phospholipase A(2) | lipoprotein-associated phospholipase A2	coronary artery disease	0	1	0.9118272066	1	0									
20479152	7941	D003327	Lp-PLA2 | PLA2G7 | lipoprotein-associated phospholipase A(2) | lipoprotein-associated phospholipase A2	coronary disease | coronary heart disease	1	1	0.9905686975	0										
20479152	7941	D057768	Lp-PLA2 | PLA2G7 | lipoprotein-associated phospholipase A(2) | lipoprotein-associated phospholipase A2	CHD events	0	1	0.7031744123	1	0									
20479152	7941	D058226	Lp-PLA2 | PLA2G7 | lipoprotein-associated phospholipase A(2) | lipoprotein-associated phospholipase A2	coronary atheroma	0	1	0.658410728	1	0.5					1	1		e	Unlike Lp-PLA2 activity, PLA2G7 variants associated with modest effects on Lp-PLA2 activity were not associated with cardiovascular risk markers, coronary atheroma or CHD.
20479250	2064	D001943	HER2	breast cancer	0	0	0.06040156633	0										
20479250	2064	D009369	HER2	tumors	0	0	0.003188890172	0										
20479250	207	D001943	AKT	breast cancer	0	0	0.01190373302	0										
20479250	207	D009369	AKT	tumors	0	0	0.003741228953	0										
20479250	23373	D001943	mTORC1	breast cancer	0	0	0.1257813722	0										
20479250	23373	D009369	mTORC1	tumors	0	0	0.004153219517	0										
20479250	2475	D001943	mTOR	breast cancer	0	0	0.02125573345	0										
20479250	2475	D009369	mTOR	tumors	0	0	0.004054915626	0										
20479250	5290	D001943	PIK3CA	breast cancer	1	1	0.9848691225	0										
20479250	5290	D009369	PIK3CA	tumors	0	0	0.02181529999	0										
20483474	267012	D012559	DAOA	Schizophrenia | schizophrenia | schizophrenic	1	1	0.9701046944	0										
20483474	84152	D012559	PPP1R1B	Schizophrenia | schizophrenia | schizophrenic	1	1	0.9006186724	0										
20483474	8542	D012559	APOL1	Schizophrenia | schizophrenia | schizophrenic	1	1	0.9512802362	0										
20489114	4292	D003123	MLH1	Lynch syndrome	1	1	0.9891168475	0										
20489114	4292	D009369	MLH1	tumor | tumors	0	0	0.03053221107	0										
20489114	4292	D015179	MLH1	colorectal cancer	0	1	0.9505247474	1	0.5				n				m	Ten patients had germline mutations in MLH1 and none of their tumors showed significant MLH1 methylation or BRAF V600E mutation.
20489114	673	D003123	BRAF	Lynch syndrome	1	1	0.7854298949	0										
20489114	673	D009369	BRAF	tumor | tumors	0	0	0.02011849359	0										
20489114	673	D015179	BRAF	colorectal cancer	0	0	0.1336944699	0										
20489584	29914	C535475	UBIAD1	Schnyder corneal dystrophy	1	1	0.9244320393	0	1								0	Newly reported p.Asp240Asn mutation in UBIAD1 suggests central discoid corneal dystrophy is a variant of Schnyder corneal dystrophy.
20489584	29914	C536778	UBIAD1	SCD	0	1	0.9893673062	1	1								0	Newly reported p.Asp240Asn mutation in UBIAD1 suggests central discoid corneal dystrophy is a variant of Schnyder corneal dystrophy.
20489584	29914	C563262	UBIAD1	central discoid corneal dystrophy	0	0	0.008196483366	0	1								0	Newly reported p.Asp240Asn mutation in UBIAD1 suggests central discoid corneal dystrophy is a variant of Schnyder corneal dystrophy.
20489584	29914	D003317	UBIAD1	corneal dystrophies | corneal dystrophy	0	1	0.9875670671	1	1								0	Newly reported p.Asp240Asn mutation in UBIAD1 suggests central discoid corneal dystrophy is a variant of Schnyder corneal dystrophy.
20508731	5915	D009216	RARbeta | retinoic acid receptor beta	High myopia | high myopia | myopia	1	1	0.9929103255	0										
20508731	5915	D047728	RARbeta | retinoic acid receptor beta	pathological myopia	0	0	0.02175274678	0										
20511662	102723407	D015451	IGHV	chronic lymphocytic leukemia	0	0	0.06390483677	0	0.5				S			1	m	unmutated IGHV genes and/or IGHV3-21 usage, 11q deletion, beta-2 microglobulin greater than 4 mg/L; 22% had a good risk (with none of the above and mutated IGHV genes). 
20511662	28444	D015451	IGHV3-21	chronic lymphocytic leukemia	1	0	0.05376074463	1	0.5				S			1	m	unmutated IGHV genes and/or IGHV3-21 usage, 11q deletion, beta-2 microglobulin greater than 4 mg/L; 22% had a good risk (with none of the above and mutated IGHV genes). 
20511662	567	D015451	beta-2 microglobulin	chronic lymphocytic leukemia	0	0	0.03966722265	0	0.5				S			1	m	unmutated IGHV genes and/or IGHV3-21 usage, 11q deletion, beta-2 microglobulin greater than 4 mg/L; 22% had a good risk (with none of the above and mutated IGHV genes). 
20511662	7157	D015451	TP53	chronic lymphocytic leukemia	1	0	0.0449742265	1	0.5				S			1	m	6% had poor risk with known TP53 loss of greater than 10%
20514429	2492	C483999	FSH receptor | FSHR	CHA	0	0	0.006611934397	0										
20514429	2492	D000568	FSH receptor | FSHR	amenorrhea	0	1	0.6651436687	1	1	only		Di					mbg	Several polymorphisms of FSH receptor (FSHR) are related to primary amenorrhea, hypoplastic ovary, and high serum levels of FSH.
20514429	2492	D004700	FSH receptor | FSHR	endocrine disorder	0	0	0.004012737423	0										
20514429	2492	D009839	FSH receptor | FSHR	oligomenorrhea or amenorrhea	0	0	0.003875644878	0										
20514429	2492	D010051	FSH receptor | FSHR	hypoplastic ovary	0	0	0.2257891744	0										
20514429	2492	D011085	FSH receptor | FSHR	PCOS | Polycystic ovary syndrome | polycystic ovary | polycystic ovary syndrome	1	1	0.9942967296	0										
20514429	2492	D017588	FSH receptor | FSHR	hyperandrogenism	0	0	0.003864431754	0	1	only							mbg	Several polymorphisms of FSH receptor (FSHR) are related to primary amenorrhea, hypoplastic ovary, and high serum levels of FSH.
20521320	7124	D012559	TNF-alpha | tumor necrosis factor-alpha	refractory schizophrenia	0	1	0.8811445236	1	0									
20521320	7124	D015430	TNF-alpha | tumor necrosis factor-alpha	weight gain	1	1	0.9362171888	0										
20530095	1027	C566321	CDKN1B | KIP1	familial isolated pituitary adenoma	0	0	0.07211175561	0	1								1bg	Germline mutations in the aryl hydrocarbon receptor-interacting protein (AIP) gene and the p27(KIP1) encoding gene CDKN1B have been associated with two well-defined hereditary conditions, familial isolated pituitary adenoma (FIPA) and multiple endocrine neoplasia type 4 (MEN4).
20530095	1027	C567787	CDKN1B | KIP1	Italian acromegalic	0	0	0.01954535209	0										
20530095	1027	D000172	CDKN1B | KIP1	acromegalic | acromegaly	1	0	0.1884626895	1	0					1			e	p27(KIP1) is unlikely to represent the common unifying nonendocrine etiology for acromegaly and cancer.
20530095	1027	D009369	CDKN1B | KIP1	cancer | multiple neoplasia | multiple tumors	0	0	0.005980242509	0										
20530095	1027	D009377	CDKN1B | KIP1	multiple endocrine neoplasia | multiple endocrine neoplasia type 4	1	1	0.6343052983	0	1								1bg	Germline mutations in the aryl hydrocarbon receptor-interacting protein (AIP) gene and the p27(KIP1) encoding gene CDKN1B have been associated with two well-defined hereditary conditions, familial isolated pituitary adenoma (FIPA) and multiple endocrine neoplasia type 4 (MEN4).
20530095	1027	D010911	CDKN1B | KIP1	pituitary adenomas | pituitary tumors	0	0	0.005650517996	0										
20530095	1027	D015175	CDKN1B | KIP1	prolactinomas	0	0	0.007599714212	0										
20530095	1027	D020821	CDKN1B | KIP1	sporadic acromegalic	0	0	0.006017432548	0										
20530095	1027	D049912	CDKN1B | KIP1	Somatotropinomas	0	0	0.006346398499	0										
20530095	3429	C566321	p27	familial isolated pituitary adenoma	0	0	0.005244386382	0										
20530095	3429	C567787	p27	Italian acromegalic	0	0	0.002589622745	0										
20530095	3429	D000172	p27	acromegalic | acromegaly	0	0	0.003167374525	0										
20530095	3429	D009369	p27	cancer | multiple neoplasia | multiple tumors	0	0	0.002354834229	0										
20530095	3429	D009377	p27	multiple endocrine neoplasia | multiple endocrine neoplasia type 4	0	0	0.006315100938	0										
20530095	3429	D010911	p27	pituitary adenomas | pituitary tumors	0	0	0.002490132581	0										
20530095	3429	D015175	p27	prolactinomas	0	0	0.002737318166	0										
20530095	3429	D020821	p27	sporadic acromegalic	0	0	0.002487112768	0										
20530095	3429	D049912	p27	Somatotropinomas	0	0	0.002584370319	0										
20530095	4221	C566321	MEN1	familial isolated pituitary adenoma	0	0	0.003082381794	0										
20530095	4221	C567787	MEN1	Italian acromegalic	0	0	0.002587245777	0										
20530095	4221	D000172	MEN1	acromegalic | acromegaly	0	0	0.002776754787	0										
20530095	4221	D009369	MEN1	cancer | multiple neoplasia | multiple tumors	0	0	0.002387994202	0										
20530095	4221	D009377	MEN1	multiple endocrine neoplasia | multiple endocrine neoplasia type 4	0	0	0.003483109875	0										
20530095	4221	D010911	MEN1	pituitary adenomas | pituitary tumors	0	0	0.002479857299	0										
20530095	4221	D015175	MEN1	prolactinomas	0	0	0.002720131306	0										
20530095	4221	D020821	MEN1	sporadic acromegalic	0	0	0.002498216461	0										
20530095	4221	D049912	MEN1	Somatotropinomas	0	0	0.002595948754	0										
20530095	9049	C566321	AIP | aryl hydrocarbon receptor-interacting protein	familial isolated pituitary adenoma	0	0	0.08269135654	0										
20530095	9049	C567787	AIP | aryl hydrocarbon receptor-interacting protein	Italian acromegalic	0	0	0.03663149104	0										
20530095	9049	D000172	AIP | aryl hydrocarbon receptor-interacting protein	acromegalic | acromegaly	0	0	0.1845894009	0										
20530095	9049	D009369	AIP | aryl hydrocarbon receptor-interacting protein	cancer | multiple neoplasia | multiple tumors	0	0	0.007292539347	0										
20530095	9049	D009377	AIP | aryl hydrocarbon receptor-interacting protein	multiple endocrine neoplasia | multiple endocrine neoplasia type 4	0	0	0.4661644101	0										
20530095	9049	D010911	AIP | aryl hydrocarbon receptor-interacting protein	pituitary adenomas | pituitary tumors	0	0	0.04817689955	0										
20530095	9049	D015175	AIP | aryl hydrocarbon receptor-interacting protein	prolactinomas	0	0	0.01264183596	0										
20530095	9049	D020821	AIP | aryl hydrocarbon receptor-interacting protein	sporadic acromegalic	0	0	0.009307849221	0										
20530095	9049	D049912	AIP | aryl hydrocarbon receptor-interacting protein	Somatotropinomas	0	0	0.01421724539	0										
20541370	57030	D012559	VGLUT1	schizophrenia | schizophrenic	0	0	0.0619016476	0										
20541370	57030	D020295	VGLUT1	mesencephalic	0	0	0.009392270818	0										
20541370	57084	D012559	VGLUT2 | vesicular glutamate transporter 2	schizophrenia | schizophrenic	1	1	0.9907797575	0										
20541370	57084	D020295	VGLUT2 | vesicular glutamate transporter 2	mesencephalic	0	0	0.1059515178	0										
20598163	79068	D001724	FTO	birth weight	0	0	0.006326244678	0										
20598163	79068	D003924	FTO	type 2 diabetes	0	0	0.1073761284	0										
20598163	79068	D007022	FTO	systolic and diastolic blood pressure	0	0	0.003594710724	0										
20598163	79068	D009765	FTO	obese | obesity	1	1	0.9943813682	0										
20609483	57194	D001321	ATP10A	autism	0	1	0.9690876603	1	0									
20609483	57194	D002869	ATP10A	chromosomal abnormalities	0	0	0.1298145056	0										
20609483	7337	D001321	UBE3A	autism	1	1	0.9942922592	0	1		1						e	Our data support a potential role of UBE3A in the complex pathogenic mechanisms of autism.
20609483	7337	D002869	UBE3A	chromosomal abnormalities	0	1	0.6293545961	1										
20621591	58191	D002340	CXC Ligand 16 | CXCL16	carotid atherosclerosis	1	1	0.9568945169	0										
20621591	58191	D020521	CXC Ligand 16 | CXCL16	stroke	1	0	0.007898236625	1	0			Di						
20621591	58191	D050197	CXC Ligand 16 | CXCL16	atherosclerosis | atherosclerotic lesions | atherosclerotic stroke	1	1	0.9944326282	0										
20627703	1312	D003865	COMT | catechol-O-methyltransferase	MDD	0	1	0.9867351055	1	1	only	1						mbg	The rs165599 SNP, which has previously been associated with response of depressive symptoms to treatment in patients with MDD, did not impact baseline pain in either gender.
20627703	1312	D003866	COMT | catechol-O-methyltransferase	depressive disorder | depressive symptoms	0	1	0.967028439	1	1	only	1						mbg	The rs165599 SNP, which has previously been associated with response of depressive symptoms to treatment in patients with MDD, did not impact baseline pain in either gender.
20627703	1312	D010146	COMT | catechol-O-methyltransferase	Overall Pain | Pain | pain	1	1	0.9911183715	0										
20634581	348	D000544	APOE	AD | Alzheimer's disease	0	1	0.8915600181	1	0									
20634581	348	D003704	APOE	dementia	0	0	0.0361767523	0										
20634581	348	D030342	APOE	Genetic deficiency	0	0	0.004757809453	0										
20634581	7941	D000544	Lp-PLA2 | PLA2G7	AD | Alzheimer's disease	1	1	0.9935252666	0	0					1			e	Genetic deficiency of Lp-PLA2 activity is not associated with a reduced risk of AD in the Japanese population.
20634581	7941	D003704	Lp-PLA2 | PLA2G7	dementia	0	1	0.966809988	1	1	only	1						1bg	High plasma lipoprotein phospholipase A2 activity (Lp-PLA2) is reported to be a risk factor for dementia.
20634581	7941	D030342	Lp-PLA2 | PLA2G7	Genetic deficiency	0	0	0.03419612721	0										
20640797	351	D000544	beta-amyloid peptide	Alzheimer's disease	1	1	0.8819157481	0										
20640797	351	D020258	beta-amyloid peptide	neurotoxic	0	0	0.01876140013	0										
20646909	1756	D006331	dystrophin	cardiac disease | cardiac muscle diseases	0	1	0.955968678	1	1	only	1						1bg	Mutations in the X-linked gene encoding dystrophin cause skeletal and cardiac muscle diseases in men.
20646909	1756	D018376	dystrophin	cardiac contractile abnormalities in dystrophinopathy	0	0	0.04358656704	0										
20646909	1756	D018487	dystrophin	left ventricular systolic dysfunction	1	0	0.3170982897	1	0				n					
20648053	1594	D001327	CYP27B1 | cytochrome P450 family 27 subfamily B peptide 1	autoimmune disease	0	0	0.004518282134	0										
20648053	1594	D003920	CYP27B1 | cytochrome P450 family 27 subfamily B peptide 1	diabetes	0	0	0.004662311636	0										
20648053	1594	D007249	CYP27B1 | cytochrome P450 family 27 subfamily B peptide 1	inflammatory disease	0	0	0.04436663911	0										
20648053	1594	D009103	CYP27B1 | cytochrome P450 family 27 subfamily B peptide 1	Multiple sclerosis | Zealand Multiple Sclerosis	1	1	0.9808021784	0										
20648053	1594	D012598	CYP27B1 | cytochrome P450 family 27 subfamily B peptide 1	sclerosis	0	0	0.006213537883	0										
20648053	7421	D001327	vitamin D receptor	autoimmune disease	0	0	0.003348740982	0										
20648053	7421	D003920	vitamin D receptor	diabetes	0	0	0.003403048962	0										
20648053	7421	D007249	vitamin D receptor	inflammatory disease	0	0	0.01304803882	0										
20648053	7421	D009103	vitamin D receptor	Multiple sclerosis | Zealand Multiple Sclerosis	0	1	0.9570780396	1	0									
20648053	7421	D012598	vitamin D receptor	sclerosis	0	0	0.003372729523	0										
20663412	64109	C565292	TSLPR | thymic stromal lymphopoietin receptor	atopic asthma	0	1	0.6748544574	1	1		1						e	Our results suggest that the SNPs of the TSLPR gene could be associated with the susceptibility to atopic asthma in the Korean population.
20663412	64109	D001249	TSLPR | thymic stromal lymphopoietin receptor	asthma	1	1	0.9936019778	0										
20663412	64109	D013224	TSLPR | thymic stromal lymphopoietin receptor	asthmatic disease	0	1	0.9754976034	1	1		1		n				e	Our results suggest that the SNPs of the TSLPR gene could be associated with the susceptibility to atopic asthma in the Korean population.
20679634	3456	D009103	IFNbeta | interferon-beta	multiple sclerosis	0	0	0.04347994551	0										
20679634	3456	D012598	IFNbeta | interferon-beta	sclerosis	0	0	0.003382978961	0										
20679634	4938	D009103	OAS1	multiple sclerosis	1	1	0.9735974073	0										
20679634	4938	D012598	OAS1	sclerosis	0	0	0.03242271766	0										
20679634	6041	D009103	RNAseL	multiple sclerosis	0	0	0.02255022153	0										
20679634	6041	D012598	RNAseL	sclerosis	0	0	0.003025102895	0										
20705357	1956	D002289	EGFR	NSCLC | non-small-cell lung cancer	0	1	0.9581562281	1	1								mbg	In particular, CHFR is frequently methylated in NSCLC and may influence outcome.
20705357	1956	D008175	EGFR	lung tumor	0	0	0.008854013868	0										
20705357	2067	D002289	ERCC1	NSCLC | non-small-cell lung cancer	0	0	0.01752712019	0										
20705357	2067	D008175	ERCC1	lung tumor	0	0	0.003212328535	0										
20705357	55743	D002289	CHFR	NSCLC | non-small-cell lung cancer	1	1	0.9838294387	0										
20705357	55743	D008175	CHFR	lung tumor	0	0	0.02234713733	0										
20712888	1351	D002289	Cox	non-small cell lung cancer	0	0	0.0112538645	0										
20712888	1351	D008175	Cox	lung cancer	0	0	0.006583095063	0										
20712888	1351	D063646	Cox	carcinogenesis	0	0	0.004405131564	0										
20712888	7422	D002289	VEGF | Vascular endothelial growth factor	non-small cell lung cancer	0	1	0.9896746278	1	1		1						e	Our study suggests that VEGF -460 C genotypes may be associated with a better survival of LA-NSCLC patients after chemoradiotherapy.
20712888	7422	D008175	VEGF | Vascular endothelial growth factor	lung cancer	1	1	0.9765218496	0	1	only							1bg	Vascular endothelial growth factor (VEGF) is a major mediator of angiogenesis involving in carcinogenesis, including lung cancer.
20712888	7422	D063646	VEGF | Vascular endothelial growth factor	carcinogenesis	0	1	0.9695068002	1	1	only							1bg	Vascular endothelial growth factor (VEGF) is a major mediator of angiogenesis involving in carcinogenesis, including lung cancer.
20720556	4846	D001943	NOS3 | endothelial nitric oxide synthase	breast cancer	1	1	0.9929710031	0										
20864298	2335	D006083	fibronectin	vascular graft failure	0	0	0.002888651099	0										
20864298	2335	D006965	fibronectin	hyperplasia	0	0	0.04018758982	0										
20864298	3315	D006083	HSP27 | heat-shock protein (HSP)27	vascular graft failure	0	0	0.04959549755	0										
20864298	3315	D006965	HSP27 | heat-shock protein (HSP)27	hyperplasia	1	1	0.9881437421	0										
20864298	9261	D006083	MK2	vascular graft failure	0	0	0.003107384779	0										
20864298	9261	D006965	MK2	hyperplasia	0	0	0.01761844009	0										
20869035	168667	C538496	BMPER | Bmper	skeletal disorder	0	0	0.133497566	0										
20869035	168667	C564305	BMPER | Bmper	Diaphanospondylodysostosis | diaphanospondylodysostosis	1	1	0.9551773071	0										
20881004	1588	D009765	CYP19A1	obesity	1	0	0.4064965844	1	1				M				e	Higher TTTA repeat numbers (&gt;7 repeats) in the aromatase gene are associated with a negative relationship between obesity and sperm count.
20920174	2688	D009369	growth hormone	cancer	0	0	0.007673408836	0										
20920174	2688	D015179	growth hormone	colorectal cancer	0	0	0.3226965666	0										
20920174	2693	D009369	GHSR | growth hormone secretagogue receptor	cancer	0	0	0.0107569648	0										
20920174	2693	D015179	GHSR | growth hormone secretagogue receptor	colorectal cancer	1	1	0.8880981207	0										
20920174	51738	D009369	GHRL | Ghrelin | ghrelin	cancer	0	0	0.02528484352	0										
20920174	51738	D015179	GHRL | Ghrelin | ghrelin	colorectal cancer	1	1	0.985861063	0										
20942981	51741	D002318	WWOX	cardiovascular diseases	1	0	0.1919433773	1	0									
20942981	51741	D006950	WWOX	FCHL | familial combined hyperlipidemia	0	1	0.88067168	1	1	only							m	The WWOX gene has been recently associated with HDL levels. This gene is located at chromosome 16q23, a region previously linked to familial combined hyperlipidemia (FCHL) and HDL.
20975374	7515	D008175	X-ray repair cross complementing group 1 | XRCC1	lung cancer	1	1	0.9904921651	0										
21044752	1401	D002318	C-reactive protein | CRP	cardiovascular disease	1	0	0.01940559223	1	1								e	The CRP+1444C&gt;T polymorphism was associated with CRP levels in Mexican adolescents and could be used as a genetic marker for the early detection of individuals at risk for developing obesity-related conditions such as cardiovascular disease or type 2 diabetes mellitus in early adulthood.
21044752	1401	D003924	C-reactive protein | CRP	type 2 diabetes mellitus	0	0	0.0780345872	0	1								e	The CRP+1444C&gt;T polymorphism was associated with CRP levels in Mexican adolescents and could be used as a genetic marker for the early detection of individuals at risk for developing obesity-related conditions such as cardiovascular disease or type 2 diabetes mellitus in early adulthood.
21044752	1401	D007249	C-reactive protein | CRP	inflammation	0	1	0.8934839368	1	0									
21044752	1401	D009765	C-reactive protein | CRP	obesity	1	0	0.2519512177	1	1								e	The CRP+1444C&gt;T polymorphism was associated with CRP levels in Mexican adolescents and could be used as a genetic marker for the early detection of individuals at risk for developing obesity-related conditions such as cardiovascular disease or type 2 diabetes mellitus in early adulthood.
21044752	3569	D002318	IL6	cardiovascular disease	1	0	0.006593509112	1	0									
21044752	3569	D003924	IL6	type 2 diabetes mellitus	0	0	0.007629390806	0										
21044752	3569	D007249	IL6	inflammation	0	0	0.3143589199	0										
21044752	3569	D009765	IL6	obesity	1	0	0.009434659034	1	0									
21044752	7124	D002318	TNFA	cardiovascular disease	1	0	0.007046772633	1	0									
21044752	7124	D003924	TNFA	type 2 diabetes mellitus	0	0	0.008298729546	0										
21044752	7124	D007249	TNFA	inflammation	0	0	0.3577253222	0										
21044752	7124	D009765	TNFA	obesity	1	0	0.01047524251	1	0									
21052000	1956	C538231	EGFR | epidermal growth factor receptor	lung adenocarcinoma	0	0	0.1440054774	0										
21052000	1956	D000230	EGFR | epidermal growth factor receptor	adenocarcinoma	1	0	0.08778074384	1	0									
21052000	1956	D002282	EGFR | epidermal growth factor receptor	bronchioloalveolar carcinomas	0	0	0.01309355814	0										
21052000	1956	D002289	EGFR | epidermal growth factor receptor	non-small cell lung cancer	0	0	0.0163712725	0										
21052000	1956	D008175	EGFR | epidermal growth factor receptor	lung cancer	1	0	0.06595918536	1	1								e	Mapping of EGFR1 mutations by alternative methods should be used in the screening of patients with non-small cell lung cancer who are candidates for EGFR inhibitor treatment.
21098263	2254	D001943	FGF9	breast cancer	0	1	0.514336586	1	1								m	Estrogen or FGF9 pretreatment induced CSC properties of breast cancer cell lines and freshly isolated breast cancer cells
21098263	2254	D009369	FGF9	aggressive cancer | cancer | tumor | tumors	0	0	0.005322590936	0										
21098263	6926	D001943	Tbx3	breast cancer	1	1	0.8223297	0										
21098263	6926	D009369	Tbx3	aggressive cancer | cancer | tumor | tumors	0	0	0.03554694727	0										
21109441	1756	D003072	dystrophin	cognitive deficits	0	1	0.8976673484	1	0					1			1bg	However, for reasons that are unclear, some boys with dystrophin mutations do not show general cognitive deficits.
21109441	1756	D008569	dystrophin	Neuropsychological impairments	0	0	0.07375140488	0										
21109441	1756	D008607	dystrophin	mental retardation	0	1	0.9020108581	1	1	only	1						1	Mutations in the dystrophin gene have long been recognised as a cause of mental retardation.
21109441	1756	D020388	dystrophin	Duchenne muscular dystrophy	1	1	0.9890536666	0										
21129728	22856	C536958	CHSY1 | Chsy1 | chondroitin synthase 1 | chsy1	autosomal-recessive Temtamy preaxial brachydactyly syndrome	1	1	0.8660404682	0										
21129728	22856	D001259	CHSY1 | Chsy1 | chondroitin synthase 1 | chsy1	limb malformations	0	1	0.9414322972	1	0									
21129728	22856	D006130	CHSY1 | Chsy1 | chondroitin synthase 1 | chsy1	short stature	0	0	0.4047292173	0										
21129728	22856	D009436	CHSY1 | Chsy1 | chondroitin synthase 1 | chsy1	developmental defects	0	0	0.03527070954	0										
21129728	22856	D034381	CHSY1 | Chsy1 | chondroitin synthase 1 | chsy1	hearing loss	0	0	0.02279037237	0										
21129728	22856	D059327	CHSY1 | Chsy1 | chondroitin synthase 1 | chsy1	brachydactyly and deafness | brachydactyly syndrome	0	1	0.8647588491	1	1		1						0	Temtamy preaxial brachydactyly syndrome is caused by loss-of-function mutations in chondroitin synthase 1, a potential target of BMP signaling.
21129728	4681	C536958	Dan	autosomal-recessive Temtamy preaxial brachydactyly syndrome	0	0	0.004165000282	0										
21129728	4681	D001259	Dan	limb malformations	0	0	0.00584417861	0										
21129728	4681	D006130	Dan	short stature	0	0	0.003337720642	0										
21129728	4681	D009436	Dan	developmental defects	0	0	0.003863637103	0										
21129728	4681	D034381	Dan	hearing loss	0	0	0.002939268015	0										
21129728	4681	D059327	Dan	brachydactyly and deafness | brachydactyly syndrome	0	0	0.008894016035	0										
21129728	4681|100532736	C536958	dan	autosomal-recessive Temtamy preaxial brachydactyly syndrome	0	0	0.004201140255	0										
21129728	4681|100532736	D001259	dan	limb malformations	0	0	0.0059416187	0										
21129728	4681|100532736	D006130	dan	short stature	0	0	0.003349729348	0										
21129728	4681|100532736	D009436	dan	developmental defects	0	0	0.003886596998	0										
21129728	4681|100532736	D034381	dan	hearing loss	0	0	0.002941531362	0										
21129728	4681|100532736	D059327	dan	brachydactyly and deafness | brachydactyly syndrome	0	0	0.009096334688	0										
21129728	649	C536958	BMP | Bmp | Bone Morphogenetic Protein	autosomal-recessive Temtamy preaxial brachydactyly syndrome	0	0	0.01591196097	0										
21129728	649	D001259	BMP | Bmp | Bone Morphogenetic Protein	limb malformations	0	0	0.0334675312	0										
21129728	649	D006130	BMP | Bmp | Bone Morphogenetic Protein	short stature	0	0	0.009324757382	0										
21129728	649	D009436	BMP | Bmp | Bone Morphogenetic Protein	developmental defects	0	0	0.3356989622	0										
21129728	649	D034381	BMP | Bmp | Bone Morphogenetic Protein	hearing loss	0	0	0.007021782454	0										
21129728	649	D059327	BMP | Bmp | Bone Morphogenetic Protein	brachydactyly and deafness | brachydactyly syndrome	0	1	0.9723654985	1	1		1						1bg	Altered Bone Morphogenetic Protein (BMP) signaling leads to multiple developmental defects, including brachydactyly and deafness.
21129728	650	C536958	bmp2b	autosomal-recessive Temtamy preaxial brachydactyly syndrome	0	0	0.004124902654	0										
21129728	650	D001259	bmp2b	limb malformations	0	0	0.005802501924	0										
21129728	650	D006130	bmp2b	short stature	0	0	0.003300090786	0										
21129728	650	D009436	bmp2b	developmental defects	0	0	0.00382157811	0										
21129728	650	D034381	bmp2b	hearing loss	0	0	0.00290252571	0										
21129728	650	D059327	bmp2b	brachydactyly and deafness | brachydactyly syndrome	0	0	0.008881758898	0										
21129728	652	C536958	Bmp2b	autosomal-recessive Temtamy preaxial brachydactyly syndrome	0	0	0.004187287297	0										
21129728	652	D001259	Bmp2b	limb malformations	0	0	0.005883743055	0										
21129728	652	D006130	Bmp2b	short stature	0	0	0.00335248746	0										
21129728	652	D009436	Bmp2b	developmental defects	0	0	0.003883762518	0										
21129728	652	D034381	Bmp2b	hearing loss	0	0	0.002950976603	0										
21129728	652	D059327	Bmp2b	brachydactyly and deafness | brachydactyly syndrome	0	0	0.008954180405	0										
21347663	3479	D001749	IGF-1 | IGF-I	bladder cancer | invasive bladder cancer	0	0	0.0966072455	0										
21347663	3479	D002295	IGF-1 | IGF-I	bladder transitional cell carcinoma	0	0	0.002917298581	0										
21347663	3479	D009369	IGF-1 | IGF-I	malignancies	0	0	0.002457597759	0										
21347663	3486	D001749	IGF-binding protein-3 | IGFBP-3 | insulin-like growth factor (IGF)-binding protein-3	bladder cancer | invasive bladder cancer	1	1	0.9940006137	0										
21347663	3486	D002295	IGF-binding protein-3 | IGFBP-3 | insulin-like growth factor (IGF)-binding protein-3	bladder transitional cell carcinoma	1	0	0.1244798005	1	1	only	1						e	Genetic polymorphism of the IGFBP-3 gene may be involved in the etiology of bladder TCC
21347663	3486	D009369	IGF-binding protein-3 | IGFBP-3 | insulin-like growth factor (IGF)-binding protein-3	malignancies	0	0	0.03669701517	0										
21347663	57008	D001749	RLFP	bladder cancer | invasive bladder cancer	0	0	0.09341862053	0										
21347663	57008	D002295	RLFP	bladder transitional cell carcinoma	0	0	0.002480132272	0										
21347663	57008	D009369	RLFP	malignancies	0	0	0.002387697808	0										
21366594	10131	C565276	TRAP1 | tumor necrosis factor receptor-associated protein-1	PINK1 defect	0	0	0.002416396979	0										
21366594	10131	D007239	TRAP1 | tumor necrosis factor receptor-associated protein-1	infection	0	0	0.002371065784	0										
21366594	10131	D010300	TRAP1 | tumor necrosis factor receptor-associated protein-1	PD | Parkinson's disease	0	0	0.01072317269	0										
21366594	10131	D010302	TRAP1 | tumor necrosis factor receptor-associated protein-1	neurodegeneration in Parkinson	0	0	0.003184427973	0										
21366594	10131	D019636	TRAP1 | tumor necrosis factor receptor-associated protein-1	neurodegenerative diseases	0	0	0.002242381452	0										
21366594	1432	C565276	p38	PINK1 defect	0	0	0.002413084265	0										
21366594	1432	D007239	p38	infection	0	0	0.002366228728	0										
21366594	1432	D010300	p38	PD | Parkinson's disease	0	0	0.01025911793	0										
21366594	1432	D010302	p38	neurodegeneration in Parkinson	0	0	0.003186620306	0										
21366594	1432	D019636	p38	neurodegenerative diseases	0	0	0.002237419831	0										
21366594	207	C565276	Akt	PINK1 defect	0	0	0.002413533162	0										
21366594	207	D007239	Akt	infection	0	0	0.002362212399	0										
21366594	207	D010300	Akt	PD | Parkinson's disease	0	0	0.01045214199	0										
21366594	207	D010302	Akt	neurodegeneration in Parkinson	0	0	0.003181598848	0										
21366594	207	D019636	Akt	neurodegenerative diseases	0	0	0.002236866159	0										
21366594	3162	C565276	HO-1 | heme oxygenase-1	PINK1 defect	0	0	0.003327660263	0										
21366594	3162	D007239	HO-1 | heme oxygenase-1	infection	0	0	0.004284160677	0										
21366594	3162	D010300	HO-1 | heme oxygenase-1	PD | Parkinson's disease	0	0	0.0402508229	0										
21366594	3162	D010302	HO-1 | heme oxygenase-1	neurodegeneration in Parkinson	0	0	0.01436392125	0										
21366594	3162	D019636	HO-1 | heme oxygenase-1	neurodegenerative diseases	0	0	0.002947653178	0										
21366594	5594	C565276	ERK	PINK1 defect	0	0	0.002411520109	0										
21366594	5594	D007239	ERK	infection	0	0	0.002362154191	0										
21366594	5594	D010300	ERK	PD | Parkinson's disease	0	0	0.01040112134	0										
21366594	5594	D010302	ERK	neurodegeneration in Parkinson	0	0	0.003177996958	0										
21366594	5594	D019636	ERK	neurodegenerative diseases	0	0	0.002235803287	0										
21366594	65018	C565276	PINK1 | tensin homolog (PTEN)-induced putative kinase 1	PINK1 defect	0	0	0.06056878343	0										
21366594	65018	D007239	PINK1 | tensin homolog (PTEN)-induced putative kinase 1	infection	0	0	0.2714039683	0										
21366594	65018	D010300	PINK1 | tensin homolog (PTEN)-induced putative kinase 1	PD | Parkinson's disease	1	1	0.9850373864	0										
21366594	65018	D010302	PINK1 | tensin homolog (PTEN)-induced putative kinase 1	neurodegeneration in Parkinson	0	0	0.2608637214	0										
21366594	65018	D019636	PINK1 | tensin homolog (PTEN)-induced putative kinase 1	neurodegenerative diseases	0	0	0.05660524964	0										
21532571	100048912	D005901	CDKN2B-AS1	glaucoma	0	0	0.02285240404	0										
21532571	100048912	D005902	CDKN2B-AS1	open angle glaucoma | open-angle glaucoma (OAG) blindness	1	1	0.9087033868	0										
21532571	100048912	D014786	CDKN2B-AS1	visual field loss	0	0	0.1657978892	0										
21532571	1029	D005901	CDKN2A	glaucoma	1	1	0.8917063475	0										
21532571	1029	D005902	CDKN2A	open angle glaucoma | open-angle glaucoma (OAG) blindness	0	0	0.1963268518	0										
21532571	1029	D014786	CDKN2A	visual field loss	0	0	0.09743498266	0										
21532571	1030	D005901	CDKN2B	glaucoma	1	1	0.8302890062	0										
21532571	1030	D005902	CDKN2B	open angle glaucoma | open-angle glaucoma (OAG) blindness	0	0	0.1480278075	0										
21532571	1030	D014786	CDKN2B	visual field loss	0	0	0.07463987917	0										
21532571	54499	D005901	TMCO1	glaucoma	0	0	0.02353593707	0										
21532571	54499	D005902	TMCO1	open angle glaucoma | open-angle glaucoma (OAG) blindness	1	1	0.9173702598	0										
21532571	54499	D014786	TMCO1	visual field loss	0	0	0.1754921228	0										
21765412	23218	D030342	NBEAL2 | neurobeachin-like 2	autosomal recessive bleeding disorder	0	0	0.0268594902	0										
21765412	23218	D055652	NBEAL2 | neurobeachin-like 2	Gray platelet syndrome | gray platelet syndrome	1	1	0.9638136625	0										
21804549	149628	D001249	PYHIN1	Asthma | asthma	1	1	0.9774340987	0										
21804549	85480	D001249	TSLP	Asthma | asthma	1	1	0.9881896973	0										
21804549	90865	D001249	IL33	Asthma | asthma	1	1	0.9900426865	0										
21804549	9173	D001249	IL1RL1	Asthma | asthma	1	1	0.988687396	0										
21866343	147495	D002289	APCDD1	NSCLC | non-small cell lung cancer	0	1	0.9823516011	1	1	only			n				m	Among the 44 validation SNPs, two SNPs (rs11080466 and rs11663246) near the APCDD1, NAPG and FAM38B genes in the 18p11.22 region were replicated.
21866343	147495	D008175	APCDD1	lung cancer	0	1	0.9282161593	1	1	only			n				m	Among the 44 validation SNPs, two SNPs (rs11080466 and rs11663246) near the APCDD1, NAPG and FAM38B genes in the 18p11.22 region were replicated.
21866343	1600	D002289	DAB1	NSCLC | non-small cell lung cancer	0	1	0.9767099023	1	0.5				n			1	m	For validation, 39 SNPs were selected from the top 50 SNPs and five additional SNPs were selected in the DAB1 gene region which showed significant associations in the GWA analysis.
21866343	1600	D008175	DAB1	lung cancer	0	1	0.8767032623	1	0.5				n			1	m	For validation, 39 SNPs were selected from the top 50 SNPs and five additional SNPs were selected in the DAB1 gene region which showed significant associations in the GWA analysis.
21866343	63895	D002289	FAM38B	NSCLC | non-small cell lung cancer	1	1	0.9815276265	0	1	only			n				m	Among the 44 validation SNPs, two SNPs (rs11080466 and rs11663246) near the APCDD1, NAPG and FAM38B genes in the 18p11.22 region were replicated.
21866343	63895	D008175	FAM38B	lung cancer	0	1	0.9178421497	1	1	only			n				m	Among the 44 validation SNPs, two SNPs (rs11080466 and rs11663246) near the APCDD1, NAPG and FAM38B genes in the 18p11.22 region were replicated.
21866343	8774	D002289	NAPG	NSCLC | non-small cell lung cancer	0	1	0.9806258678	1	1				nM				e	Our result suggests the 18p11.22 region as a novel lung cancer susceptibility locus in never smokers.
21866343	8774	D008175	NAPG	lung cancer	0	1	0.9099968076	1	1				nM				e	Our result suggests the 18p11.22 region as a novel lung cancer susceptibility locus in never smokers.
22032556	3170	D000505	FOXA2	baldness	0	0	0.006901712622	0	1	only		Dk	n				1bg	Research has shown that it is caused by genetic factors. Numerous studies have unequivocally identified two major genetic risk loci for AGA: the X-chromosomal AR/EDA2R locus, and the PAX1/FOXA2 locus on chromosome 20.
22032556	3170	D006201	FOXA2	hair loss	0	0	0.004668783862	0										
22032556	5075	D000505	PAX1	baldness	0	0	0.007248777896	0	1	only		Dk	n				1bg	Research has shown that it is caused by genetic factors. Numerous studies have unequivocally identified two major genetic risk loci for AGA: the X-chromosomal AR/EDA2R locus, and the PAX1/FOXA2 locus on chromosome 20.
22032556	5075	D006201	PAX1	hair loss	0	0	0.004877692088	0										
22032556	60401	D000505	EDA2R	baldness	1	0	0.007276174147	1	1	only		Dk	n				1bg	Research has shown that it is caused by genetic factors. Numerous studies have unequivocally identified two major genetic risk loci for AGA: the X-chromosomal AR/EDA2R locus, and the PAX1/FOXA2 locus on chromosome 20.
22032556	60401	D006201	EDA2R	hair loss	0	0	0.004887970164	0										
22032556	9734	D000505	HDAC9 | histone deacetylase 9	baldness	0	1	0.9507554173	1	1		1						0	Susceptibility variants on chromosome 7p21.1 suggest HDAC9 as a new candidate gene for male-pattern baldness.
22032556	9734	D006201	HDAC9 | histone deacetylase 9	hair loss	0	0	0.03829179704	0										
22039417	2203	D006528	FBP1 | fructose-1,6-bisphosphatase-1	hepatocellular carcinoma	1	1	0.9424491525	0										
22039417	2203	D009369	FBP1 | fructose-1,6-bisphosphatase-1	cancer | tumor	0	0	0.009003254585	0										
22039417	2203	D013274	FBP1 | fructose-1,6-bisphosphatase-1	gastric cancer	1	1	0.85468328	0										
22039417	2203	D015179	FBP1 | fructose-1,6-bisphosphatase-1	colon cancer | colon tumor	0	1	0.9920223951	1	1		1						e	In summary, epigenetic inactivation of FBP1 is also common in human liver and colon cancer.
22039417	2203	D063646	FBP1 | fructose-1,6-bisphosphatase-1	colon carcinogenesis | liver carcinogenesis	0	1	0.5777308941	1	1		1						e	 FBP1 appears to be a functional tumor suppressor involved in the liver and colon carcinogenesis.
22153697	3949	D050197	LDLR | low density lipoprotein receptor	atherosclerosis	1	1	0.9813628197	0										
22153697	5563	D050197	AMP-activated protein kinase | AMPK	atherosclerosis	0	0	0.01028163172	0										
22153697	6720	D050197	SREBP-1	atherosclerosis	0	0	0.009747683071	0										
22153697	6721	D050197	SREBP-2 | sterol regulatory element-binding protein-2	atherosclerosis	0	0	0.0104688881	0										
22311042	5243	D001943	MDR1 | Multidrug resistance 1 | P-glycoprotein | P-gp	breast cancer	1	0	0.05404083803	1	1	only			LC				m	In the stratified analyses, the increased risks were more pounced among hematologic malignances (OR = 1.27, 95% CI: 1.10-1.46, P (heterogeneity) = 0.415), breast cancer (1.42, 1.04-1.94, 0.018), renal cancer (1.77, 1.28-2.46, 0.307), Caucasians (1.21, 1.07-1.38, 0.000) and population-based studies (1.20, 1.05-1.36, 0.000) in a dominant model.
22311042	5243	D007680	MDR1 | Multidrug resistance 1 | P-glycoprotein | P-gp	renal cancer	1	0	0.02027118951	1	1	only			LC				m	In the stratified analyses, the increased risks were more pounced among hematologic malignances (OR = 1.27, 95% CI: 1.10-1.46, P (heterogeneity) = 0.415), breast cancer (1.42, 1.04-1.94, 0.018), renal cancer (1.77, 1.28-2.46, 0.307), Caucasians (1.21, 1.07-1.38, 0.000) and population-based studies (1.20, 1.05-1.36, 0.000) in a dominant model.
22311042	5243	D009369	MDR1 | Multidrug resistance 1 | P-glycoprotein | P-gp	cancer	0	1	0.9856783748	1	1								e	The results suggested that the MDR1 C3435T polymorphism may contribute to cancer risk.
22311042	5243	D019337	MDR1 | Multidrug resistance 1 | P-glycoprotein | P-gp	hematologic malignances	1	0	0.01867608167	1	1	only			LC				m	In the stratified analyses, the increased risks were more pounced among hematologic malignances (OR = 1.27, 95% CI: 1.10-1.46, P (heterogeneity) = 0.415), breast cancer (1.42, 1.04-1.94, 0.018), renal cancer (1.77, 1.28-2.46, 0.307), Caucasians (1.21, 1.07-1.38, 0.000) and population-based studies (1.20, 1.05-1.36, 0.000) in a dominant model.
22341971	55532	C548016	SLC30A10	hypermanganesemia	1	0	0.3067685366	1	1	only	1						0	Mutations in SLC30A10 cause parkinsonism and dystonia with hypermanganesemia, polycythemia, and chronic liver disease.
22341971	55532	D004421	SLC30A10	dystonia	0	0	0.02935260721	0										
22341971	55532	D005234	SLC30A10	steatosis and cirrhosis	0	0	0.006128357723	0										
22341971	55532	D006402	SLC30A10	hematologic disturbances	0	0	0.01714761741	0										
22341971	55532	D006521	SLC30A10	chronic hepatic disease	0	0	0.006158365868	0										
22341971	55532	D008107	SLC30A10	liver disease	0	0	0.007471187506	0										
22341971	55532	D009422	SLC30A10	neurologic disorders	0	0	0.006167460233	0										
22341971	55532	D010302	SLC30A10	parkinsonism	0	0	0.335010469	0										
22341971	55532	D011086	SLC30A10	polycythemia	0	0	0.01139875874	0										
22341971	55532	D030342	SLC30A10	genetic defect | recessive disease	0	0	0.0111927446	0										
22348037	1302	D009369	PARP	cancer | cancers	0	0	0.003096183296	0										
22348037	1302	D010190	PARP	pancreatic cancer	0	0	0.01641239226	0										
22348037	3718	D009369	JAK3	cancer | cancers	0	0	0.003206806025	0										
22348037	3718	D010190	JAK3	pancreatic cancer	0	0	0.02814242058	0										
22348037	6774	D009369	STAT3 | Signal Transducer and Activator of Transcription 3	cancer | cancers	0	0	0.3899573386	0										
22348037	6774	D010190	STAT3 | Signal Transducer and Activator of Transcription 3	pancreatic cancer	1	1	0.9915213585	0										
22348037	836	D009369	caspase-3	cancer | cancers	0	0	0.003155442886	0										
22348037	836	D010190	caspase-3	pancreatic cancer	0	0	0.01711856574	0										
22430674	1378	D000544	CR1	AD | Alzheimer's disease	0	1	0.9775721431	1	1	only							m	After exclusion of loci already known to be involved in AD (APOE, BIN1 and CR1), 91 regions with suggestive haplotype effects were identified.
22430674	274	D000544	BIN1	AD | Alzheimer's disease	0	1	0.9777532816	1	1	only							m	After exclusion of loci already known to be involved in AD (APOE, BIN1 and CR1), 91 regions with suggestive haplotype effects were identified.
22430674	348	D000544	APOE	AD | Alzheimer's disease	0	1	0.9765507579	1	1	only							m	After exclusion of loci already known to be involved in AD (APOE, BIN1 and CR1), 91 regions with suggestive haplotype effects were identified.
22430674	55691	D000544	FRMD4A	AD | Alzheimer's disease	1	1	0.9934926629	0										
22664332	1621	C535468	dopamine beta-hydroxylase	copper deficiency	0	0	0.004623036366	0										
22664332	1621	D007706	dopamine beta-hydroxylase	Menkes disease	0	0	0.07469215989	0										
22664332	1621	D019636	dopamine beta-hydroxylase	genetic neurodegenerative disorder	0	0	0.003522997955	0										
22664332	538	C535468	ATP7A	copper deficiency	0	0	0.04461089522	0										
22664332	538	D007706	ATP7A	Menkes disease	1	0	0.4248558879	1	1	only	1						1	Menkes disease (MD) is a genetic neurodegenerative disorder characterized by copper deficiency due to a defect in ATP7A.
22664332	538	D019636	ATP7A	genetic neurodegenerative disorder	0	0	0.004238460679	0										
22949511	1278	C537406	type I procollagen	Bruck syndrome	0	0	0.005428004079	0										
22949511	1278	D003286	type I procollagen	contractures | joint contractures	0	0	0.003239804413	0										
22949511	1278	D010013	type I procollagen	osteogenesis imperfecta	0	0	0.128811568	0										
22949511	1278	D012600	type I procollagen	scoliosis	0	0	0.002741704229	0										
22949511	1278	D050723	type I procollagen	fractures	0	0	0.003844274906	0										
22949511	5352	C537406	LH2 | PLOD2	Bruck syndrome	0	0	0.01053671911	0										
22949511	5352	D003286	LH2 | PLOD2	contractures | joint contractures	0	0	0.003172710072	0										
22949511	5352	D010013	LH2 | PLOD2	osteogenesis imperfecta	0	0	0.1226086617	0										
22949511	5352	D012600	LH2 | PLOD2	scoliosis	0	0	0.002668493195	0										
22949511	5352	D050723	LH2 | PLOD2	fractures	0	0	0.003883452853	0										
22949511	60681	C537406	FKBP10 | FKBP65	Bruck syndrome	1	0	0.2026076466	1	1		1						0	Mutations in FKBP10, which result in Bruck syndrome and recessive forms of osteogenesis imperfecta, inhibit the hydroxylation of telopeptide lysines in bone collagen.
22949511	60681	D003286	FKBP10 | FKBP65	contractures | joint contractures	0	0	0.006940234918	0										
22949511	60681	D010013	FKBP10 | FKBP65	osteogenesis imperfecta	0	1	0.9837127924	1	1		1						0	Mutations in FKBP10, which result in Bruck syndrome and recessive forms of osteogenesis imperfecta, inhibit the hydroxylation of telopeptide lysines in bone collagen.
22949511	60681	D012600	FKBP10 | FKBP65	scoliosis	0	0	0.005199061707	0										
22949511	60681	D050723	FKBP10 | FKBP65	fractures	0	0	0.009713227861	0										
22949511	871	C537406	SERPINH1	Bruck syndrome	0	0	0.004999864381	0										
22949511	871	D003286	SERPINH1	contractures | joint contractures	0	0	0.002870321739	0										
22949511	871	D010013	SERPINH1	osteogenesis imperfecta	0	0	0.09387983382	0										
22949511	871	D012600	SERPINH1	scoliosis	0	0	0.002566091716	0										
22949511	871	D050723	SERPINH1	fractures	0	0	0.003497279249	0										
23392203	117145	D004487	CTMP | carboxyl-terminal modulator protein	swelling	0	1	0.8774984479	1	0									
23392203	117145	D006528	CTMP | carboxyl-terminal modulator protein	H-ras12V liver cancer | hepatocellular carcinoma	1	1	0.9799078703	0										
23392203	117145	D009369	CTMP | carboxyl-terminal modulator protein	cancer | tumor | tumors	0	0	0.1136151701	0										
23392203	207	D004487	Akt1	swelling	0	0	0.009640342556	0										
23392203	207	D006528	Akt1	H-ras12V liver cancer | hepatocellular carcinoma	0	0	0.008127602749	0										
23392203	207	D009369	Akt1	cancer | tumor | tumors	0	0	0.002644517226	0										
23392203	3954	D004487	LETM1 | Leucine zipper/EF hand-containing transmembrane-1	swelling	0	1	0.8771090508	1	0									
23392203	3954	D006528	LETM1 | Leucine zipper/EF hand-containing transmembrane-1	H-ras12V liver cancer | hepatocellular carcinoma	1	1	0.9776703119	0										
23392203	3954	D009369	LETM1 | Leucine zipper/EF hand-containing transmembrane-1	cancer | tumor | tumors	0	0	0.08900138736	0										
25017104	3596	D004342	IL-13 | interleukin (IL)-13	allergic disease | allergic hypersensitivity | allergic sensitization	0	1	0.9677529335	1	1								e	We propose a model that elucidates the tissue specific nature of EoE that involves the interplay of allergic sensitization with an EoE-specific, IL-13-inducible esophageal response involving CAPN14.
25017104	3596	D009220	IL-13 | interleukin (IL)-13	inflammatory disorder	0	0	0.005641480442	0										
25017104	3596	D057765	IL-13 | interleukin (IL)-13	Eosinophilic esophagitis | eosinophilic esophagitis	0	0	0.06490682811	0	1								e	We propose a model that elucidates the tissue specific nature of EoE that involves the interplay of allergic sensitization with an EoE-specific, IL-13-inducible esophageal response involving CAPN14.
25017104	440854	D004342	CAPN14	allergic disease | allergic hypersensitivity | allergic sensitization	0	1	0.9754272699	1	1								e	We propose a model that elucidates the tissue specific nature of EoE that involves the interplay of allergic sensitization with an EoE-specific, IL-13-inducible esophageal response involving CAPN14.
25017104	440854	D009220	CAPN14	inflammatory disorder	0	0	0.006568040699	0										
25017104	440854	D057765	CAPN14	Eosinophilic esophagitis | eosinophilic esophagitis	1	0	0.09927328676	1	1								e	We propose a model that elucidates the tissue specific nature of EoE that involves the interplay of allergic sensitization with an EoE-specific, IL-13-inducible esophageal response involving CAPN14.
25038754	57561	D001943	ARRDC3	breast cancer	1	1	0.9864789844	0										
25038754	9055	D001943	PRC1	breast cancer	1	1	0.9865409732	0										
25038754	9877	D001943	ZC3H11A	breast cancer	0	1	0.9866010547	1	1								1bg	In a three-stage genome-wide association study among East Asian women including 22,780 cases and 24,181 controls, we identified three novel genetic loci associated with breast cancer risk, including rs4951011 at 1q32.1 (in intron 2 of the ZC3H11A gene, P = 8.82 x 10-9), rs10474352 at 5q14.3 (near the ARRDC3 gene, P = 1.67 x 10-9), and rs2290203 at 15q26.1 (in intron 14 of the PRC1 gene, P = 4.25 x 10-8).
25307878	23476	D009369	BRD4 | bromodomain-containing protein 4	cancers	0	0	0.002974311356	0										
25307878	23476	D012516	BRD4 | bromodomain-containing protein 4	osteosarcoma	0	0	0.3934949636	0										
25307878	2475	D009369	mTOR | mammalian target of rapamycin	cancers	0	0	0.002989324974	0										
25307878	2475	D012516	mTOR | mammalian target of rapamycin	osteosarcoma	0	0	0.4271715581	0										
25307878	4609	D009369	c-MYC	cancers	0	0	0.004276644439	0										
25307878	4609	D012516	c-MYC	osteosarcoma	0	1	0.6237945557	1	0									
25307878	644914	D009369	p21	cancers	0	0	0.003419858404	0										
25307878	644914	D012516	p21	osteosarcoma	0	0	0.4389250278	0										
25307878	860	D009369	RUNX2	cancers	0	0	0.004050775431	0										
25307878	860	D012516	RUNX2	osteosarcoma	1	1	0.9172347784	0										
25410422	117581	C536385	TWIST2	Setleis syndrome	1	1	0.9898803234	0										
25577287	57620	C566108	STIM2	Stormorken syndrome	0	0	0.004046014976	0										
25577287	57620	D001791	STIM2	Platelet syndrome | platelet abnormalities | platelet syndrome	0	0	0.004323197529	0										
25577287	57620	D007153	STIM2	immune deficiency	0	0	0.005263503175	0										
25577287	57620	D009135	STIM2	myopathy | non-syndromic myopathies	0	0	0.003406278323	0										
25577287	57620	D013921	STIM2	thrombocytopenia	0	0	0.003498501144	0										
25577287	57620	D015877	STIM2	syndromic forms of miosis	0	0	0.004456153139	0										
25577287	57620	D053447	STIM2	channelopathy	0	0	0.0106977541	0										
25577287	57620	D061325	STIM2	syndromic	0	0	0.004216116853	0										
25577287	6786	C566108	STIM1	Stormorken syndrome	1	0	0.02534462512	1	1	only							mbg	Heterozygous gain-of-function mutations in STIM1 cause non-syndromic myopathies as well as syndromic forms of miosis and myopathy with tubular aggregates and Stormorken syndrome
25577287	6786	D001791	STIM1	Platelet syndrome | platelet abnormalities | platelet syndrome	0	0	0.05222859234	0	1	only							0	York platelet syndrome is a CRAC channelopathy due to gain-of-function mutations in STIM1
25577287	6786	D007153	STIM1	immune deficiency	0	0	0.3583257496	0										
25577287	6786	D009135	STIM1	myopathy | non-syndromic myopathies	0	0	0.0147663597	0	1	only							mbg	Heterozygous gain-of-function mutations in STIM1 cause non-syndromic myopathies as well as syndromic forms of miosis and myopathy with tubular aggregates and Stormorken syndrome
25577287	6786	D013921	STIM1	thrombocytopenia	0	0	0.01740225963	0										
25577287	6786	D015877	STIM1	syndromic forms of miosis	0	0	0.01782603189	0	1	only							mbg	Heterozygous gain-of-function mutations in STIM1 cause non-syndromic myopathies as well as syndromic forms of miosis and myopathy with tubular aggregates and Stormorken syndrome
25577287	6786	D053447	STIM1	channelopathy	0	1	0.9385402799	1	1	only							0	York platelet syndrome is a CRAC channelopathy due to gain-of-function mutations in STIM1
25577287	6786	D061325	STIM1	syndromic	0	0	0.07473576069	0										
25577287	84876	C566108	ORAI1	Stormorken syndrome	0	0	0.004037421662	0										
25577287	84876	D001791	ORAI1	Platelet syndrome | platelet abnormalities | platelet syndrome	0	0	0.004336368293	0										
25577287	84876	D007153	ORAI1	immune deficiency	0	0	0.04096856341	0										
25577287	84876	D009135	ORAI1	myopathy | non-syndromic myopathies	0	0	0.004368054215	0										
25577287	84876	D013921	ORAI1	thrombocytopenia	0	0	0.003542442806	0										
25577287	84876	D015877	ORAI1	syndromic forms of miosis	0	0	0.004364049528	0										
25577287	84876	D053447	ORAI1	channelopathy	0	0	0.01074173301	0										
25577287	84876	D061325	ORAI1	syndromic	0	0	0.004263533279	0										
25705178	3784	D006311	Kv7.1 | hKv7.1	auditory | auditory defects	0	1	0.6209774613	1	1	only							1bg	As a result of cell-specific functions of voltage-activated K+ channels, such as Kv7.1, mutations in this channel produce profound cardiac and auditory defects.
25705178	3784	D008133	Kv7.1 | hKv7.1	long QT syndrome	0	0	0.00719388295	0										
25705178	3784	D029593	Kv7.1 | hKv7.1	Lange-Nielsen syndrome | cardio-auditory syndrome	1	1	0.6802918911	0										
25705178	3784	D029597	Kv7.1 | hKv7.1	RWS | Romano-Ward syndrome	1	1	0.9800798297	0										
26383258	4842	D010300	NOS1 | Nitric Oxide Synthase | Nitric oxide synthase | nitric oxide synthase	Parkinson's Disease | Parkinson's disease	1	1	0.9768100381	0										
26383258	4843	D010300	NOS2A	Parkinson's Disease | Parkinson's disease	0	0	0.02606733143	0										
26383258	5444	D010300	PON1 | paraoxonase 1	Parkinson's Disease | Parkinson's disease	0	0	0.07171815634	0										